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Abstract 
RPGRIP1L and FTO – genes implicated in the effects of FTO intronic sequence variants on 
food intake – also affect adipogenesis and adipocyte biology.  
 Jayne F. Martin Carli 
 
Single nucleotides in the first intron of FTO convey effects on adiposity by mechanisms 
that remain unclear, but appear to include modulation of expression of FTO itself, as well as 
other genes (e.g. RPGRIP1L, IRX3) in the vicinity of FTO. This locus affects food intake, the 
browning of white adipose tissue and risk of type 2 diabetes (independent of its effects on body 
weight). FTO and RPGRIP1L expression are decreased in fibroblasts and iPSC-derived human 
neurons of individuals segregating for obesity risk alleles of FTO at rs8050136 and rs1421085. 
These alleles exhibit decreased binding of isoform p110 of the CUX1 transcription factor. This 
isoform activates transcription of both FTO and RPGRIP1L. The FTO locus conveys effects on 
adiposity via hyperphagia, in part, by regulating FTO and RPGRIP1L expression in the 
hypothalamus. We examined whether FTO and RPGRIP1L also modify adipogenesis and 
adipose tissue lipid storage. Such effects would influence systemic consequences of the 
hyperphagia driven by the actions of the genes in the hypothalamus.  
Given the role in energy homeostasis of genes encoding elements of the primary cilium, 
we hypothesized that mice hypomorphic for Rpgrip1l would display increased adiposity. In 
confirmation, we find that Rpgrip1l+/− mice are hyperphagic and obese, and display diminished 
suppression of food intake in response to leptin administration. These findings suggest that 
RPGRIP1L may be partly or exclusively responsible for the obesity susceptibility signal at the 
FTO intronic locus. 
We describe effects of Rpgrip1l in adipocytes which may contribute to the adiposity 
phenotype observed in these animals, and possibly humans. Loss of Rpgrip1l in 3T3-L1 
preadipocytes increased the number of cells capable of differentiating into mature adipocytes. 
Knockout of Rpgrip1l in mature adipocytes (using Adipoq-Cre) did not increase adiposity in 
mice fed chow or high fat diet. Neither did we observe any effects of Rpgrip1l knockdown in 
mature 3T3-L1 adipocytes in vitro. Thus, to the extent that Rpgrip1l affects cell-autonomous 
adipose tissue function, it appears to do so by effects conveyed in preadipocytes, a cell type in 
which the primary cilium – as a mediator of developmental signals – may have functional 
importance. We propose that decreased RPGRIP1L expression in preadipocytes in humans 
segregating for FTO-associated obesity risk alleles increases the potential storage capacity of 
adipose tissue. Such capacity would influence the metabolic consequences of positive energy 
balance due to the action of these alleles within the brain.  
Fto expression is upregulated during adipogenesis in murine and human cells in vitro, 
and is more highly expressed in isolated mouse adipocytes than in preadipocytes. Here we 
demonstrate that FTO is required for the maintenance of adipocyte lipid filling and endocrine 
function in murine 3T3-L1 cells and human adipose tissue-derived stromal cells. RNAseq 
analysis indicates that this effect on adipocyte programming is conveyed in part by modulation 
of C/ebpβ- and C/ebpδ-regulated transcription, consistent with reports that Fto acts a 
transcriptional coactivator. Fto-/- mice have normal fat mass in early life, but spontaneously lose 
adipose tissue as they age. We propose that Fto is required to maintain adipocyte viability, a 
function critical to the prevention of ectopic lipid accumulation in obese states. Such 
accumulation – both total and in specific anatomic regions – has adverse metabolic 
consequences.  
In addition to the developmental effects on adiposity mediated by RPGRIP1L, and the 
effects conveyed on adipocyte function related to FTO, the FTO locus could also impact 
systemic energy homeostasis by modifying production of humoral signals that are integrated 
centrally to regulate energy balance. We explored molecular modifiers of adipocyte production 
of leptin identified by GWAS that may modify obesity risk. The FTO locus was associated with 
circulating leptin concentration, but this association was abrogated when corrected for BMI, 
indicating that this locus does not contribute to adiposity by dysregulating leptin production. Our 
in vitro findings are consistent in this regard, as knockdown of Rpgrip1l and Fto in 3T3-L1 cells 
did not affect leptin production per adipocyte. These results, however, are not inconsistent with a 
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Chapter 1 Introduction 
Identification of the obesity-associated FTO locus 
Almost simultaneously in 2007, three independent groups reported studies which took 
advantage of the decreased cost and increased density of single nucleotide polymorphism (SNP) 
genotyping to identify an association between adiposity and risk of overweight/obesity in 
Europeans and a group of highly related SNPs within the first intron of a gene called FTO on the 
long arm of chromosome 16 at position 12.2 (SNPs: rs9939609 (Frayling, Timpson et al. 2007, 
Scuteri, Sanna et al. 2007), rs1421085 and rs17817449 (Dina, Meyre et al. 2007)). The first 
among these groups originally identified an association for this region with type 2 diabetes 
(T2D) while performing case control studies in a UK population (Frayling, Timpson et al. 2007). 
Following adjustment for BMI, the association was completely abrogated, indicating that the 
effect of this genetic region on T2D status is mediated predominantly by its effect on adiposity, a 
potent enabler of T2D by effects on insulin resistance and intermediary metabolism. The group 
then followed up their analysis of this association using thirteen cohorts comprising 
approximately 30,000 white European adults and children. There was no association of the 
obesity risk alleles with birth weight. However, at the earliest timepoint in childhood examined, 
i.e. at 7 years old, each copy of the FTO risk allele for increased adiposity was associated with an 
increase of 0.08 BMI Z-score units (odds ratio (OR) of obesity at 11 years = 1.35; 95% CI = 1.14 
- 1.61 and OR of overweight = 1.27; 95% CI = 1.16 - 1.39), reflecting an elevated body weight 
that was observed at all ages studied, with a per-allele effect of 0.09 Z-score units, or 
approximately 1.2 kg body weight in adults (OR for obesity = 1.31, 95% CI = 1.23 to 1.39; for 
overweight, OR = 1.18, 95% CI = 1.13 to 1.24), a modest effect size that has been replicated in 
other populations to yield a signal at least one hundred orders of magnitude greater in statistical 
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significance than most other known variants associated with body weight (Locke, Kahali et al. 
2015). In all adult cohorts characterized, there was no difference in the magnitude of the effect 
between men and women. The effect on body weight is conveyed entirely by fat mass, with no 
effect on lean mass, as measured by dual-energy x-ray absorptiometry (DEXA). Notably, there 
was no association between height and risk allele status. Increased food intake (with preference 
for higher caloric density), rather than decreased energy expenditure, is the primary cause of this 
increased body weight in individuals segregating for FTO risk alleles (Cecil, Tavendale et al. 
2008, Speakman, Rance et al. 2008, Wardle, Carnell et al. 2008, Tanofsky-Kraff, Han et al. 
2009).  
The SNPs originally genotyped are in linkage disequilibrium (LD) with other SNPs 
spanning 47 kilobases. This LD block encompasses portions of the first two introns and the 
intervening exon (exon 2) of FTO (Dina, Meyre et al. 2007, Frayling, Timpson et al. 2007). 
None of the adiposity-associated SNPs suggested themselves as functional variants and 
sequencing of the region in a subset of subjects with extreme obesity did not yield evidence to 
suggest modified FTO protein sequence or splicing of the FTO transcript (Frayling, Timpson et 
al. 2007). Both Frayling et al. and Dina et al. found FTO to be ubiquitously expressed in human 
tissues, with particularly high levels of expression in the cerebral cortex, parietal lobe and 
hypothalamus (Dina, Meyre et al. 2007, Frayling, Timpson et al. 2007). At the time, no structural 
domains could be identified in FTO to shed light on its possible effect on adiposity. More recent 
approaches utilizing fine mapping and studies of individuals of African descent, which have 
smaller regions of LD, have reduced the interval associated with obesity to include only SNPs 
within the first intron of FTO (Hassanein, Lyon et al. 2010, Peters, North et al. 2013, 




Search for genes that convey effects on adiposity with regard to allelic variation in the first 
intron of the FTO locus  
Figure 1.1 The obesity-associated FTO locus and surrounding genes 
 
 
The region shaded red contains SNPs associated with adiposity by GWAS in 2007 (Dina, Meyre 
et al. 2007, Frayling, Timpson et al. 2007, Scuteri, Sanna et al. 2007). 
 
Deletion of Fto was first described in the Fused toes mouse, the eponymous model 
generated by insertional mutagenesis that caused the loss of a 1.6 megabase region encompassing 
six genes on mouse Chr 8 (van der Hoeven, Schimmang et al. 1994, Peters, Ausmeier et al. 
2002); three genes of the IroquoisB (IrxB) cluster (Irx3, Irx5 and Irx6) as well as novel genes 
designated Ft1, now Fts (Lesche, Peetz et al. 1997), Fantom/Ftm, now Rpgrip1l (Vierkotten, 
Dildrop et al. 2007) and Fatso/Fto (Peters, Ausmeier et al. 1999). Originally named due to its 
large size (~350 kb), FTO was renamed “Fat Mass and Obesity Associated” (Frayling, Timpson 
et al. 2007) to avoid pejorative implications with regard to the gene’s association with human 
adiposity. The homozygous Fused toes mouse dies around E10. Associated anomalies include 
loss of left-right asymmetry, pericardial enlargement and severe craniofacial malformation, with 
almost complete loss of the telencephalon and mesencephalon. Heterozygous mice survive but 
display syndactyly as well as thymic hyperplasia (van der Hoeven, Schimmang et al. 1994). 
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These animals have not been described as obese but their body composition has not been 
completely characterized.  
GWAS have been utilized to identify numerous variants that are associated with human 
disease, the vast majority of which are noncoding, and are customarily identified by the gene 
closest to the SNP that conveys the strongest signal. Some of these SNPs alter the function or 
expression of the genes in which they were identified. For example, rs1061170, located within 
complement factor H (CFH) encodes a coding variant that leads to age-related macular 
degeneration (Day, Willis et al. 1988, Klein, Zeiss et al. 2005). Several SNPs in distinct 
populations have been identified in the enhancer region of the human lactase gene (LCT) which 
regulate its expression, leading to hypolactasia, or lactose intolerance (Tishkoff, Reed et al. 
2007). When many GWAS-implicated loci are interrogated carefully however, the causal SNPs 
are not necessarily those closest to the genes they regulate. For example, low-density lipoprotein 
cholesterol- and myocardial infarction-related SNP rs12740374 modulates hepatic VLDL 
secretion by regulating expression of Sortilin (SORT1), a gene ~25 kb away (Musunuru, Strong 
et al. 2010). Obesity, a complex human trait, has been associated with the FTO locus as well as 
many others, including SNP rs17782313, near the gene encoding the melanocortin 4 receptor 
(MC4R). This risk allele is associated with decreased MC4R expression, a known regulator of 
food intake in rodents and humans (Loos, Lindgren et al. 2008, Tang, Jin et al. 2017). 
Several groups have assessed the possible roles of genes in the vicinity of FTO in 
conveying the effects of some, or all, of its intronic alleles with adiposity. Expression 
quantitative trait loci (eQTL) mapping has been used for this purpose. In eQTL analyses, SNP 
genotypes are related to tissue-specific transcript levels. An early eQTL study examining 
expression in lymphocytes of FTO as well as surrounding genes identified an association 
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between rs8050136, an adiposity-associated SNP in the first intron of FTO, and expression of 
Retinoblastoma-like 2 (RBL2), approximately 270 kb away from FTO (Jowett, Curran et al. 
2010). RBL2 is a member of the Retinoblastoma family of tumor suppressor genes (Sun, Bagella 
et al. 2007) and protein levels are downregulated in the mitotic clonal expansion phase of 
adipogenesis in 3T3-L1 cells, suggesting a role for Rbl2 in the maintenance of the preadipocyte 
state (Richon, Lyle et al. 1997). Jowett et al. did not observe any association between rs8050136 
and FTO expression per se (Jowett, Curran et al. 2010). Two other groups have used eQTL 
mapping to identify a role for Iroquois (IRX) homeobox genes in the development of obesity 
related to the FTO locus. One demonstrated an association between 11 SNPs in and around the 
FTO locus and an increase in IRX3 expression in human cerebellum (Smemo, Tena et al. 2014) 
The other found increased expression of IRX3 and IRX5 in primary subcutaneous preadipocytes - 
following a short period of differentiation - from patients segregating for the FTO risk allele at 
rs1421085 (Claussnitzer, Dankel et al. 2015). Neither group found evidence of a relationship in 
these tissue/cell types between risk allele status and expression of FTO per se. 
While there is little evidence supporting an effect of RBL2 on body weight in humans, a 
compelling case has been made for the involvement of IRX3 and IRX5 in the development of 
obesity associated with risk alleles in intron 1 of FTO. Profiles of genomic interactions in mouse 
brains exhibit long-range physical interactions between the Irx3 promoter and the obesity-
associated interval in FTO. The obesity-associated allele of SNP s9930506 was associated with 
an increase in IRX3 expression in human cerebellum. Irx3 knockout mice are hypermetabolic and 
have lower total body weights and less fat mass; these animals are resistant to weight gain when 
fed a high fat diet (Smemo, Tena et al. 2014). Tissue-specific Irx3 knockout models have 
implicated both the hypothalamus and adipose tissue as regulators of this phenotype. A 
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hypothalamus-specific model of dominant-negative Irx3 recapitulates the whole-body knockout 
with regard to body weight and fractional fat mass. Additionally, these hypothalamic Irx3 
dominant negative mutants exhibit increased adipose tissue “browning”, which contributes to 
increased energy expenditure by uncoupled oxidative phosphorylation (Smemo, Tena et al. 
2014). However, an adipose tissue-specific Irx3 knockout model also phenocopies the whole-
body knockout (Claussnitzer, Dankel et al. 2015). Claussnitzer et al. have demonstrated a cell-
autonomous role for IRX3 and IRX5 in adipocyte browning by showing that the loss of these 
genes induces thermogenesis in primary human preadipocytes differentiated in vitro and that 
overexpression of these genes inhibits thermogenesis. Importantly, they also implicated 
rs1421085 as the causal SNP, located within an ARID5B repressor binding location. The 
protective T allele binds ARID5B whereas the C risk allele does not, accounting for the elevated 
IRX3 and IRX5 expression seen in primary preadipocytes of those individuals segregating for the 
risk allele. Targeted genome editing of rs1421085 from C to T in risk allele carriers decreased 
IRX3 and IRX5 expression and restored thermogenesis in preadipocytes. T to C editing in 
preadipocytes from protective allele carriers resulted in elevated IRX3 and IRX5 expression. This 
suggests that expression of IRX3 and IRX5 is decreased in individuals segregating for the 
protective allele, resulting in increased thermogenesis. Notably, however, the demonstrated 
effect of Irx3 on body mass in mice is due to alterations in energy expenditure without an effect 
on food intake, whereas, in humans, the primary effect of the FTO locus is conveyed by 
increased food intake (Speakman 2015).  
The strength of the statistical signal associating the FTO locus to adiposity is sufficiently 
large to suggest that there may be multiple causative variants in the region, and/or that there may 
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be effects on multiple genes in many different tissues. Exploration of this locus should not, 
therefore, be restricted to any single gene in this region.  
Our group has identified two SNPs in the first intron of FTO that modify transcriptional 
regulation of FTO and Retinitis pigmentosa GTPase regulator-interacting protein-1 like 
(RPGRIP1L), a gene ~100 bp 5’ of FTO (Stratigopoulos, Padilla et al. 2008, Stratigopoulos, 
LeDuc et al. 2011, Stratigopoulos, Burnett et al. 2016). In silico analysis of the locus identified 
rs17817449 and rs8050136 as Cut-like homeobox 1 (CUX1) binding sites. CUX1 was originally 
described as a CCAAT-displacement protein and is expressed as a full-length isoform, p200, 
which acts as a transcriptional repressor. Proteolytic cleavage by cathepsin L generates a smaller 
isoform, p110, that can act as a transcriptional activator or repressor (Sansregret and Nepveu 
2008). Chromatin immunoprecipitation of DNA from human fibroblasts followed by 
pyrosequencing identified differential binding of CUX1 to the rs8050136 allele, with elevated 
CUX1 binding to the protective C allele, and decreased binding to the risk (increased adiposity) 
A allele. CUX1 knockdown decreased expression of both FTO and RPGRIP1L in human 
fibroblasts. Electrophoretic mobility shift assays (EMSAs) demonstrated that this preferential 
protective allele binding and transcriptional activation was specific to the proteolytically 
processed p110 isoform of CUX1 that acts as a transcriptional activator. The inhibitory CUX1 
isoform p200 preferentially binds the risk allele, and a reporter assay utilizing the minimal 
promoter regions of both FTO and RPGRIP1L demonstrated that CUX1 p200 decreased 
expression of FTO, without affecting RPGRIP1L expression. These findings were confirmed in 
murine hypothalamic N41 cells where overexpression of Cux1 p110 elevated both Fto and 
Rpgrip1l expression and overexpression of Cux1 p200 decreased Fto expression alone 
(Stratigopoulos, Padilla et al. 2008, Stratigopoulos, LeDuc et al. 2011).  
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Another SNP in the FTO locus, rs1421085, was associated with obesity in individuals of 
African descent (Peters, North et al. 2013) and is also predicted to be a CUX1 binding site 
(Stratigopoulos, Burnett et al. 2016). EMSA studies of this SNP revealed that, similar to 
rs8050136, transcriptional inhibitor CUX1 p200 bound preferentially to the obesity-risk C allele 
of rs1421085 and transcriptional activator CUX1 p110 bound preferentially to the obesity-
protective T allele. Promoter probing of this SNP by luciferase transcriptional assay 
demonstrated that CUX1 p110 activates transcription of FTO and RPGRIP1L while CUX1 p200 
inhibits FTO expression alone. These findings suggest that individuals segregating for CUX1-
related FTO risk alleles would exhibit decreased FTO and RPGRIP1L expression, whereas those 
with the protective alleles would display elevated FTO expression in tissues mediating the 
effects of these alleles on adiposity. 
Fto and Rpgrip1l expression is decreased in the arcuate nucleus (ARC) and ventromedial 
nucleus (VMH) of the hypothalamus as well as mesenteric adipose tissue upon fasting in 
C57BL/6 mice, and in Lepob/ob hyperphagic mice. Leptin treatment restored Fto and Rpgrip1l 
expression in the hypothalamus, suggesting that decreased expression of these genes is 
associated with an increased drive to eat (Gerken, Girard et al. 2007, Stratigopoulos, Padilla et al. 
2008, Poritsanos, Lew et al. 2011, Stratigopoulos, LeDuc et al. 2011). Individuals segregating for 
FTO risk alleles may have decreased FTO and RPGRIP1L expression in the hypothalamus or 
other brain regions which may influence ingestive behaviors.  
 
Investigating a role for Rpgrip1l in obesity 
RPGRIP1L encodes a protein which localizes to the transition zone of the primary cilium, 
a sensory organelle present on almost all non-dividing cells (Vierkotten, Dildrop et al. 2007). 
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Rpgrip1l assembles two modules of the transition zone of the primary cilium, the Meckel 
Syndrome (MKS) module and the nephronophthisis (NPHP) module, and facilitates their 
assembly. These modules then function as a “ciliary gate” modulating the compartmentalization 
of ciliary proteins (Williams, Li et al. 2011, Jensen, Li et al. 2015), thereby regulating the 
signaling faculties of the primary cilium.  
It has been previously reported that the expression patterns of RPGRIP1L and FTO in 
human tissues are quite similar (Frayling, Timpson et al. 2007), and work by our group, detailed 
above, has highlighted the impact of the obesity-associated FTO locus on these two vicinal 
genes. Chapter 2 reports experiments demonstrating increased adiposity in mice systemically 
hypomorphic for Rpgrip1l. These mice are hyperphagic, in part, as a result of impaired leptin 
sensitivity in the hypothalamus. In Chapter 3 we endeavored to determine if there are any 
“peripheral” cellular processes and metabolic signals contributing to this hyperphagia and 
adiposity. We knocked down Rpgrip1l in 3T3-L1 preadipocytes prior to adipogenesis and found 
increased proliferation and differentiation in these cells, suggesting that Rpgrip1l restrains 
adipogenesis. We did not find evidence of an effect on peripheral signals such as leptin or 
adiponectin due to Rpgrip1l knockdown that could contribute to the hyperphagia observed in 
Rpgrip1l hypomorphic animals. However, we anticipate that the increased adipogenesis we 
observed after Rpgrip1l knockdown could contribute to the establishment of increased adiposity 
during development.  
 
Investigating a role for Fto in adiposity 
FTO was identified as a member of the ALKB homolog family of non-heme 
dioxygenases (Fe(II)- and α-ketoglutarate dependent dioxygenases) by sequence analysis 
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(Gerken, Girard et al. 2007, Sanchez-Pulido and Andrade-Navarro 2007). FTO was also 
demonstrated to exhibit RNA N6-methyladenosine (m6A) and 3-methyluridine (m3U) 
demethylation activity in vivo (Jia, Fu et al. 2011). M6A constitutes an abundant mRNA 
modification and has been proposed to play a role in the regulation of mRNA stability, splicing 
and translation. M6A RNA modifications are increased around stop codons and 3’UTRs, as well 
as within long exons (Dominissini, Moshitch-Moshkovitz et al. 2012, Meyer, Saletore et al. 
2012, Fu, Dominissini et al. 2014).  
Classical gain- and loss-of-function experiments in rodents of have been used to assess 
the possible role of the Fto molecule per se in the regulation of body weight. Several Fto 
knockout mouse models have been generated (Fischer, Koch et al. 2009, Gao, Shin et al. 2010, 
McMurray, Church et al. 2013) which recapitulate many aspects of the human malformation 
syndrome caused by congenital absence of FTO (described below), including growth retardation 
and postnatal lethality. Some mice do survive into adulthood and exhibit decreased adiposity in 
adulthood and protection from high fat diet (HFD)-induced obesity (Fischer, Koch et al. 2009, 
Ronkainen, Huusko et al. 2015). A milder Fto loss-of-function model was described using an 
ENU mutagenized mouse with a dominant negative isoform of Fto (Church, Lee et al. 2009). 
Mice that were either heterozygous or homozygous for this mutation had decreased adiposity in 
adulthood with no change in lean body mass when fed chow and were also protected from HFD-
induced obesity. Additionally, they did not exhibit any of the growth impairment or lethality 
phenotypes that characterize Fto knockout models. Congenital overexpression of Fto in mice 
results in a dose-dependent increase in body weight and adiposity, due to an increase in food 
intake (Church, Moir et al. 2010). Lean mass is also increased in these mice.  
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The decreases in adiposity seen in Fto-/- mice have been reported in adulthood (~20 
weeks old) (Fischer, Koch et al. 2009, Ronkainen, Huusko et al. 2015). However, we 
(Stratigopoulos, Burnett et al. 2016) and others (Gao, Shin et al. 2010, McMurray, Church et al. 
2013) have found that at earlier timepoints (≤15 weeks), adiposity is actually increased as a 
percentage of body weight in Fto-/- mice. And, consistent with reports by Fischer et al. and 
Ronkainen et al., we also observed dramatic loss of adipose tissue as these mice aged (G. 
Stratigopoulos, personal communication). We anticipate that this early increase in adiposity is 
due to the primary role of Fto in regulating energy balance centrally, and that the loss in 
adiposity seen later in life is due to a defect in adipose tissue structure and function. Mice lacking 
Fto display decreased overall adiposity late in life, exhibit smaller adipocytes and eventually lose 
almost all adipose tissue (Fischer, Koch et al. 2009). Conversely, Fto-overexpressing mice have 
larger adipocytes (Church, Moir et al. 2010). These phenotypes suggest a role for Fto in enabling 
adipose tissue expansion, possibly in the context of diet-induced obesity. Despite decreased body 
weight, mice with the dominant negative Fto mutation exhibit increased fasting glucose, 
triglyceride, cholesterol and high-density lipoprotein (HDL) levels, possibly reflecting a 
lipodystrophic metabolic profile (Church, Lee et al. 2009, Unger and Scherer 2010, Virtue and 
Vidal-Puig 2010).  
 
FTO mutations in humans cause an extreme malformation syndrome 
eQTL studies in humans, which thus far have failed to identify an effect of the FTO 
adiposity-associated genetic locus on FTO or RPGRIP1L expression, may be limited in assessing 
the timing and cell-specificity of the effects of the risk alleles; not all tissues and cell types can 
be probed in a sufficiently large number of subjects or at the appropriate developmental 
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timepoints to ascertain whether a relationship exists (Pastinen and Hudson 2004). Several groups 
have sequenced FTO in lean and obese individuals as an alternative approach to this question; to 
determine whether FTO per se is responsible for the association with obesity. Missense 
mutations have been identified with similar frequency in both groups, suggesting that any 
relationship between the FTO gene product per se and obesity is limited (Meyre, Proulx et al. 
2010, Deliard, Panossian et al. 2013, Zheng, Hong et al. 2013). Among these mutations, 
however, only a small number of variants were located within the catalytic domain (R322Q and 
R316Q) or within the so-called “substrate recognition lid” (R96H). Heterozygous mutations in 
these domains were found in almost equal numbers in both lean (3) and obese (2) individuals in 
this western European cohort. The small number of individuals with these mutations makes it 
difficult to draw any conclusions regarding effects on adiposity. Similar findings regarding the 
number of missense mutations in FTO identified in lean and obese populations have also been 
described in Chinese (Zheng, Hong et al. 2013) and African American populations (Deliard, 
Panossian et al. 2013), but none of these mutations have been confirmed to be deleterious. Case 
studies of individuals homozygous for loss-of-function mutations in the catalytic domain have 
been described with severe developmental phenotypes and failure to thrive (Boissel, Reish et al. 
2009, Daoud, Zhang et al. 2016, Rohena, Lawson et al. 2016). A large, consanguineous, 
Palestinian family included nine affected (R316Q) individuals all of whom displayed growth 
retardation as well as impaired brain development and function including postnatal microcephaly 
as well as hypertonicity and hydrocephalus, lissencephaly and/or seizures (Boissel, Reish et al. 
2009). Additionally, cardiovascular defects such as ventricular septal and atrial ventricular 
defects, patent ductus arteriosus and hypertrophic cardiomyopathy were also observed. The 
R316Q mutation impairs the catalytic activity of FTO, as demonstrated by decreased 
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decarboxylation of 2-oxoglutarate to succinate. A Canadian patient of Tunisian origin 
homozygous for FTO S319F presented with similar phenotypes (overall growth retardation, 
brain malformation and cardiac defects) (Daoud, Zhang et al. 2016). This mutation also impairs 
FTO’s catalytic activity, evident by impaired 2-oxoglutarate conversion to succinate as well as 
demethylation of 3-methylthymine. No obvious structural differences were apparent by circular 
dichroism spectroscopy of the recombinant mutant protein. Two other individuals have presented 
with homozygous mutations in the catalytic domain of FTO (R322Q). Both were offspring of a 
Yemeni consanguineous union and both exhibited failure to thrive and developmental delay as 
well as characteristic facial features (Rohena, Lawson et al. 2016). In most of these instances, 
however, the affected individuals died prior to 6 years of age, in some instances due to severe, 
chronic infections, indicating that FTO is a critical component of structural development as well 
as systemic homeostasis. Information about the parents of these individuals, which, in cases not 
involving de novo mutations would be obligate heterozygotes for these mutations, is limited. The 
death of individuals homozygous for mutations in FTO at such a young age, in addition to their 
extreme malformations, prevents observations of the effect of FTO on body weight throughout 
life.  
 
Understanding the physiological and cellular functions of Fto in central regulation of 
metabolic homeostasis 
Expression of FTO in both humans and rodent models is ubiquitous, with the highest 
levels consistently being observed in the brain (Frayling, Timpson et al. 2007, Gerken, Girard et 
al. 2007, Fredriksson, Hagglund et al. 2008, Stratigopoulos, Padilla et al. 2008, Boissel, Reish et 
al. 2009) where it is widely expressed but restricted to neurons (Fredriksson, Hagglund et al. 
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2008, McTaggart, Lee et al. 2011). Both transcript and protein levels are enriched in areas of the 
brain that regulate feeding behavior, specifically, the ARC, as well as the paraventricular (PVH) 
and dorsomedial nuclei (DMH) of the hypothalamus (Gerken, Girard et al. 2007, Fredriksson, 
Hagglund et al. 2008, Stratigopoulos, Padilla et al. 2008, Olszewski, Radomska et al. 2011, 
Poritsanos, Lew et al. 2011). Additionally, the ventral tegmental area (VTA) and substantia nigra 
(SN) of the midbrain express Fto (Hess, Hess et al. 2013). Notably, Fto is expressed in POMC-, 
TH- and oxytocin-producing neurons, which are key regulators of food intake (Fischer, Koch et 
al. 2009, Olszewski, Fredriksson et al. 2009, Tung, Ayuso et al. 2010, McTaggart, Lee et al. 
2011, Olszewski, Fredriksson et al. 2011, Hess, Hess et al. 2013).  
A neuron-specific Fto knockout mouse model, utilizing Nestin-Cre, recapitulates the 
growth retardation effects seen in the whole-body knockouts, with decreased body length and 
lower lean body mass; however, these mice exhibit an increase in food intake when normalized 
for lean body mass (Gao, Shin et al. 2010). This increase in food intake is consistent with 
evidence that hypothalamic Fto expression is decreased following fasting and restored upon 
leptin treatment, suggesting a drive to eat that is mediated by reduced neuronal levels of Fto 
(Stratigopoulos, LeDuc et al. 2011). In rats, overexpression of Fto in the ARC by stereotactic 
injection of AAV decreased food intake, and Fto knockdown by AAV shRNA increased food 
intake. Overexpression in the PVN also decreased food intake, whereas Fto knockdown in this 
region had no effect (Tung, Ayuso et al. 2010). These central effects of Fto are likely the primary 
regulators of body weight in Fto-/- animals, although Fto likely plays additional roles in 




Identification of a primary role for Fto in adipocyte development 
While FTO is primarily expressed in the brain, mRNA expression has also been observed 
in adipose tissue, suggesting a role in adipocyte function and/or development (Frayling, Timpson 
et al. 2007, Stratigopoulos, Padilla et al. 2008, Willer, Speliotes et al. 2009). A number of groups 
have attempted to relate adipose tissue FTO expression to adipose depot location, measures of 
body mass, as well as risk allele genotype (Kloting, Schleinitz et al. 2008, Wahlen, Sjolin et al. 
2008, Grunnet, Nilsson et al. 2009, Zabena, Gonzalez-Sanchez et al. 2009, Lappalainen, 
Kolehmainen et al. 2010, Samaras, Botelho et al. 2010, Terra, Auguet et al. 2010, Susleyici-
Duman, Zengin et al. 2011, Bravard, Veilleux et al. 2013). There is no clear consensus that FTO 
is expressed most highly in any particular adipose depot in humans (Kloting, Schleinitz et al. 
2008, Wahlen, Sjolin et al. 2008, Zabena, Gonzalez-Sanchez et al. 2009, Samaras, Botelho et al. 
2010, Terra, Auguet et al. 2010, Susleyici-Duman, Zengin et al. 2011, Bravard, Veilleux et al. 
2013). Similarly, the relationship between adipose tissue FTO expression and BMI or obesity is 
unclear, with some groups finding an inverse correlation (Kloting, Schleinitz et al. 2008, Terra, 
Auguet et al. 2010, Susleyici-Duman, Zengin et al. 2011) while others report a direct relationship 
(Wahlen, Sjolin et al. 2008, Grunnet, Nilsson et al. 2009, Zabena, Gonzalez-Sanchez et al. 2009, 
Lappalainen, Kolehmainen et al. 2010, Tews, Fischer-Posovszky et al. 2011). Of the populations 
studied, none has exhibited a relationship between FTO expression in whole adipose tissue and 
FTO risk allele genotype (Kloting, Schleinitz et al. 2008, Wahlen, Sjolin et al. 2008, Grunnet, 
Nilsson et al. 2009, Zabena, Gonzalez-Sanchez et al. 2009, Lappalainen, Kolehmainen et al. 
2010). The lack of a correlation of FTO expression with numbers of risk alleles, however, does 
not preclude a role for this gene in adipose tissue or adipocytes per se. Adipose depots consist of 
adipocytes in addition to immune cells (Weisberg, McCann et al. 2003, Wu, Ghosh et al. 2007, 
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Elgazar-Carmon, Rudich et al. 2008, Duffaut, Galitzky et al. 2009, Liu, Divoux et al. 2009, 
Winer, Winer et al. 2011, Wu, Molofsky et al. 2011), and adipocyte precursors (Ng, Poznanski et 
al. 1971). A correlation between FTO expression and risk allele genotype in any one of these cell 
types may be obscured in measurements of whole tissue. Additionally, any role for FTO during 
adipose tissue development may not be apparent in mature tissue of weight-stable individuals.  
Another approach has been to analyze expression of FTO throughout the course of 
adipogenesis in isolated preadipocytes or commercially available preadipocyte cell lines. Studies 
performed in primary human preadipocytes and murine 3T3-L1 cells described in Chapter 4 
demonstrate an increase in the expression of FTO during the process of adipogenesis. 
Additionally, isolated murine adipocytes exhibit higher Fto expression (>3-fold) than the 
preadipocyte-containing stromal vascular fraction. 
In order to more directly investigate Fto’s role in adipocyte development and function, a 
number of groups, including our own, have performed gain- and loss-of-function studies in 
isolated primary preadipocytes and preadipocyte cell lines, described in Chapter 4. Such studies 
have provided convincing evidence for a role of Fto in adipocyte development and function. The 
loss of Fto impairs development of adipocytes in vitro, while Fto overexpression increases 
adipocyte differentiation (Zhao, Yang et al. 2014, Merkestein, Laber et al. 2015, Wang, Zhu et 
al. 2015, Zhang, Zhang et al. 2015, Chen, Zhou et al. 2016, Jiao, Zhang et al. 2016). We find that 
the loss of Fto decreases the number of preadipocytes that are able to undergo adipogenesis and 
limits the lipid handling and endocrine functions of mature adipocytes. In particular, Fto’s m6A 
demethylase activity is necessary for adipogenesis, as overexpression of catalytically inactive Fto 
(H231A/D233A/ H307A) was incapable of rescuing the inhibitory effect of Fto knockdown, 
whereas wild type Fto did so (Zhao, Yang et al. 2014). Fto (R96Q), which cannot demethylate 
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m6A (Han, Niu et al. 2010), acts as a dominant negative, inhibiting adipogenesis to an extent 
similar to Fto knockdown (Zhang, Zhang et al. 2015). Knockdown of the m6A methyltransferase 
Mettl3 in preadipocytes increased subsequent adipocyte differentiation, whereas Mettl3 
overexpression inhibited adipogenesis (Zhao, Yang et al. 2014). When Mettl3 levels were 
manipulated in mature porcine adipocytes, overexpression inhibited triglyceride levels via 
decreased expression of Fatty Acid Synthase (Fas) (Wang, Zhu et al. 2015). Additionally, 
chemical regulators of m6A methylation affect adipogenesis similarly to endogenous regulators 
of m6A methylation. Cycloleucine, which inhibits m6A methyltransferase, increased triglyceride 
accumulation in porcine adipocytes and betaine, a methyl donor, decreased triglyceride 
accumulation, further highlighting the relationship between m6A status of the transcriptome and 
adipogenesis (Wang, Zhu et al. 2015), although it remains unclear what transcripts may be 
conveying these effects. 
The mechanism(s) by which Fto affects adipogenesis remain incompletely characterized. 
Merkestein and colleagues have demonstrated an effect of Fto on mitotic clonal expansion early 
in the adipogenesis program in murine MEFs and primary preadipocytes, where the loss of Fto 
inhibits cell division, but does not affect cell survival. Conversely, Fto overexpression increases 
cell division (Merkestein, Laber et al. 2015). Chen et al. have confirmed this effect of Fto on cell 
division in porcine intramuscular preadipocytes (Chen, Zhou et al. 2016), and Jiao et al. found 
the same effect in 3T3-L1 cells (Jiao, Zhang et al. 2016). It remains unclear whether Fto’s effect 
on adipogenesis is simply due to its regulation of total cell number or whether there is a 
developmental (maturational) component altered by Fto as well. Pparg activation by 
Rosiglitazone restores adipogenesis in 3T3-L1 cells expressing a dominant negative Fto (R96Q), 
providing evidence for a developmental role for Fto beyond regulating proliferation (Zhang, 
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Zhang et al. 2015). In studies reported in this thesis, I provide evidence that C/ebpβ and C/ebpδ-
mediated transcription is disrupted in adipocytes following Fto knockdown, as is Pparg2 
expression, impairing critical components of the adipogenic program.  
As systemic congenital Fto-/- models do develop adipose tissue, and at early time points 
even exhibit greater adiposity than wild type animals, it is clear that a loss of Fto does not induce 
lipodystrophy, as might be inferred from the in vitro studies described above. There must be 
other signals in vivo driving adipogenesis that have not been recapitulated in cell culture models. 
Alternatively, Fto may affect developmental adipogenesis and obesogenic adipogenesis observed 
in mature organisms distinctly. The upregulation in FTO expression in mature adipocytes 
differentiating in vitro, consistent with the dramatically elevated FTO expression in isolated 
mature adipocytes compared to isolated adipocyte precursors, suggests that FTO’s role may be 
most critical in mature adipocytes, enabling them to carry out their critical lipogenic and lipolytic 
as well as endocrine functions. Knockdown of Fto in mature adipocytes inhibited expression of 
adipocyte effectors and endocrine signals, such as Pparg2, Fapb4, Glut4, Lpl and Adipoq.  
 
Adipose tissue-intrinsic effects on body weight and metabolic homeostasis 
The ability of animals to regulate food intake so that it matches energy expenditure is 
remarkable in both its accuracy and flexibility. Landmark studies in the middle of the 20th 
century demonstrated that the hypothalamus plays an important role in this coordination. 
Lesioning in the region of the VMH caused rats to become obese due to pronounced hyperphagia 
(Hetherington and Ranson 1940, Hervey 1959), whereas lesioning of the lateral hypothalamus 
(LHA) induced anorexia to the point of death (Anand and Brobeck 1951). Conversely, electrical 
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stimulation of the VMH caused aphagia and stimulation of the LHA induced hyperphagia 
(Hoebel and Teitelbaum 1962).  
The afferent signals regulating these hypothalamic responses were unknown at the time 
and Gordon Kennedy proposed that the adipose tissue of these rats was producing a factor which 
reported its lipid content to the hypothalamus, a theory which has been termed the Lipostatic 
Model (Kennedy 1953). G. Romaine Hervey postulated that this signal must be a circulating 
factor. Rats parabiosed to each other, so that there is blood exchange between the two, with one 
of the pair lesioned in the VMH caused the non-lesioned rat to die of starvation. Hervey 
interpreted these results to suggest that there was a satiety factor being produced by the 
hyperphagic VMH-lesioned animal that circulated to the contralateral animal through the blood. 
The VMH-lesioned animal was no longer sensitive to this satiety factor, while the non-lesioned 
animal retained sensitivity and became hypophagic (Hervey 1959).  
Doug Coleman in the 1960s characterized two interesting spontaneous mutations in mice 
at the Jackson Laboratory, ob (obesity) and db (diabetes). He noted the similarities between 
parabiosed ob/ob and db/db mice and the VMH-lesioned rats parabiosed to non-lesioned rats 
described by Hervey (Hervey 1959). The ob/ob mice became aphagic to the point of death after 
parabiosis with db/db mice, which remained obese, like the VMH-lesioned rats (Coleman 1973). 
Coleman concluded that the ob/ob mice were deficient in a satiety factor to which the db/db mice 
were insensitive. In the years since this discovery, relentless effort to characterize this satiety 
factor and its sensor resulted in the identification of the ob and db genes as leptin and the leptin 
receptor, respectively (Zhang, Proenca et al. 1994, Tartaglia, Dembski et al. 1995, Chen, Charlat 
et al. 1996, Chua, Chung et al. 1996).  
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Leptin, a circulating 16 kDa polypeptide, is as predicted by Kennedy, produced by 
adipocytes in proportion to their triglyceride content (Zhang, Proenca et al. 1994, Halaas, 
Gajiwala et al. 1995, Maffei, Halaas et al. 1995). It reports this information to the hypothalamus, 
where it modulates both energy intake and expenditure. Leptin stimulates the leptin receptor, 
expressed in pro-opiomelanocortin (POMC) expressing neurons of the ARC, signaling through 
the JAK2/STAT3 pathway. Leptin activates these glutamatergic neurons to express POMC, 
producing a cleavage product, α melanocyte-stimulating hormone (αMSH), which activates the 
melanocortin 4 receptor (MC4R) on second order neurons in the PVH. These second order 
neurons decrease food intake and increase energy expenditure. Leptin receptors are also 
expressed on neuropeptide Y (NPY) neurons in the ARC. NPY neurons are gamma-
aminobutyric acid (GABA)ergic neurons that produce agouti related protein (AgRP), an inverse 
agonist of MC4R that inhibits MC4R neurons, leading to an orexigenic response. Leptin inhibits 
NPY neurons, relieving their inhibition of downstream MC4R neurons and blunting their 
orexigenic effect. These interactions form the basis of the central regulation of metabolism by 
the hypothalamus (reviewed in (Zhang and Leibel 2017)).  
Other brain regions, including the nucleus of the solitary tract (NTS) of the brainstem and 
the lateral parabrachial nucleus (PBN) of the hindbrain convey the signals generated by neurons 
in the hypothalamus and are sensitive to leptin in their own regard. Additionally, leptin regulates 
the dopaminergic reward system that is overlaid on the feeding circuitry by acting on neurons of 
the ventral tegmental area (VTA) which innervates the nucleus of accumbens (NAc) of the 
ventral striatum and the central nucleus of the amygdala (CeA). Lepr expressing neurons in the 
aforementioned LHA innervate VTA neurons, regulating dopamine production (Morton, Meek et 
al. 2014, Zhang and Leibel 2017).  
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Leptin is a critical determinant of food intake and energy expenditure, and therefore, 
body weight overall. Circulating leptin concentrations are positively correlated with total body 
adiposity (Rosenbaum, Nicolson et al. 1996). Moreover, larger adipocytes produce more leptin 
than smaller adipocytes, to the extent that adipose tissue from an obese individual produces more 
leptin per gram than adipose tissue from a lean individual (Lonnqvist, Nordfors et al. 1997, 
Zhang and Leibel 2017). Variations in leptin production by adipose tissue could conceivably 
impact overall body weight (Kilpeläinen, Carli et al. 2016). 
It is unclear if adipose tissue itself is a determinant (in a cell-autonomous manner) of 
depot size beyond its effect on leptin production and systemic energy balance. Lipectomy studies 
provide strong evidence that the total amount of adiposity among individuals is accurately 
defended. In rodents, total body adiposity was restored within a few months of lipectomy, with 
either partial regrowth of the lipectomized adipose depot and/or compensatory growth of other 
adipose depots (Schemmel, Mickelsen et al. 1971, Faust, Johnson et al. 1977, Larson and 
Anderson 1978, Faust, Johnson et al. 1984, Michel and Cabanac 1999). Regrowth of the 
lipectomized epidydimal adipose depot was usually limited, whereas lipectomized subcutaneous 
adipose depots were generally fully restored. Liposuction in humans provokes equal regeneration 
and/or compensation of adipose tissue (Kral 1975, Hernandez, Kittelson et al. 2011, Seretis, 
Goulis et al. 2015). A model of inducible lipoatrophy, the FAT-ATTAC mouse, also 
demonstrated regeneration of adipose tissue after virtual ablation of adipose tissue (Pajvani, 
Trujillo et al. 2005). These results demonstrate a clearly established and zealously defended level 
of adiposity in mature individuals.  
White adipocytes derive from mesenchymal stem cells that form adipocyte precursors 
before committing to becoming preadipocytes (Rosen and Spiegelman 2014). In humans, 
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adipose tissue grows by hyperphagia within the first year or two of life, followed by a reduction 
in adipocyte size. The number of adipocytes does not increase until children are approximately 
10 years of age in lean individuals. In obese children, hyperplasia begins earlier than in non-
obese children (Knittle, Timmers et al. 1979). Subcutaneous white adipose tissue is formed 
prenatally in humans and mice (Poissonnet, Burdi et al. 1984, Wang, Tao et al. 2013). The 
visceral gonadal depot develops shortly after birth (Siegel, Hildebolt et al. 2007, Spalding, Arner 
et al. 2008, De Lucia Rolfe, Modi et al. 2013, Wang, Tao et al. 2013, Kim, Lun et al. 2014). 
Peter Arner’s group has pioneered the use of 14C testing assays of genomic DNA to establish the 
time of generation and ages of adipocytes as well as neurons. Atmospheric 14C was generated 
during aboveground nuclear bomb tests in the mid-20th century and levels quickly equilibrated 
around the globe. Since then, diffusion from the atmosphere has caused an exponential decrease 
in atmospheric 14C levels. Incorporation of 14C into vegetation, and the subsequent consumption 
of such plant matter, results in DNA labeling of human cells as they are born with a 14C level 
matching the concentration found in the environment at that time (Spalding, Arner et al. 2008). 
This method was used to confirm that adult adipocyte number is established during childhood 
and adolescence, and remains relatively constant throughout adulthood. These cells turn over at a 
rate of approximately 10% per year, a rate that has been supported using a prospective 
measurement of cell birth rate utilizing stable isotope tracers (Guillermier, Fazeli et al. 2017).  
Developmental sufficiency of energy balance has important consequences for subsequent 
adiposity. In humans, maternal nutrition has been well established to affect the adiposity of 
offspring later in life. This was described in studies performed on young men of the Dutch 
military who had been born following the Dutch “Winter Hunger” near the end of World War II. 
The Winter Hunger was a famine caused by the German blockade of food and fuel shipments to 
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the German-occupied region of the Netherlands in 1944-1945 (Ravelli, Stein et al. 1976). Infants 
that had been exposed to famine during the first half of gestation grew into adults with elevated 
obesity rates, whereas those exposed to famine in the second half of pregnancy, the time during 
which adipose tissue is developing, displayed decreased obesity later in life. Rodent models 
show similar effects. Rats reared in small litters received more milk from their mothers and when 
weaned, display greater food intake and grow to larger body weights than rats reared in large 
litters with limited access to milk (Widdowson and Kennedy 1962, Oscai and McGarr 1978). 
Findings by Spalding and colleagues using 14C labeling of adipocytes, indicate that adiposity 
level is established during childhood and is set by adolescence. Obese adolescents had larger 
number of adipocytes than lean adolescents, a difference that was maintained throughout 
adulthood (Spalding, Arner et al. 2008). Differences in food intake are the most likely 
determinants of such a disparity, but modifiers of adipose tissue expansion may play a secondary 
role in determining the size and anatomic location of the adipose depots.  
Lipectomy studies have not been conducted in early life and such studies could shed light 
on the role adipose tissue per se plays in setting the level of adiposity. Adipose transplant studies 
provide some evidence that adipocytes/adipose tissue have cell-autonomous capacities that could 
influence fat cell size and number. When adipose tissue of C57BL/6 mice segregating for the 
Lepob mutation and transplanted into lean C57BL/6 mice, the transplant adopted the phenotype of 
the lean host (smaller adipocytes), indicating that the primary determinant of adipocyte size is 
the cell’s environment (Ashwell, Meade et al. 1977). However, adipose tissue from these mice 
differed only in their ability to produce leptin. Adipose tissue explants from 5-day old obesity-
susceptible mice (NH strain) and obesity-resistant mice (DBA/2 strain) were transplanted onto 
the ears of NH-DBA/2 hybrid mice. After 90 days, the transplants from the obesity-susceptible 
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strains were significantly larger than the transplants from the resistant strains. This difference is 
independent of effects of food intake, as the different transplants grew in the same environment 
in a single mouse (Liebelt 1963). These data suggest that there are adipose/adipocyte 
determinants of adipose depot size beyond that determined by effects on food intake. 
Adipose tissue development and expansion are carefully regulated. An informative model 
has been generated by the Scherer group, which allows for inducible labeling of mature 
adipocytes. Pulse-chase experiments using these “AdipoTracker” mice provide distinction 
between mature adipocytes labeled during the pulse, and the birth of nascent adipocytes during 
the chase, which are unlabeled. This model indicates that during diet-induced obesity, 
adipogenesis (hyperplasia) occurs following adipocyte hypertrophy. This hyperplasia occurs 
primarily in the epididymal adipose depot in male mice, and has been shown to be concurrent 
with the death of hypertrophic adipocytes (Strissel, Stancheva et al. 2007). Hyperplasia follows 
hypertrophic adipose tissue growth in human obesity as well (Hirsch and Batchelor 1976). 
Subsequent weight loss reduces the size but not the number of adipocytes present in adipose 
tissue (Salans, Knittle et al. 1968). Another elegant pulse-chase labeling model illustrated 
hyperplasia in epididymal adipose tissue of male mice fed a high fat diet. Mature adipocytes 
were pulse labeled green, with all remaining adipocyte precursor cells retaining a red label. A 
chase period of high fat diet feeding induced rapid proliferation of red labeled adipocyte 
precursor cells in the epididymal adipose depot (Jeffery, Church et al. 2015). Using this same 
model, it was demonstrated that in female mice, hyperplasia is primarily observed in the 
subcutaneous depot, and this subcutaneous hyperplasia is inhibited in ovariectomized animals. 
Furthermore, in male mice, estrogen injections induced adipocyte hyperplasia in the 
subcutaneous depot, indicating that the expansion of this depot is hormonally influenced (Jeffery, 
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Wing et al. 2016). In humans, these depot-specific differences are also apparent and well 
characterized in terms of their metabolic consequences. Males tend to accumulate adipose tissue 
viscerally and women subcutaneously in the abdominal, gluteal and femoral regions, colloquially 
identified as apple- or pear-shaped distributions (Vague 1956, Karastergiou, Smith et al. 2012, 
Palmer and Clegg 2015). This unequal distribution plays out physiologically to the detriment of 
men, where increased visceral adipose tissue leads to T2D, dyslipidemia, fatty liver and 
cardiovascular disease (Gesta, Tseng et al. 2007). There is little evidence that FTO risk alleles 
affect adipose tissue distribution with regard to waist-hip-ratio (WHR) a common measure 
signifying differential distribution of adipose tissue in the visceral or subcutaneous depots 
(Vasan, Fall et al. 2013). The FTO locus was associated with elevated adiposity to the same 
extent in both males and females, suggesting that sex hormones play a minimal role in the 
association (Frayling, Timpson et al. 2007). However, it remains possible that there are anatomic 
regional differences in the FTO-mediated effects on adipocyte lipid handling function, further 
contributing to the effects of FTO genotypes on insulin sensitivity and T2D risk. 
Experiments described in Chapter 3 detail that the loss of Rpgrip1l in 3T3-L1 
preadipocytes increases the number of cells able to differentiate into mature adipocytes. Rpgrip1l 
knockdown in 3T3-L1 preadipocytes increases the number of cells that are able to undergo 
adipogenesis. We anticipate that Rpgrip1l, a key protein regulating the ability of primary cilia to 
accurately sense the extracellular environment, may regulate adipogenesis, and in turn, the 
development of the adipose depot, especially in the context of positive energy balance. 
Individuals segregating for FTO obesity risk alleles could exhibit hypomorphism of RPGRIP1L 
due to differential CUX1 binding and therefore enlarge the adipose anlagen, setting a permissive 




Effects of the FTO locus on metabolic status beyond fat mass per se 
While the effect of the FTO locus on adiposity is clear, there is growing evidence to 
suggest that individuals segregating for the FTO risk allele are more susceptible to T2D, even 
when their level of adiposity is taken into account (Hertel, Johansson et al. 2011, Rees, Islam et 
al. 2011, Li, Kilpelainen et al. 2012, Fall, Hagg et al. 2013, Yang, Liu et al. 2017) consistent with 
the original association between the FTO locus and T2D (Frayling, Timpson et al. 2007). Both 
increased adiposity and impairments of adipose tissue expansion are associated with reduced 
insulin sensitivity and disordered glucose metabolism (Moitra, Mason et al. 1998, Pajvani, 
Trujillo et al. 2005, Arner and Spalding 2010). Stable isotope tracing in mice suggests that 
adipogenesis decreases as animals age, and is associated with impairments in insulin sensitivity 
(Kim, Lun et al. 2014). The same holds true as humans age (Guillermier, Fazeli et al. 2017). The 
“adipose tissue expandability hypothesis” as stated by Scherer, Vidal-Puig, and colleagues 
suggests that each individual has a genetically and environmentally determined limit on the 
amount that adipose tissue can expand. Beyond this, the organ cannot serve as a lipid sink and 
lipid accumulates ectopically, inducing lipotoxicity and leading to the disorders associated with 
the so-called “metabolic syndrome”: diabetes, atherosclerosis, and fatty liver (Unger and Scherer 
2010, Virtue and Vidal-Puig 2010).  
We propose that Fto may play a role in adipose tissue expandability, which may 
contribute to the T2D risk associated with the FTO locus, independent of its association with 
BMI. The late-onset loss of adipose tissue in Fto-/- mice (Church, Lee et al. 2009, Fischer, Koch 
et al. 2009, Ronkainen, Huusko et al. 2015) suggests that there is a limit in these animals on the 
extent of adipose depot expansion, consistent with the decreased adipogenesis we have observed 
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in vitro following Fto knockdown in 3T3-L1 cells. This decrease in FTO expression may be 
partially recapitulated in adipose tissue of individuals segregating for FTO obesity risk alleles, 
where differential CUX1 binding may lead to the repression of FTO expression (Stratigopoulos, 
Padilla et al. 2008, Stratigopoulos, LeDuc et al. 2011, Stratigopoulos, Burnett et al. 2016). 
 
Investigating genetic modifiers of adipocyte function with regard to leptin secretion 
As previously mentioned, the amount of leptin produced per unit of body mass is 
somewhat variable among individuals. In an effort to better understand the molecular basis for 
such differences, we have identified loci associated with circulating leptin concentrations 
adjusted for BMI or body fat. Efforts detailed in Chapter 5 were made to interrogate the causal 
genes at specific loci by molecular vetting of candidate genes using adipose tissue expression 
studies in mice. These candidates were knocked down in adipose tissue explants to evaluate their 
effects on leptin production and secretion. The FTO locus was initially identified as a regulator 
of circulating leptin concentrations but this effect was abrogated when leptin was normalized to 
BMI. This underscores our results from in vitro studies of Fto and Rpgrip1l knockdown, where 
leptin secretion was not changed when normalized to the number of adipocytes, suggesting that 
insomuch as FTO and RPGRIP1L are responsible for the adiposity effects of the FTO locus, they 




Peripheral roles for RPGRIP1L and FTO may partially account for the adiposity and 
metabolic dysfunction associated with the FTO locus. 
Here we present evidence that Fto and Rpgrip1l play opposing roles in the differentiation 
of adipocytes. We suggest that RPGRIP1L plays a role early in the development of adipocytes, 
when primary cilia are displayed, responding to tissue environmental signals such as Shh, Wnts 
and Pdgfs to determine whether and how cells differentiate. We suggest that a decrease of 
RPGRIP1L expression, due to segregation of obesity-risk alleles within the FTO locus, could 
increase the cellular anlagen of adipose tissue mass during development by triggering 
proliferation and differentiation of adipocyte precursors, setting a permissive stage for elevated 
body weight throughout adulthood. The dramatic upregulation of FTO expression during 
adipogenesis suggests that FTO functions primarily in mature adipocytes. Our data indicate that 
FTO is required for the maintenance of the adipocyte state. In individuals segregating for FTO 
risk alleles, which decrease FTO expression, lipid handling function of the adipose tissue of 
mature individuals could be impaired via decreased glucose and fatty acid uptake and decreased 
lipogenesis. This diminished lipid storage capacity would predispose to ectopic fat deposition 
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The following has been abridged to emphasize the potentially adipocyte-specific role of 




Common polymorphisms in the first intron of FTO are associated with increased body 
weight in adults. Previous studies have suggested that a CUX1-regulatory element within the 
implicated FTO region controls expression of FTO and the nearby ciliary gene, RPGRIP1L. 
Given the role of ciliary genes in energy homeostasis, we hypothesized that mice hypomorphic 
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for Rpgrip1l would display increased adiposity. We find that Rpgrip1l+/− mice are hyperphagic 
and fatter and display diminished suppression of food intake in response to leptin administration. 
In the hypothalamus of Rpgrip1l+/− mice, and in human fibroblasts with hypomorphic mutations 
in RPGRIP1L, the number of AcIII-positive cilia is diminished, accompanied by impaired 
convening of the leptin receptor to the vicinity of the cilium, and diminished pStat3 in response 
to leptin. These findings suggest that RPGRIP1L may be partly or exclusively responsible for the 




Common single-nucleotide Common polymorphisms in the first intron of FTO are 
associated with increased body weight in adults. Previous studies have suggested that a CUX1-
regulatory element within the implicated FTO region controls expression of FTO and the nearby 
ciliary gene, RPGRIP1L. Given the role of ciliary genes in energy homeostasis, we hypothesized 
that mice hypomorphic for Rpgrip1l would display increased adiposity. We find that Rpgrip1l+/− 
mice are hyperphagic and fatter and display diminished suppression of food intake in response to 
leptin administration. In the hypothalamus of Rpgrip1l+/− mice, and in human fibroblasts with 
hypomorphic mutations in RPGRIP1L, the number of AcIII-positive cilia is diminished, 
accompanied by impaired convening of the leptin receptor to the vicinity of the cilium, and 
diminished pStat3 in response to leptin. These findings suggest that RPGRIP1L may be partly or 
exclusively responsible for the obesity susceptibility signal at the FTO locus. 
polymorphisms (SNPs) within an ∼47 Kb interval located in the first intron of the Fat 
Mass and Obesity-Associated (FTO) gene are associated with a dose-dependent body weight 
difference in humans (Frayling, Timpson et al. 2007, Scuteri, Sanna et al. 2007, Meyre, 
Delplanque et al. 2009). FTO encodes a nuclear protein that is orthologous to proteins of the 
AlkB family of deoxygenases and appears to function as a DNA or RNA demethylase (Han, 
Huang et al. 2010). In mice and rats, manipulations of Fto gene expression have produced 
changes in body weight, but not in a consistent direction (Stratigopoulos, Padilla et al. 2008, 
Church, Moir et al. 2010, Tung, Ayuso et al. 2010, Stratigopoulos, LeDuc et al. 2011, Wang, 
Yang et al. 2011), and humans heterozygous for null alleles of FTO show no consistent effects 
on body weight (Meyre, Proulx et al. 2010). Retinitis Pigmentosa GTPase Regulator-Interacting 
Protein-1 Like (RPGRIP1L) is located >100 bp 5′ in the opposite transcriptional orientation of 
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FTO (Figure 1.1), and encodes a protein localized at the transition zone of the primary cilium 
(Liu, Zhang et al. 2011, Williams, Li et al. 2011). Functional derangements of the primary cilium 
in Bardet-Biedl and Alström syndromes are associated with obesity (Baker and Beales 2009). 
We have previously demonstrated that fasting reduces hypothalamic expression of Rpgrip1l in 
mice which is restored by exogenous leptin administration (Stratigopoulos, LeDuc et al. 2011). 
The first intron of FTO contains a binding site for the CUX1 p110 isoform—capable of long-
range regulation of transcription (Vadnais, Awan et al. 2013)—that increases promoter activity 
and expression of RPGRIP1L in vitro, and the obesity-risk allele of intronic SNP rs8050136 
(Scuteri, Sanna et al. 2007) located in the CUX1 binding site lowers the affinity of the CUX1 
p110 isoform for DNA (Stratigopoulos, LeDuc et al. 2011). The long isoform of the leptin 
receptor (Lepr-b) localizes to the vicinity of the primary cilium in cultured neuronal cells, and in 
vitro knockdown of Rpgrip1l reduces Lepr-b localization in the vicinity of the cilium and 
decreases leptin signaling (Stratigopoulos, LeDuc et al. 2011). Thus, it is possible that some or 
all of the association with obesity of the intron 1 SNPs of FTO is actually conveyed by reduced 
expression of RPGRIP1L. In mice, homozygosity for a null allele of Rpgrip1l is embryonically 
lethal (Vierkotten, Dildrop et al. 2007), but based on the allele-dosage effect of the FTO intronic 
SNPs on human adiposity, and our identification of a CUX1-regulatory element in FTO intron 1 
that controls Rpgrip1l expression, we hypothesized that mice heterozygous for a null allele of 
Rpgrip1l would be fatter than wild-type animals. Here we show that these animals are indeed 






Deletion of Rpgrip1l in mice, as well as biallelic RPGRIP1L mutations in Joubert 
patients, is linked with severe brain and craniofacial abnormalities (Arts, Doherty et al. 2007, 
Delous, Baala et al. 2007, Vierkotten, Dildrop et al. 2007). In addition, Rpgrip1l-deleted 
embryos display polydactyly (Vierkotten, Dildrop et al. 2007), which is also characteristic of 
mutations in cilia-related proteins related to human syndromic obesity (e.g., (Zaghloul and 
Katsanis 2009)). Nevertheless, RPGRIP1L mutations have not been directly linked to obesity in 
mice or humans. Deletion of Rpgrip1l is embryonic lethal in mice, and patients with 
homozygous or compound heterozygous loss-of-function mutations in RPGRIP1L show severe 
renal and skeletal developmental defects that may mask a role of RPGRIP1L in energy 
homeostasis. We obtained mice segregating for a Rpgrip1l allele in which LacZ is knocked into 
intron 4 (Figure 2.1B). LacZ is downstream of the Engrailed-2 exon-2 splice acceptor, resulting 
in a functionally null Rpgrip1l allele. Interbreeding of heterozygous mice failed to produce 
viable mice homozygous for the knockin allele, in agreement with the embryonic lethality 
previously reported (Vierkotten, Dildrop et al. 2007). Rpgrip1l mRNA and protein levels in the 
hypothalamus of heterozygous mice were decreased by ∼50%, and Rpgrip1l mRNA was also 
decreased by ∼50% in subcutaneous fat (Figure 2.1C), demonstrating that these mice are 
systemically heterozygous for Rpgrip1l (Rpgrip1l+/−). Conversely, Fto mRNA remained 
unchanged in the hypothalamus and subcutaneous fat of Rpgrip1l+/− mice, and mRNA levels of 
nearby genes Chd9, Rbl2, Aktip, and Irx3-6 in the hypothalami of Rpgrip1l+/− mice were 
equivalent to control mice. Rpgrip1l+/− C57BL6/J mice generated viable Rpgrip1l+/− mice at 
expected Mendelian ratios. By 10 weeks of age, male and female Rpgrip1l+/− mice fed regular 
chow (9% of calories as fat) ad libitum were ∼10% heavier than +/+ animals (Figure 2.2A and 
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Figure 2.3A). Thereafter, we concentrated on male Rpgrip1l+/− mice. At 18 weeks of age, male 
Rpgrip1l+/− mice fed regular chow were ∼12% heavier due to a ∼40% difference in fat mass 
(Figure 2.2B–2.2D). After 1 week of ad libitum feeding of a high-fat diet (HFD; 65% of calories 
as fat), 19-week old male Rpgrip1l+/− mice were ∼15% heavier (∼4 g) and had ∼80% more body 
fat (∼2.5 g) and 6% more lean mass (∼1.5 g) than Rpgrip1l+/+ littermates (Figure 2.2E–2.2G). 
Energy intake was significantly increased (∼23%) in Rpgrip1l+/− mice consuming the HFD 
during the 12 hr light phase compared with Rpgrip1l+/+ littermates (Figure S1B). No statistically 
significant differences in energy expenditure or physical activity were detected between 
Rpgrip1l+/− and Rpgrip1l+/+ mice when ingesting the HFD (Figure 2.3C and 2.3D). After 18 
weeks of ad libitum feeding of regular chow followed by 7 days of the HFD, male Rpgrip1l+/− 
mice had ∼82% more subcutaneous fat, ∼65% more perigonadal and perirenal fat, and ∼50% 
more mesenteric fat than +/+ littermates (Figure 2.2H). The ∼2-fold increase in serum leptin 
concentrations of male Rpgrip1l+/− mice correlated with their increased adiposity (Figure 2.3E 
and 2.3F). No notable differences by genotype where observed in blood glucose concentrations 
of fed or fasted Rpgrip1l+/− and Rpgrip1l+/+ mice (Figure 2.3G). 
Rpgrip1l+/− male mice fed regular chow showed increased food intake as early as 4 weeks 
old (Figure 2.2I). At this age, both groups weighed the same, had the same amount of fat mass, 
and displayed the same activity levels, whereas energy expenditure was ∼25% lower in 
Rpgrip1l+/− mice (Figures 2.2J, 2.3H, and 2.3I). By 5 weeks of age, after being switched to the 
HFD for 1 week, Rpgrip1l+/− mice ate more and displayed ∼20% lower energy expenditure 
compared to the control group (Figures 2.2K and 2.3J). At this age, body weight, body 
composition, and physical activity levels were indistinguishable between Rpgrip1l+/− and control 
mice (Figures 2.2J and 2.3K).  
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Other research from our group has demonstrated that Rpgrip1l+/- mice were less sensitive 
to leptin injection, evident by decreased pStat3 staining, resulting in increased food intake 
(Figure 2.2K). Using skin-derived primary fibroblasts, exogenously expressed LEPR-b was 
shown to localize to the area surrounding the base of the primary cilium upon leptin treatment, 
and co-immunoprecipitated with RPGRIP1L. This LEPR trafficking did not occur in fibroblasts 
derived from patients with mutations in RPGRIP1L, and pSTAT3 signaling was decreased in 
these cells. The same Lepr-b mislocalization and impaired pStat3 signaling were observed in 




We have previously shown that the protective C allele of rs8050136, one of the FTO 
intronic SNPs associated with increased BMI (Scuteri, Sanna et al. 2007), favors binding of the 
short isoform of Cut-like homeobox 1 (CUX1 P110) that acts as a transcriptional activator of 
RPGRIP1L and FTO (Stratigopoulos, LeDuc et al. 2011). As in the case of mouse embryos 
lacking functional Rpgrip1l, loss of Fto in zebrafish results in multiple developmental defects 
that are due in part to ciliary structural defects accompanied by dysregulated β-catenin-dependent 
Wnt signaling (Vierkotten, Dildrop et al. 2007, Huang, Szymanska et al. 2011, Osborn, 
Roccasecca et al. 2014). CUX1 p110 controls the expression of genes that participate in the β-
catenin-dependent Wnt pathway (Cadieux, Kedinger et al. 2009). Moreover, CUX1 P110 is a 
positive regulator of leptin signaling, whereas FTO knockdown results in diminished leptin 
signaling in vitro (Stratigopoulos, LeDuc et al. 2011). Therefore, it is conceivable that 
individuals segregating for the obesity-risk A allele at rs8050136 have lower hypothalamic 
RPGRIP1L and FTO expression levels due to lower DNA binding affinity of P110 at that 
cognate CUX1-binding site. Consequently, due to pre- and/or postnatal consequences of 
RPGRIP1L hypomorphism, these individuals would have diminished leptin signaling resulting in 
increased food intake and adiposity, thus providing a mechanism that links the allelic variation at 
FTO intron 1 with increased food intake and adiposity. 
The possibility that SNPs associated with adiposity are embedded in regulatory elements 
of nearby genes that extend within the first intron of FTO is supported by the finding that the 
promoter of the homeobox gene IRX3 interacts with the obesity-associated FTO interval through 
long-range DNA looping (Smemo, Tena et al. 2014). This recent report has suggested that the 
intronic region of FTO implicated in obesity interacts at a distance (of ∼0.5 Mbp) with IRX3 to 
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increase adiposity primarily by effects on energy expenditure. The susceptibility allele of FTO 
has been proposed to increase IRX3 expression resulting in lower energy expenditure due to 
diminished activation of brown adipose tissue and limited “browning” of white adipose tissue 
(Smemo, Tena et al. 2014). However, in humans, the implicated FTO allele conveys its impact 
on adiposity, proportional to allele dose, primarily by effects on energy intake (Cecil, Tavendale 
et al. 2008, Speakman, Rance et al. 2008, Wardle, Carnell et al. 2008, den Hoed, Westerterp-
Plantenga et al. 2009, Haupt, Thamer et al. 2009, Tanofsky-Kraff, Han et al. 2009, Wardle, 
Llewellyn et al. 2009, Rutters, Lemmens et al. 2010). IRX3 expression was not affected in 
proportion to dosage of the FTO obesity risk allele in human brain, and an intermediate adiposity 
phenotype in mice segregating for a single Irx3 null allele was not reported (Smemo, Tena et al. 
2014). It is certainly possible, of course, that intronic FTO has effects on the expression of 
several genes (Jowett, Curran et al. 2010). Our data support a quantitatively important role for 
RPGRIP1L in conveying the orexigenic effects of intronic sequence variants in FTO.  
We anticipate that there may be peripheral effects of Rpgrip1l that contribute to the 
adiposity phenotype described here. Effects on the adipogenic capacity of preadipocytes or the 
endocrine or lipid-storage functioning of mature adipocytes attributable to Rpgrip1l could 
conceivably influence the metabolic homeostasis and resultant adiposity of these animals. These 




Mice heterozygous for the Rpgrip1l floxed-LacZ allele (Rpgrip1ltm1a(EUCOMM)Wtsi; referred 
to here as Rpgrip1l+/−) were derived from targeted embryonic stem cells on a C57BL/6NTac 
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background, purchased from the International Knockout Mouse Consortium 
(http://www.mousephenotype.org/martsearch_ikmc_project/), and maintained on a C57BL/6J 
background. Targeting was confirmed by the International Knockout Mouse Consortium. Mice 
were housed and handled according to Columbia University animal welfare guidelines. All 
procedures were approved by the Columbia University Institutional Animal Care and Use 
Committee (IACUC). 
Diet and Dietary Treatment 
Female Rpgrip1l+/− (n = 6) and control (Rpgrip1l+/+) littermates (n = 5) were fed regular 
chow (9% Kcal from fat; Picolab 5058; Purina Mills, USA) until 12 weeks of age. Male 
Rpgrip1l+/− (n = 10) and control (Rpgrip1l+/+) littermates (n = 6) were fed regular chow ad 
libitum until 18 weeks of age and switched to a HFD (65% of calories as fat; catalog number 
D12492; Open Source Diets) for 1 week. An additional five Rpgrip1l+/− and seven control 
(Rpgrip1l+/+) male mice were fed regular chow ad libitum until 13 weeks of age and their body 
weights measured at 8, 12, and 13 weeks of age. A second experimental group of male 
Rpgrip1l+/− (n = 6) and control (Rpgrip1l+/+) mice (n = 6) were fed regular chow ad libitum until 
4 weeks of age and then switched to the HFD for 1 week. After 2 days of ad libitum ingestion of 
the HFD, mice were fasted overnight for 10 hr in order to assure that both groups were identical 
with regard to metabolic and feeding status. Food was reintroduced, and serial intraperitoneal 
saline injections were performed in all mice to accustom them to handling. Nine hours after 
refeeding, mice were administered leptin (4 μg/g). This higher than customary (2 μg/g) dose was 
used in order to accentuate distinctions in behavioral responses between +/+ and +/− animals. 
Room temperature was constant at 23°C on a 12 hr light/12 hr dark cycle (lights were turned off 




Mice were weighed and their body composition determined before individually caged in 
a LabMaster-CaloSys-Calorimetry System (TSE Systems). Calorimetry was performed on the 
18-week-old Rpgrip1l+/− (n = 10) and control (Rpgrip1l+/+; n = 6) experimental groups for ∼72 hr 
while fed regular chow ad libitum, and then for another 3 days after the groups were switched to 
the HFD ad libitum. Calorimetry was also performed on the 3-week-old Rpgrip1l+/− (n = 6) and 
control (Rpgrip1l+/+; n = 6) groups for 1 week while being fed regular chow ad libitum, and then 
for another week after the groups were switched to the HFD ad libitum. Forty hours after they 
were switched to the HFD, mice were fasted overnight for 10 hr and administered saline 
intraperitoneally at 2, 4, and 6 hr after a 10 hr overnight fast, followed by intraperitoneal leptin 
administration (4 μg/g) at the start of the dark cycle. During this period, food intake and energy 
expenditure were automatically recorded every 26 min by the calorimeter. Mice were allowed to 
acclimate during the first ∼24 hr. Energy intake was calculated by multiplying cumulative food 
intake for a 24 hr period by the metabolizable energy present in the HFD (5.24 Kcal/g) and 
regular chow (3.56 Kcal/g). 
Body Mass and Composition Measurements 
Mice were weighed on an electronic scale. Body composition was determined by TD-
NMR using a Minispec Analyst AD lean fat analyzer (Bruker Optics, Silberstreifen Germany). 
The TD-NMR was calibrated using mouse carcasses that ranged from 5 to 70 g in mass 
(Halldorsdottir et al., 2009). 
Isolation of Total RNA and Nuclear Protein Extracts 
Total RNA was extracted and DNase treated using the RNeasy Lipid Tissue Mini Kit 
(QIAGEN, Gaithersburg, MD) according to the manufacturer’s instructions. Nuclear protein 
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extracts were isolated in the presence of Halt Protease and Phosphatase Inhibitor cocktail (Pierce, 
Rockford, IL) using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce) 
according to the manufacturer’s instructions. Total protein levels were measured using a 
Bradford Assay (Pierce).  
cDNA Synthesis 
cDNA synthesis from 1 μg of total RNA was performed utilizing the Transcriptor First 
Strand cDNA Synthesis Kit (Roche, Indianapolis, IN) with Oligo (dT)20 and Random Hexamer 
primer mix according to the manufacturer’s instructions. 
qPCR 
For expression analysis, a set of male mice were kept singly caged, fed regular chow till 
18 weeks of age, and thereafter fed either the HFD for 7 days (four Rpgrip1l+/− and four 
Rpgrip1l+/+ males) or fed the HFD for 6 days and fasted for 24 hr (four Rpgrip1l+/− and four 
Rpgrip1l+/+ males). Murine whole brains were placed on a dissection block, and the 
hypothalamus was dissected from the rostral border of the optic chiasm to the rostral border of 
the mammillary body. Fto and Rpgrip1l mRNA levels were measured by quantitative PCR as 
described elsewhere (Stratigopoulos et al., 2011). Similarly, quantitative PCR was performed to 
validate mRNA levels of Cdh9 (F-CATGGCTCAAACTCAGCTGCAA, R-
GCAGCTTAGTGTATGTCCCAG), Rbl2 (F-GGCCTGGAGCAGCTACCGCAG, R-
GATACATAGTTTCCTTCAGCGGT), Aktip (F-GCAGCGCAGTCAACAAACGGC, R-
CAGAGCGGTAAGATGGCTGTAC), Irx3 (F-CAATGTGCTTTCATCAGTGTACG, R-
GGATGCTGGACGCCAGGGCTGT), Irx5 (F-GCACGGATGAGCTCGGCCGCTC, R-
GGGTGATATCCCAAGGAACCTG), and Irx6 (F-CTCAGTATGAGTTCAAGGATGCTG, R-
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CTCCCTTGTGGCATTCTTCCTG) in the hypothalamus of Rpgrip1l+/− and Rpgrip1l+/+ 
littermates. mRNA levels were normalized as described elsewhere (Stratigopoulos et al., 2011). 
Antibodies 
Anti-RPGRIP1L (1:200; human and mouse; provided by Daniel Doherty) was used for 
determining Rpgrip1l protein levels in Rpgrip1l+/− mice by western blotting. Phospho-Stat3 
(Tyr705) antibody purchased from Cell Signaling Technology (1:1,000; catalog number 9131, 
Danvers, MA) was also utilized for western blotting. β-tubulin (1:2,000; catalog number 05-661; 
Millipore, Bedford MA) was used as an internal control. 
Analysis 
Data are expressed as mean ± SE. Statistical analysis was performed using Student’s t 
test (StatView 5.0, SAS Institute Inc.). Levels of statistical significance were set at two-tailed p 
alpha < 0.05. All error bars represent SEM. 
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(A) Genomic organization of the human FTO/RPGRIP1L interval on chromosome 16. SNPs 
rs8050136 and rs9939609 are associated with increased BMI. Figure not drawn to scale. (B) 
Targeted disruption of the murine Rpgrip1l allele. A cassette comprised of the promoterless 
LacZ gene and the promoter-driven Neomycin resistance (neo) gene separated by a loxP site and 
flanked by FRT sites. The LacZ gene is flanked by the Engrailed-2 exon-2 splice acceptor 
(En2SA) and an internal ribosome entry site (IRES) designed to integrate the LacZ cDNA 
with Rpgrip1l exon 4 resulting in premature transcriptional termination of the Rpgrip1l mRNA. 
Figure not drawn to scale. (C) Fto and Rpgrip1l transcript levels and Rpgrip1l protein levels 
assessed by western blotting and RT-PCR, respectively, in the hypothalamus of Rpgrip1l+/− (+/−) 
and Rpgrip1l+/+ (+/+) mice. Fto and Rpgrip1l mRNA levels were also assessed in subcutaneous 
(Subc) fat. Transcript levels of nearby genes Chd9, Rbl2, Aktip, Irx3, Irx5, and Irx6 were 









(A) Total body weight increased in male Rpgrip1l+/− versus Rpgrip1l+/+ mice fed regular 
chow (LFD) over an 18-week period. Total body weight (B and E), fat mass (C and F), 
and lean mass (D and G) increased in 18-week-old 
male Rpgrip1l+/− versus Rpgrip1l+/+mice fed LFD and a high-fat diet (HFD = 65% of 
calories as fat) respectively. (H) Increase in weight of various adipose tissue depots 
of Rpgrip1l+/− compared with Rpgrip1l+/+ mice after being fed regular chow for 18 weeks 
followed by the HFD for 7 days. Food intake (I and K) and body composition (J) of 
male Rpgrip1l+/− and Rpgrip1l+/+ mice fed LFD up to 4 weeks of age and subsequently 




Figure 2.3 Energy expenditure, food intake, blood glucose and serum leptin concentrations in 





(A) Total body weight is higher in 10-week old female Rpgrip1l+/- compared with Rpgrip1l+/+ 
mice fed regular chow (LFD). (B) Energy intake during the light cycle of 19-week old male 
Rpgrip1l+/- and Rpgrip1l+/+ mice having been fed a high fat diet (HFD = 65% of calories as fat) 
for 3 days. Energy expenditure (C) and total movement counts (D) of 19-week old male 
Rpgrip1l+/- and Rpgrip1l+/+ mice having been fed HFD for 3 days. Serum leptin concentration 
(E) and serum leptin adjusted for fat mass (F) of Rpgrip1l+/- and Rpgrip1l+/+ mice having been 
fed the high-fat diet for 7 days before they were sacrificed. (G) Blood glucose concentrations of 
19-week old male mice fed HFD for 7 days, or fed HFD for 6 days and subsequently fasted for 
24h. Energy expenditure (H, J) and total movement counts (I, K) of 4-week old and 5-week old 
male Rpgrip1l+/- and Rpgrip1l+/+ mice fed regular chow (LFD) or HFD for one week, 




Chapter 3 The role of Rpgrip1l (a component of the primary cilium) in adipocyte 
development  
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Abstract 
Single nucleotide polymorphisms (SNPs) in the first intron of FTO have been strongly 
associated with a modest increase in adiposity and a 1.2 and 1.3-fold risk of overweight or 
obesity, respectively. We have previously demonstrated that two of these SNPs, rs8050136 and 
rs1421085, are binding sites for the transcriptional regulator CUX1, with the activating isoform 
(p110) preferentially binding to the protective alleles of these SNPs, thereby increasing 
expression of both FTO and RPGRIP1L. FTO encodes an RNA m6A demethylase; RPGRIP1L 
encodes a protein critical to the formation and function of the primary cilium. Rpgrip1l+/- mice 
exhibit increased adiposity, in part due to hyperphagia. Here, we describe effects of Rpgrip1l in 
adipocytes which may contribute to the adiposity phenotype observed in these animals, and 
possibly humans. Loss of Rpgrip1l in 3T3-L1 preadipocytes increased the number of cells 
capable of differentiating into mature adipocytes. Knockout of Rpgrip1l in mature adipocytes 
49 
 
(using Adipoq-Cre) did not increase adiposity in mice fed chow or high fat diet. Neither did we 
observe any effects of Rpgrip1l knockdown in mature 3T3-L1 adipocytes. Thus, to the extent 
that Rpgrip1l affects cell-autonomous adipose tissue function, it may do so by effects conveyed 
in preadipocytes, a cell type in which the primary cilium may have functional importance. We 
propose that decreased RPGRIP1L expression in preadipocytes in humans segregating for 
obesity risk alleles may increase the potential storage capacity of adipose tissue for the 




The strongest genetic signal associated with increased adiposity in large groups of 
humans is located within the first intron of FTO (16q12.2). Originally identified by GWAS in 
2007, SNPs within a 47-kb region of linkage disequilibrium are associated with a ~0.36 kg/m2 
increase in BMI (per risk allele), corresponding to a ~1.2 kg increase in body weight in adults 
(Dina, Meyre et al. 2007, Frayling, Timpson et al. 2007, Scuteri, Sanna et al. 2007). The genetic 
mechanism(s) for this association are unclear; the primary proximal phenotypic effect is 
increased food intake (Berentzen, Kring et al. 2008, Cecil, Tavendale et al. 2008, Speakman, 
Rance et al. 2008, Timpson, Emmett et al. 2008). Studies of loss- and gain-of-function 
manipulations of Fto per se in mice have found conflicting results on adiposity (Church, Lee et 
al. 2009, Fischer, Koch et al. 2009, Gao, Shin et al. 2010, McMurray, Church et al. 2013). The 
effects of the obesity-associated intronic variants on vicinal genes have implicated IRX3 and 
IRX5, by mechanisms that include decreased energy expenditure due to impaired “browning” of 
adipose tissue, which drives thermogenesis due to oxidative phosphorylation uncoupling 
(Smemo, Tena et al. 2014, Claussnitzer, Dankel et al. 2015).  
RPGRIP1L, the transcriptional start for which is ~100 bases 5’ of FTO, in the opposite 
orientation, has been studied by us for its roles in hypothalamic control of energy homeostasis. 
We have previously demonstrated that risk alleles rs8050136 and rs1421085 within intron 1 of 
FTO are binding sites for isoforms of the transcription factor CUX1 and thereby regulate the 
expression of both FTO and RPGRIP1L (Stratigopoulos, Padilla et al. 2008, Stratigopoulos, 
LeDuc et al. 2011, Stratigopoulos, Burnett et al. 2016). Rpgrip1l is a component of the transition 
zone of the primary cilium (Vierkotten, Dildrop et al. 2007). The primary cilium, functioning as 
a cellular antenna, plays a key role in coordinating a wide range of signal transduction systems, 
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including those related to body weight homeostasis (Mariman, Vink et al. 2016, Vaisse, Reiter et 
al. 2017). Mice heterozygous for a null Rpgrip1l allele are hyperphagic and obese 
(Stratigopoulos, Martin Carli et al. 2014, Stratigopoulos, Burnett et al. 2016). Rpgrip1l functions 
to congregate and assemble two modules of the transition zone of the primary cilium: the Meckel 
Syndrome (MKS) module and the nephronophthisis (NPHP) module. The transition zone then 
functions as a “ciliary gate” regulating the compartmentalization of ciliary proteins, restraining 
them to the ciliary axoneme (Williams, Li et al. 2011, Jensen, Li et al. 2015).  
The increased adiposity we observed in Rpgrip1l+/- mice was associated with reduced 
hypothalamic sensitivity to leptin effects on Stat3 signaling and food intake. We hypothesized 
that there might be additional primary effects of Rpgrip1l hypomorphism affecting adipogenesis 
and/or the regulation of adipocyte secretion of molecules such as leptin. We found that loss of 
Rpgrip1l in 3T3-L1 preadipocytes enhanced the differentiation capacity of these cells. In vivo, 
this effect could contribute to the obesity of Rpgrip1l+/- mice by increasing the compliant 






Cell culture and gene knockdown 
3T3-L1 preadipocytes were purchased from ATCC and maintained in culture without 
achieving confluence. Growth medium consisted of DMEM (with 25mM glucose, GlutaMAX™, 
and sodium pyruvate) supplemented with 10% newborn calf serum (both Thermo Fisher). To 
amplify the magnitude of the increased adipogenesis seen in the Rpgrip1l knockdown condition, 
we limited differentiation by treating cells with differentiation media containing DMEM plus 
insulin (from Bovine Pancreas 1 μg/ml), dexamethasone (0.25 μM) and isobutylmethylxanthine 
(IBMX; 0.5mM; all Sigma-Aldrich) supplemented with 10% fetal bovine serum (Thermo Fisher) 
as soon as cells reached confluence. Two days later, differentiation media was replaced with 
maintenance media (DMEM containing only 1 μg/ml insulin and 10% FBS). Maintenance media 
was replaced every two to three days and cells filled with lipid by days 6-12; at which point we 
refer to them as “mature adipocytes”. We observed lot-to-lot variability in the differentiation 
capacity of 3T3-L1 cells, with a diminished, but still appreciable, increase in adipogenesis after 
Rpgrip1l knockdown in better differentiating lots. Experiments reported here were performed on 
a lot with moderate differentiation potential to more effectively interrogate the phenotype. 
Using either Lipofectamine 2000 or 3000 (Thermo Fisher) 3T3-L1 cells were transfected 
prior to differentiation with a mix of 3 Stealth siRNAs (Thermo Fisher) targeted either to 
Rpgrip1l or non-targeted controls. Mature 3T3-L1 adipocytes were electroporated with the same 
non-targeted control or Rpgrip1l siRNAs using a Bio-Rad GenePulser II (Jiang, Zhou et al. 2003, 
Okada, Mori et al. 2003). 
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RNA isolation and quantification  
RNA was isolated using the RNeasy lipid tissue kit including DNase treatment of 
columns (Qiagen) and reverse transcribed using Transcriptor First Strand cDNA Synthesis Kit 
(Roche) using both OligoDT and random hexamer primers. Quantitative PCR (qPCR) was 
performed on a Lightcycler 480 using SYBR Green I Master (Roche). Expression was 
determined by the Lightcycler 480 software (Roche) using the 2nd derivative max calculation 
based on a standard curve. Transcript levels were normalized to 36B4 when comparing a single 
cell type or tissue, or to the mean of Actb, Gapdh and Ppia when multiple tissues or cell types 
were compared. Primers were designed using Primer 3: http://bioinfo.ut.ee/primer3/ to span 
exon-exon junctions.  
36B4 (Rplp0): F:ACCTCCTTCTTCCAGGCTTTGG, R:CGAAGGAGAAGGGGGAGATGTT;  
ActB: F:CGGGCTGTATTCCCCTCCAT, R:GGGCCTCGTCACCCACATAG;  
Gapdh: F:CTGGAGAAACCTGCCAAGTATGATG, R:GAGACAACCTGGTCCTCAGTGTAGC;  
Ppia: F:CTTCGAGCTGTTTGCAGACAAAGTT, R:GGAGGAACCCTTATAGCCAAATCCT;  
Rpgrip1l ex4F:CCAAACAGCAGCTCCAAGTCCAGGG,  
ex5R:GAGCGTGGGTTGTACAGTTTCTGCTTC;  
Rpgrip1l: ex21F:TGCCTCAGGAAGTGTGGCTTC,  
ex22R:TCATCACTGTCTGAAGCTGATCTGTC;  
Glut4: F:AGCTGTGCTTGGCTCCCTTC, R:CCCAGCCACGTTGCATTGTA;  
Fabp4: F:TTGGTCACCATCCGGTCAGA, R:TCCACCACCAGCTTGTCACC;  
Plin1: F:GTGTACAGGGTGCCAGCAA, R:CTCTGCAGGCCAACTCATTG;  
Lep: F:CGAGGAATCGTTCTGCAAATCC, R:GCCAGGTTAAGTGCAGCTATCACA;  
Adipoq: F:CAGGCCGTGATGGCAGAGAT, R:GTGGCCCTTCAGCTCCTGTC;  
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Pparg2: F:TTTGAAAGAAGCGGTGAACCA, R:CGAAGTTGGTGGGCCAGAAT  
Cebpa: F:GCCATGCCGGGAGAACTCTA, R:GGGCTCTGGAGGTGACTGCT  
Lpl: F:CCACAGCAGCAAGACCTTCG, R:TACAGGGCGGCCACAAGTTT 
Shh: F:GGAGCAGACCGGCTGATGAC, R:TCGGTCACTCGCAGCTTCAC;  
Ptch1: F:ATCTCGAGACCAACGTGGAG, R:GCCTCTTCTCCTATCTTCTGACG;  
Gata2: F:ATCTCGACTCGCAGGGCAAC, R:AGTGTGGTCGGCACATCTGG;  
Gata3: F:CAGGGCTACGGTGCAGAGGT, R:GGTGGCTGCTCAGGGCTTT;  
Gli1: F:TGGTACCATGAGCCCTTCTT, R:GTGGTACACAGGGCTGGACT;  
Gli3: F:CCTTACCGTGGGACTGTGTT, R:ATGGAAGGCAGGGAAAAGAT;  
Lef1: F:CCAATATGAACAGCGACCCG, R:GGAGTTGACATCTGACGGGA;  
Ctnnb1: F:CTTTTCCCAGTCCTTCACGC, R:ATGCCCTCATCTAGCGTCTC 
Protein quantification 
Leptin and Adiponectin ELISAs were performed using kits from R&D Systems. Cell 
culture supernatants from mature adipocytes were removed 3 days after media had been changed. 
Samples (from 12 well plates) were diluted 1:20 for Leptin ELISA and 1:1,000 for Adiponectin 
ELISA.  
Lipid staining 
Oil Red O staining was performed on mature adipocytes fixed with 4% paraformaldehyde 
for 10 minutes. A stock solution of 25mg Oil Red O (Sigma) in 50ml isopropanol was freshly 
mixed with water at a 3:2 ORO:H2O ratio. This solution was filtered and cells were stained for 
30 mins. Following a PBS wash, cells were imaged and Oil Red O was extracted in 300µl of 
isopropanol with 4% IGEPAL CA-630 for 5 mins (Sigma). 100µl were taken to measure 
absorbance at 490nm (Church, Berry et al. 2014). The Nile Red staining protocol was adapted 
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from Smyth et al (Smyth and Wharton 1992). In brief, mature adipocytes were trypsinized, fixed 
for 10 minutes with 4% paraformaldehyde and stained with Nile Red at a final concentration of 
500ng/µl (Thermo-Fisher). We added equal volumes of 8.0-12.9 µm counting beads (2.5x104 per 
condition; Spherotech) prior to acquisition by flow cytometry using the PE-TR channel to 
measure Nile Red fluorescence.  
Mice 
Mice were housed and handled according to guidelines established by Columbia 
University and protocols were approved by Columbia University Institutional Animal Care and 
Use Committee (IACUC). Room temperature was maintained at 23°C ±1°C with a 12 hr light 
(beginning at 7AM)/12 hr dark cycle. Animals had ad libitum access to food and water. Mice 
were fed either regular chow (Purina #5058) or high fat diet (HFD; 60% of calories from fat; 
Research Diets #D12492i) as indicated. Mice were weighed weekly and body weight 
composition was obtained by TD-NMR with a Minispec Analyst AD analyzer (Bruker Optics).  
Mice segregating for a Rpgrip1l “knockout-first” allele containing an IRES:lacZ trapping 
cassette and a floxed promoter-driven neo cassette (Rpgrip1ltm1a(EUCOMM)Wtsi; International 
Knockout Mouse Consortium; (Skarnes, Rosen et al. 2011, Stratigopoulos, Martin Carli et al. 
2014)) were crossed with Flp deleter mice (C57BL/6-Tg(CAG-Flpe)2Arte; Taconic) segregating 
for the Flp recombinase allele under the control of the β-actin promoter to excise the lacZ and 
neo cassettes and restore gene activity (Rpgrip1ltm1c(EUCOMM)Wtsi referred to here as “Rpgrip1lfl/fl”) 
while retaining LoxP sites surrounding exon 5. Rpgrip1lfl/fl mice were then crossed to Adipoq-
Cre mice (B6;FVB-Tg(Adipoq-cre)1Evdr/J; Jackson) to generate Rpgrip1ltm1d(EUCOMM)Wtsi 
(Rpgrip1l+/fl;Adipoq-Cre) mice and their offspring were intercrossed to obtain 
Rpgrip1lfl/fl;Adipoq-Cre, Rpgrip1l+/fl;Adipoq-Cre and Rpgrip1l+/+;Adipoq-Cre mice. Exon 5 of 
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Rpgrip1l was deleted in only the adipose tissue of Rpgrip1lfl/fl;Adipoq-Cre mice, causing a 
frameshift mutation triggering nonsense mediated decay of any remaining transcript (Skarnes, 
Rosen et al. 2011). We also generated Rpgrip1lfl/fl;Adipoq-Cre and Rpgrip1lfl/fl littermates by 
crossing Rpgrip1lfl/fl;Adipoq-CreCre/+ and Rpgrip1lfl/fl mice. 
We compared either Rpgrip1lfl/fl;Adipoq-Cre or Rpgrip1lfl/+;Adipoq-Cre mice to 
Rpgrip1l+/+;Adipoq-Cre mice for the chow feeding study. Rpgrip1lfl/fl;Adipoq-Cre mice were 
compared to Rpgrip1lfl/fl mice without Adipoq-Cre in the HFD feeding study. Genotyping was 
performed as in (Stratigopoulos, Martin Carli et al. 2014) without the internal Neo primer. Using 
Rpgrip1l forward primer (GTCTTGGACAGATCTTGGTCCAGTCTCC; upstream of the LoxP 
site and exon 5) and reverse primer (GTGGGTTGTACAGTTTCTGCTTCATCCAC; located 
within exon 5), we generated a band of 1407 bases indicating the wild type Rpgrip1l allele. A 







Rpgrip1l knockdown enhances adipogenesis  
To assess possible cell autonomous effects of systemic inactivation of Rpgrip1l on 
adipose tissue development, we knocked down Rpgrip1l (Fig. 3.1A) in 3T3-L1 preadipocytes 
using siRNA. Knockdown persisted throughout differentiation, and in mature adipocytes was 
still decreased by 60%. Lipid accumulation per well was increased in the Rpgrip1l-knockdown 
condition (Oil Red O; Fig. 3.1B&C). A partial differentiation protocol was employed, limiting 
the time that 3T3-L1 cells spent at confluence prior to differentiation, increased the magnitude of 
the difference between the Rpgrip1l and control knockdown. To identify whether this increase in 
lipid accumulation was due to increased efficiency of differentiation, the amount of lipid per cell, 
or both, we performed flow cytometry on Nile Red stained cells. The observed increase in lipid 
was attributable mainly to an increase in the percentage of cells containing lipid (Fig. 3.1D), 
although there was a trend toward an increase in the amount of lipid per adipocyte (Fig. 3.1E; 
p=0.12) in Rpgrip1l knockdown cells. Additionally, we observed an increase in the total number 
of live cells following Rpgrip1l knockdown, suggesting that Rpgrip1l limits cell survival and/or 
proliferation (Fig. 3.1F). Rpgrip1l-knockdown adipocytes exhibited increased expression of 
genes involved in glucose uptake (Glut4), lipid uptake (Fabp4, Lpl) and storage (Plin1), as well 
as adipokines (Lep, Adipoq). We also observed increased expression of developmental regulators 
of adipogenesis, Pparg2 & Cebpa (Fig. 3.1G), indicating that differentiation itself as well as 
functional regulators of adipocyte biology are enhanced by Rpgrip1l knockdown. 
Rpgrip1l has been previously reported to modulate the sonic hedgehog (Shh) signaling 
pathway (Vierkotten, Dildrop et al. 2007), a known inhibitor of adipogenesis (Spinella-Jaegle, 
Rawadi et al. 2001, Suh, Gao et al. 2006, Fontaine, Cousin et al. 2008). We observed decreased 
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expression of Shh target genes in Rpgrip1l-knockdown mature adipocytes; however, we also 
observed decreased expression of Shh itself (Fig. 3.1H), indicating that Rpgrip1l may not 
directly regulate Shh signaling. The effect of Rpgrip1l knockdown on Shh targets may be a 
consequence of increased adipogenesis per se with a secondary decrease in Shh expression 
(James, Leucht et al. 2010). Consistent with this inference is the fact that after Rpgrip1l 
knockdown, neither Shh or Shh target genes are changed in either confluent preadipocytes (Fig. 
3.1I) or preadipocytes that have been treated with differentiation media for two days (Fig. 3.1J).  
To examine whether suppression of Rpgrip1l was sufficient to induce adipogenesis on its 
own, we knocked down Rpgrip1l expression in preconfluent 3T3-L1 preadipocytes and 
measured adipogenesis in cells 9 days after they reached confluence. Rpgrip1l knockdown 
persisted (-26%; Fig. 3.2A) for this length of time, but we did not see any evidence of 
adipogenesis in the siRpgrip1l condition (Oil Red O: Fig. 3.2B&C; Nile Red staining: Fig. 3.2D; 
qPCR of adipocyte markers: Fig. 3.2E) in the absence of chemically induced differentiation. 
Rpgrip1l knockdown does not affect production or secretion by adipocytes of factors 
regulating food intake 
Rpgrip1l hypomorphic mice are obese, due primarily to hyperphagia resulting from 
impaired hypothalamic leptin sensitivity (Stratigopoulos, Martin Carli et al. 2014). We measured 
leptin (Fig. 3.3A) and adiponectin (Fig. 3.3B) secretion (by ELISA) by mature 3T3-L1 
adipocytes transfected with anti-Rpgrip1l siRNA prior to differentiation. Although we observed 
increased secretion of both of these hormones in the Rpgrip1l knockdown condition, when 
normalized to the number of adipocytes in each condition (measured by Nile Red staining 
detected by flow cytometry; Fig. 3.3C), there was no change in the production of these hormones 
per cell (Fig. 3.3D&E). 
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Adipocyte-specific knockout of Rpgrip1l does not alter body weight in mice. 
To determine whether the increased lipid filling capacity observed in Rpgrip1l-
knockdown adipocytes contributed to the adiposity phenotype previously observed in systemic, 
congenital Rpgrip1l heterozygotes, we generated adipocyte-specific Rpgrip1l knockout mice 
(Rpgrip1lfl/fl;Adipoq-Cre) which we compared to either to Rpgrip1l+/+;Adipoq-Cre or Rpgrip1lfl/fl 
controls.  
Rpgrip1l transcript was decreased in subcutaneous and perigonadal adipose depots of 
male (Fig. 3.4A; SCAT: -69%, PGAT: -67%) Rpgrip1lfl/fl;Adipoq-Cre mice compared to 
Rpgrip1lfl/fl controls. Additionally, Rpgrip1l expression was decreased or trended toward a 
decrease in perirenal and mesenteric adipose depots, respectively. Rpgrip1l expression was 
decreased similarly in female mice (data not shown). Adipose tissue contains diverse cell types, 
so we separated the stromal vascular and adipocyte fractions in male SCAT. We detected Cre 
transcript only in the adipocyte fraction (Fig. 3.4B); and this fraction had a greater decrease in 
Rpgrip1l expression (SCAT: -83%, PGAT: -63%) than whole tissue (SCAT: -67%, PGAT: -
28%) (Fig. 3.4C). There was no change in Rpgrip1l expression in the preadipocyte-containing 
stromal vascular fraction.  
To ensure that the decrease in expression of Rpgrip1l was due to excision of the Rpgrip1l 
allele, rather than to an off-target effect of the Adipoq-Cre allele, we quantified expression of 
Rpgrip1l in PGAT of male Rpgrip1lfl/fl;Adipoq-Cre, Rpgrip1lfl/+;Adipoq-Cre and 
Rpgrip1l+/+;Adipoq-Cre mice and found that the homozygous and heterozygous Rpgrip1l-floxed 
animals exhibited dose-response related decreases in Rpgrip1l expression (Fig. 3.5A). 
Additionally, as the aforementioned measurements utilized primers detecting the exon 4-5 
junction of Rpgrip1l, which is disrupted by Cre recombinase activity, we verified that levels of 
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Rpgrip1l transcript downstream of the Cre recombination site were also decreased in 
Rpgrip1lfl/fl;Adipoq-Cre animals compared to Rpgrip1l+/+;Adipoq-Cre controls (Fig. 3.5B). The 
Adipoq-Cre mouse used to generate this loss-of-function allele of Rpgrip1l is highly specific to 
adipose tissue (Eguchi, Wang et al. 2011, Lee, Russell et al. 2013), consistent with our 
observation that in non-adipose tissues there was no difference in Rpgrip1l expression in 
Rpgrip1lfl/fl;Adipoq-Cre animals compared with Rpgrip1l+/+;Adipoq-Cre controls (Fig. 3.5C).  
We monitored the body weight of these animals until they reached 23 weeks of age. 
During this period, the Rpgrip1lfl/fl;Adipoq-Cre and Rpgrip1l+/fl;Adipoq-Cre mice did not exhibit 
any difference in weight gain compared to their Rpgrip1l+/+;Adipoq-Cre littermates (Fig. 3.6A). 
At 12 weeks, we analyzed body composition, and did not detect any differences in either fat 
mass (Fig. 3.6B) or lean mass (Fig. 3.6C). We considered the possibility that Rpgrip1l may not 
affect body weight unless the animals are over-fed. We fed another cohort of mice a high fat 
(60% calories as fat) diet for 17 weeks. We did not observe any differences in body weight, body 
composition, plasma glucose or leptin concentrations between Rpgrip1lfl/fl;Adipoq-Cre mice and 
Rpgrip1lfl/fl controls (Fig. 3.7A-E). The regression lines relating circulating leptin concentration 
to fat mass were not different (Fig. 3.7F), indicating that hypomorphism for Rpgrip1l in 
adipocytes did not affect production/release of leptin.  
Knockdown of Rpgrip1l in mature 3T3-L1 adipocytes does not alter lipid content.  
As the Adipoq-Cre driver is not turned on until after well after preadipocytes have started 
to undergo adipogenesis, it is possible that the Rpgrip1lfl/fl;Adipoq-Cre model did not alter 
Rpgrip1l expression until after its physiologically relevant effects on adipogenesis had occurred. 
We attempted to model this possibility by knocking down (-54%) Rpgrip1l in fully mature 
adipocytes (Fig. 3.8A) and observed no difference in lipid content quantified by Oil Red O (Fig. 
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3.8B&C) or Nile Red staining (Fig. 3.8D&E) in the Rpgrip1l-knockdown condition. 
Additionally, we did not see any differences in mRNA expression of adipocyte developmental 
(Pparg and Cebpa) and functional genes (Glut4, Fabp4, Plin1, Lpl, Lep, Adipoq) after Rpgrip1l 






We have shown previously that RPGRIP1L expression is decreased in iPSC-derived 
neurons of humans segregating for obesity-risk alleles in intron 1 of FTO (Stratigopoulos, 
Burnett et al. 2016). Two of the obesity-associated SNPs (rs8050136 and rs1421085) in this 
interval are binding sites for the transcriptional regulator CUX1. Specifically, the risk alleles of 
these two SNPs exhibit decreased in vitro binding of an activating isoform of CUX1 (p110), 
decreasing expression of both RPGRIP1L and FTO by their minimal promoters in N2a murine 
neuroblastoma cells (Stratigopoulos, LeDuc et al. 2011, Stratigopoulos, Burnett et al. 2016). 
Rpgrip1l+/- mice are hyperphagic and obese (Stratigopoulos, Martin Carli et al. 2014). Here, we 
tested whether a decrease in Rpgrip1l expression had any direct, cell-autonomous effect on 
adipocyte development and function that might contribute to the increased adiposity of 
Rpgrip1l+/- mice. 
We identified an effect of Rpgrip1l knockdown on adipogenesis in 3T3-L1 cells, to 
enhance differentiation and proliferation via a combination of reciprocal effects on expression of 
pro- and anti-adipogenic factors. However, congenital adipocyte-specific loss of Rpgrip1l did not 
alter body weight or adiposity in mice. The absence of an effect under these latter circumstances 
suggests that the function of Rpgrip1l in adipogenesis precedes the expression of the Adipoq-Cre 
recombinase in this model (discussed further below). Consistent with this possibility, knockdown 
of Rpgrip1l in mature adipocytes in vitro does not cause detectable change in lipid content or 
expression of adipocyte developmental or functional genes.  
The primary cilium, developing from the mother centriole in quiescent cells, is an 
organelle present in almost all mammalian cell types which coordinates cellular development and 
environmental interactions (Satir and Christensen 2007). The role of RPGRIP1L in the assembly 
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of the primary cilium’s transition zone qualifies it to regulate differentiation of a wide variety of 
cell types (Williams, Li et al. 2011, Jensen, Li et al. 2015) as the transition zone participates in 
compartmentalization of specific signal transduction proteins such as Shh, Wnt and Pdgfrα 
signaling components within the ciliary membrane (Goetz and Anderson 2010, Li, Jensen et al. 
2016). Mice homozygous for a null allele of Rpgrip1l die embryonically with craniofacial and 
neural tube defects as well as deranged left-right asymmetry (Vierkotten, Dildrop et al. 2007). 
Humans homozygous for null alleles of RPGRIP1L present with either Joubert syndrome, a 
developmental disorder with mid-hindbrain malformation, as well as renal and hepatic defects 
(Arts, Doherty et al. 2007), or Meckel syndrome, an autosomal recessive lethal syndrome also 
characterized by CNS malformations that typically include occipital encephalocele (Delous, 
Baala et al. 2007). Obesity has not been described in patients with these syndromes. However, 
the resultant severe systemic consequences are sufficiently severe to mask effects on adiposity. It 
may be informative to evaluate adiposity in the obligate heterozygous parents of these 
individuals.  
“Ciliopathies” comprise a genetically heterogeneous class of disorders characterized by 
mutations in genes encoding over 40 proteins that contribute to the establishment and/or function 
of the primary cilium (Mariman, Vink et al. 2016). Phenotypes shared among members of this 
class of disorders include renal and retinal dysfunction as well as developmental malformations 
such as polydactyly and defects of the CNS. Some ciliopathies (i.e. Bardet-Biedl Syndrome and 
Alström Syndrome) also present with co-morbid obesity (Mariman, Vink et al. 2016, Vaisse, 
Reiter et al. 2017). Hyperphagia – presumably of hypothalamic origin – is a primary contributor 
to the obesity of these individuals (Sherafat-Kazemzadeh, Ivey et al. 2013); primary 
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developmental changes in adipose tissue development and/or function have also been implicated 
(Marion, Mockel et al. 2012).  
Bardet-Biedl Syndrome (BBS) is one such ciliopathy, caused by mutations in at least 20 
genes, several of which encode proteins that form a complex known as the BBSome (Nachury, 
Loktev et al. 2007). This complex regulates intraflagellar trafficking of ciliary structural 
components as well as receptors conveying signals mediating food intake (e.g. Sstr3 and Mchr1) 
(Berbari, Lewis et al. 2008, Jin, White et al. 2010). Loss of BBSome components decreases 
leptin sensitivity in mice, possibly due to impaired leptin receptor (LepR) trafficking to the trans-
Golgi network (Rahmouni, Fath et al. 2008, Seo, Guo et al. 2009). We have shown that 
congenital absence of Rpgrip1l also causes decreased leptin sensitivity, due to impaired LepR 
trafficking in relation to the primary cilium (Stratigopoulos, Martin Carli et al. 2014). Knockout 
of Rpgrip1l in POMC- or LepR-expressing neurons partially phenocopies the increased body 
weight seen in the Rpgrip1l hypomorph (Stratigopoulos, Burnett et al. 2016). However, it is 
possible that decreased leptin sensitivity in mice null for Bbs genes is secondary to their 
increased adiposity, as leptin concentrations and signaling are normal in Bbs4-/- mice prior to the 
onset of obesity (Berbari, Pasek et al. 2013).  
Knockdown of BBSome proteins increases adipogenesis in human mesenchymal stem 
cells and murine 3T3-F442A cells (Marion, Mockel et al. 2012, Aksanov, Green et al. 2014), 
suggesting that disruption of the BBSome could convey primary effects on adipogenesis in 
addition to CNS-mediated effects on food intake. Adipose tissue develops in a temporally 
coordinated manner, with the subcutaneous depot developing prenatally in both humans and 
mice, followed by the visceral gonadal depot developing shortly after birth (Poissonnet, Burdi et 
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al. 1984, Siegel, Hildebolt et al. 2007, Spalding, Arner et al. 2008, De Lucia Rolfe, Modi et al. 
2013, Wang, Tao et al. 2013, Kim, Lun et al. 2014).  
White adipocytes derive from mesenchymal stem cells that form adipocyte precursors 
before committing to becoming preadipocytes (Rosen and Spiegelman 2014). Adipocyte number 
is established during childhood and adolescence, and adipose tissue expands initially by 
adipocyte filling (hypertrophy) followed by recruitment, proliferation and differentiation of 
preadipocytes (hyperplasia). Adipose tissue cellularity then remains relatively constant 
throughout adulthood. Obese individuals have larger numbers of adipocytes from an early age 
(Knittle, Timmers et al. 1979, Spalding, Arner et al. 2008). In mice, diet-induced expansion of 
adipose tissue occurs initially by hypertrophy, followed by hyperplasia. In mice, adipocyte cell 
death is linked with hyperplasia of new adipocytes, and in males, this occurs primarily in the 
epididymal depot (Strissel, Stancheva et al. 2007, Wang, Tao et al. 2013, Kim, Lun et al. 2014). 
Diet-induced adipose tissue expansion in humans also begins with hypertrophy followed by 
hyperplasia (Hirsch and Batchelor 1976). Increased age is associated with diminished capacity 
for adipocyte turnover and this reduction in adipose tissue storage capacity can lead, in turn, to 
insulin resistance due to ectopic lipid deposition in liver and muscle (Heilbronn, Smith et al. 
2004, Kim, Lun et al. 2014, Guillermier, Fazeli et al. 2017). Developmental and “obesogenic” 
adipogenesis, or that induced by positive energy balance, appear to be regulated distinctly with 
the latter dependent on the PI3K-Akt2 pathway (Jeffery, Church et al. 2015). It is unclear 
whether Rpgrip1l differentially inhibits these two pathways. 
Are there cell autonomous contributions by adipocytes to the establishment of body 
weight? or does CNS regulation of energy intake or energy expenditure entirely drive adiposity? 
Liebelt et al. described transplantation of adipose tissue from 5-day old "obese" (NH strain) or 
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"lean" (DBA/2 strain) onto the ears of hybrid NH-DBA/2 mice. After 90 days, the NH grafts 
were significantly larger (~30%) than the DBA/2 grafts (Liebelt 1963), indicating that there may 
be adipose-intrinsic control of adipose depot size. It is reasonable to expect that adipose tissue-
cell autonomous limitations on hyperplasia might contribute to an upper limit of somatic fat gain. 
In Akt2-/-;Lepob/ob mice in which adipocyte progenitor proliferation is impaired, fat gain is limited 
(Jeffery, Church et al. 2015). Conversely, Lepob/ob mice which constitutively overexpress 
adiponectin develop massive obesity with extreme adipose hyperplasia compared to their Lepob/ob 
littermates (Kim, van de Wall et al. 2007), suggesting that promoting the development of 
increased numbers of adipocytes can facilitate the storage of body fat. None of these experiments 
has focused explicitly on the developmental biology of the preadipocyte, however, which would 
determine whether differentiation potential of the preadipocyte itself is responsible for the 
consequences of these genetic manipulation on body fat. These critical questions highlight the 
necessity of access to genetic tools with which preadipocyte development can be manipulated. 
Preadipocyte genes such as Pparg2, Pdgfra and Prx1 are attractive candidates for promoters as 
Cre drivers; however, none of these genes are specific to preadipocytes, confounding efforts to 
isolate preadipocyte-autonomous roles in the control of body fat stores (Berry, Jeffery et al. 
2014, Krueger, Costa et al. 2014).  
The molecular physiology governing how restrictive or expansive adipose tissue 
geometry affects overall adiposity is not completely understood. The brain is the ultimate 
regulator of food intake, but adipose tissue that expands readily might prevent inhibitory 
feedback, leading to facilitated accommodation of increased food intake (Ravussin, Leibel et al. 
2014, Zhang and Leibel 2017). If the Rpgrip1l knockdown-induced effect on adipogenesis does 
contribute to the whole-body adiposity of Rpgrip1+/- mice, we hypothesized that one way that 
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adipocytes per se might influence food intake is via dysregulated production of appetite-
regulating factors, such as leptin and/or adiponectin. We observed increased expression of both 
of these hormones in 3T3-L1 adipocytes after Rpgrip1l knockdown prior to differentiation, but 
when normalized to the increased number of adipocytes observed, there was no change in 
production on a per cell basis. 
As a driver of Hh signaling (Vierkotten, Dildrop et al. 2007), Rpgrip1l might be expected 
to limit adipogenesis, as Hh has previously been demonstrated to inhibit adipogenesis in both 
rodent and human mesenchymal cells (Spinella-Jaegle, Rawadi et al. 2001, Suh, Gao et al. 2006, 
Fontaine, Cousin et al. 2008). Hedgehog signaling maintains 3T3-L1 cells in a preadipocyte 
state, and is decreased as they differentiate into adipocytes (Suh, Gao et al. 2006). Inhibition of 
this pathway alone, however, is not sufficient to induce adipogenesis in 3T3-L1 preadipocytes 
(Cousin, Dani et al. 2006), a finding consistent with what we have observed in Rpgrip1l-KD 
preadipocytes cultured without differentiation factors. Additionally, while we did observe 
decreased expression of Shh targets in mature adipocytes after Rpgrip1l knockdown, Shh itself 
was decreased. The reduction of Shh target gene expression may be a secondary effect of the 
increased adipogenesis seen in these cells, as Shh production is decreased after adipogenesis 
(James, Leucht et al. 2010).  
Other signaling molecules known to regulate adipogenesis – such as PdgfRα, Igf1R and 
Wnt effectors – localize to the ciliary membrane upon growth arrest and ciliogenesis/ciliary 
elongation (Schneider, Clement et al. 2005, Marion, Stoetzel et al. 2009, Zhu, Shi et al. 2009, 
May-Simera and Kelley 2012, Dalbay, Thorpe et al. 2015, Sun, Berry et al. 2017). There is 
extensive crosstalk among pathways mediated by these molecules (Christensen, Morthorst et al. 
2017), and evidence that Rpgrip1l may participate in some of this coordination (Mahuzier, 
68 
 
Gaude et al. 2012, Gerhardt, Lier et al. 2013). Recently, an ortholog of Rpgrip1l in C. elegans, 
Mks5, has been shown to establish a “ciliary zone of exclusion” which limits 
phosphatidylinositol 4,5-bisphosphate (PIP2) localization in the ciliary membrane, thereby 
forming a “lipid gate” restricting access of membrane-bound proteins to the ciliary compartment. 
Additionally, Mks5 mutants exhibited dysregulated intraflagellar transport (IFT) velocity 
(Jensen, Li et al. 2015). Collectively, these findings suggest a critical role for Rpgrip1l in cell 
fate commitment.  
Cilia are present on confluent, non-dividing human preadipocytes in vitro, and 
dexamethasone treatment elicits ciliary elongation in the first few days of differentiation, 
concurrent with inhibition of Hedgehog signaling. Ciliary length then decreases or the cilium 
disappears as cells become terminally differentiated, although it remains unclear whether ciliary 
length per se alters signaling (Marion, Stoetzel et al. 2009, Dalbay, Thorpe et al. 2015, Forcioli-
Conti, Lacas-Gervais et al. 2015). In the absence of RPGRIP1L, cilia may elongate more readily 
in response to dexamethasone or may lessen the requirement for dexamethasone. Cilia might also 
be maintained into later stages of the differentiation program, increasing sensitivity to pro-
adipogenic factors and enhancing the strength of signal transduction in response to these factors, 
or inhibiting the response to anti-adipogenic factors. Reduction of ciliary proteins such as Ift88, 
Kif3a and Alms1, which can be associated with decreased ciliary length, impairs adipogenesis 
(Zhu, Shi et al. 2009, Huang-Doran and Semple 2010, Heydet, Chen et al. 2013, Dalbay, Thorpe 
et al. 2015). However, impaired ciliogenesis in human white preadipocytes with BBS10 and 
BBS12 knockdown is associated with increased adipogenesis, underscoring the complicated 
nature of the effect of cilia on adipogenesis (Marion, Stoetzel et al. 2009).  
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The timing of ciliary elongation and disassembly may be critical to understanding why 
we did not observe effects on adiposity in the Rpgrip1lfl/fl;Adipoq-Cre animals fed either chow or 
high fat diet. The expression of adiponectin, and therefore Cre recombinase in these mice, is not 
expressed in preadipocytes, and is only turned on late in adipogenesis (Scherer, Williams et al. 
1995). Hence, the Adipoq-Cre driver may not have been expressed early enough in adipogenesis 
to affect ciliary functioning in preadipocytes. Consistent with this possibility, knockdown of 
Rpgrip1l in fully mature 3T3-L1 adipocytes did not affect lipid content or expression of 
adipocyte genes, whereas knockdown of Rpgrip1l in preadipocytes increased the differentiation 
capacity of 3T3-L1 cells. 
Here, we propose a role for Rpgrip1l in the developing adipocyte that may contribute 
permissively to the increased body adiposity observed in Rpgrip1l+/- mice. This could ultimately 
play a role in the effect of the FTO locus in body weight regulation, where RPGRIP1L 
expression may be decreased due to the loss of CUX1 p110 binding of the risk allele. Loss of 
Rpgrip1l in mature adipocytes, as we modeled in the Rpgrip1lfl/fl;Adipoq-Cre mice, may be too 
late in the ontogeny of adipocyte development to have any consequential biological effects. The 
increased adipogenesis seen in the early Rpgrip1l knockdown condition in 3T3 L1 cells could 
implicate Rpgrip1l hypomorphism in adipose tissue – by facilitating preadipocyte production and 
differentiation – in the increased adiposity of Rpgrip1l+/- mice. A larger depot fat capacity would 
permit greater fat storage before suppressive consequences on food intake might be invoked 
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mRNA expression of Rpgrip1l in mature adipocytes after siRNA-induced knockdown prior to 
differentiation (A; siCtr: black bars, siRpgrip1l: light gray bars). Representative image (B) and 
quantification (C) of Oil Red O staining of mature adipocytes treated with siRNA against 
Rpgrip1l prior to differentiation. Percentage of cells positive for Nile Red staining for 
intracellular lipid acquired by flow cytometry (D) and median fluorescence intensity of Nile Red 
+ cells (E). Total number of live cells normalized to number of flow cytometry counting beads 
(F). mRNA expression (G) of developmental (Pparg & Cebpa) and functional genes (Glut4, 
Fabp4, Plin1, Lpl, Adipoq and Lep) in mature adipocytes when Rpgrip1l was knocked down 
prior to differentiation. Expression of Shh and target genes of the Shh pathway in mature 
adipocytes (H), confluent preadipocytes (I) and differentiating preadipocytes (J; treated for 2 
days with differentiation media). mRNA expression has been normalized to 36B4. n=4-




Figure 3.2 Rpgrip1l knockdown is not sufficient to induce adipogenesis of 3T3-L1 adipocytes in 
the absence of differentiation factors. 
 
mRNA expression of Rpgrip1l (A; siCtr: black bars, siRpgrip1l: light gray bars) 9 days after 
confluence of 3T3-L1 cells treated with siRNA against Rpgrip1l prior to confluence. 
Representative image (B) and quantification (C) of Oil Red O staining. Percentage of cells 
positive for Nile Red staining for intracellular lipid acquired by flow cytometry (D). mRNA 
expression (E) of developmental genes (Pparg & Cebpa). mRNA expression has been 





Figure 3.3 Rpgrip1l knockdown does not alter production of leptin or adiponectin by 3T3-L1 
adipocytes.  
 
Secretion of leptin (A) and adiponectin (B) into culture media by mature adipocytes 3 days after 
media change (siCtr: black bars, siRpgrip1l: light gray bars). Leptin (D) and adiponectin (E) 
levels in media normalized to number of adipocytes, measured by Nile Red stained cells 
acquired by flow cytometry. Adipocyte number was normalized to counting beads (C). 




Figure 3.4 Rpgrip1l knockout is specific to adipocytes in Rpgrip1lfl/fl;Adipoq-Cre mice.  
 
qPCR analysis of Rpgrip1l mRNA expression (A) in subcutaneous (SCAT), perigonadal 
(PGAT), perirenal (PRAT) and mesenteric (MesAT) adipose depots of male Rpgrip1lfl/fl;Adipoq-
Cre mice (light gray bars) compared to Rpgrip1lfl/fl controls (black bars). SCAT and PGAT 
depots were separated by collagenase digestion into adipocytes and cells from the stromal 
vascular fraction (SVCs) prior to qPCR analysis for Cre (B) and Rpgrip1l (C) expression in 25 
week old male Rpgrip1lfl/fl;Adipoq-Cre mice (n=3) and Rpgrip1lfl/fl controls (n=2) fed high fat 
diet. Transcript levels have been normalized to 36B4. N=6 per condition. * p<0.05, ** p<0.01, 




Figure 3.5 Rpgrip1l knockout is specific to adipose tissue of Rpgrip1lfl/fl;Adipoq-Cre mice. 
 
 
mRNA expression of Rpgrip1l using primers for exons 4-5 (A) and 21-22 (B) in PGAT from 
male Rpgrip1lfl/fl;Adipoq-Cre (light gray bars) and Rpgrip1l+/fl;Adipoq-Cre mice (dark gray bars) 
compared to Rpgrip1l+/+;Adipoq-Cre controls (black bars). (C) Rpgrip1l mRNA expression in 
non-adipose tissues (muscle, liver and hypothalamus) in 1 month old male Rpgrip1lfl/fl;Adipoq-
Cre, Rpgrip1l+/fl;Adipoq-Cre and Rpgrip1l+/+;Adipoq-Cre animals. N=2 per condition. Transcript 
levels have been normalized to the arithmetic mean of bAct, Gapdh and Ppia. * p<0.05, ** 




Figure 3.6 Adipocyte-specific loss of Rpgrip1l function does not affect body weight or fat mass 
in chow-fed mice. 
 
Weekly body weight measurements of male (A) Rpgrip1lfl/fl;Adipoq-Cre (light gray bars; n=3), 
Rpgrip1l+/fl;Adipoq-Cre mice (dark gray bars; n=14) and Rpgrip1l+/+;Adipoq-Cre controls (black 
bars; n=6) fed chow. Fat mass (B) and lean mass (C) were measured by NMR at 12 weeks of 




Figure 3.7 Adipocyte-specific loss of Rpgrip1l function does not affect body weight or fat mass 
in high fat diet-fed mice. 
 
Weekly body weight measurements of male (A) Rpgrip1lfl/fl;Adipoq-Cre mice (black squares; 
n=13) and Rpgrip1lfl/fl controls (light gray squares; n=26) fed high fat diet (HFD = 60% of 
calories) starting at 6 weeks. Fat mass (B) and lean mass (C) were measured by NMR at 12 
weeks of age in a subset of these (Rpgrip1lfl/fl;Adipoq-Cre n=9; Rpgrip1lfl/fl n=18). Serum 
glucose (D) and leptin (E) concentrations. Correlation of serum leptin concentration with fat 




Figure 3.8 Knockdown of Rpgrip1l in 3T3-L1 mature adipocytes does not affect lipid storage. 
 
mRNA expression of Rpgrip1l (A) 3 days after knockdown in mature adipocytes (siCtr: black 
bars, siRpgrip1l: light gray bars). Representative image (B) and quantification (C) of Oil Red O 
staining of mature Rpgrip1l-knockdown adipocytes. Percentage of cells positive for Nile Red 
staining for intracellular lipid acquired by flow cytometry (D) and median fluorescence intensity 
(E) of Nile Red + cells. mRNA expression (F) of developmental (Pparg & Cebpa) and 
functional genes (Glut4, Fabp4, Plin1, Lpl, Lep & Adipoq) in mature adipocytes. Expression has 




Chapter 4 The role of FTO in adipogenesis and adipocyte lipid balance.  
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Abstract 
Single nucleotides in the first intron of FTO convey effects on adiposity by mechanisms 
that remain unclear, but appear to include modulation of expression of FTO itself, as well as 
other genes (e.g. RPGRIP1L, IRX3) in the vicinity of FTO. This locus also affects T2D risk 
independent of its effects on body weight. FTO expression is decreased in fibroblasts and iPSC-
derived human neurons of individuals segregating for obesity risk alleles of FTO at rs8050136 
and rs1421085. These alleles exhibit decreased binding of the CUX1 activator isoform p110. 
Here we demonstrate that Fto expression is upregulated during adipogenesis, and is required for 
the maintenance of adipocyte lipid filling and endocrine function in murine 3T3-L1 cells and 
human adipose tissue-derived stromal cells. RNAseq analysis indicates that this effect on 
adipocyte programming is conveyed in part by modulation of C/ebpβ- and C/ebpδ-regulated 
transcription, consistent with reports that Fto acts a transcriptional coactivator. Fto-/- mice have 
normal fat mass in early life, but spontaneously lose adipose tissue as they age. We propose that 
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Fto is required to maintain adipocyte viability, a function critical to the prevention of ectopic 
lipid accumulation in obese states. Such accumulation – both total and in specific anatomic 





Multiple genes in the region surrounding FTO may convey the obesity risk associated with 
this locus  
Single nucleotide polymorphisms (SNPs) in a region of strong LD within the first intron 
of the Fat Mass and Obesity Associated (FTO) gene are very highly associated with adiposity; 
each minor allele is associated with respective increases of BMI of ~0.36 kg/m2 (or body weight 
of ~1.2 kg in adults (Dina, Meyre et al. 2007, Frayling, Timpson et al. 2007, Scuteri, Sanna et al. 
2007). The increased body weight in individuals segregating for the FTO risk allele rs9939609 is 
attributable primarily to increased food intake (with preference for higher caloric density) rather 
than decreased energy expenditure (Cecil, Tavendale et al. 2008, Speakman, Rance et al. 2008, 
Wardle, Carnell et al. 2008, Tanofsky-Kraff, Han et al. 2009). 
The Fto gene was first identified in the “fused toes mouse” which was deleted for a 1.6 
megabase region on Chr 8, encompassing six genes, including Fto. Originally named Fatso for 
its large intronic regions (Peters, Ausmeier et al. 1999), the gene was renamed “Fat Mass and 
Obesity Associated” after the discovery of the association with adiposity in human subjects 
(Frayling, Timpson et al. 2007). The mechanism by which this association is conveyed is still 
unclear. Neighboring IRX3 has been implicated on the basis of long-range genetic interactions 
between the IRX3 promoter and non-coding sequences in the first intron of FTO, which may 
regulate IRX3 expression. Irx3 knockout mice are protected from diet-induced obesity by an 
increase in basal metabolic rate putatively due to increased thermogenesis driven by adipose 
tissue “browning” (Smemo, Tena et al. 2014). Additionally, a SNP (rs1421085) within the intron 
disrupts binding of the ARID5B repressor, increasing IRX3 expression (Claussnitzer, Dankel et 
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al. 2015). Increased IRX3 expression in human primary preadipocytes impairs browning, driving 
them toward a white adipocyte phenotype.  
The statistical strength of the association with adiposity and the large number of SNPs 
within the obesity-associated locus in the first intron of FTO, suggests that there may be multiple 
causal variants contributing to the observed effect. For example, we have demonstrated that two 
SNPs in the obesity-associated locus (rs8050136 and rs1421085) differentially bind the 
transcription factor CUX1. The protective alleles of these SNPs preferentially bind the activating 
isoform of CUX1, p110, proteolytically processed by Cathepsin L, increasing expression of FTO 
and neighboring RPGRIP1L (Stratigopoulos, Padilla et al. 2008, Stratigopoulos, LeDuc et al. 
2011, Stratigopoulos, Burnett et al. 2016).  
 
FTO affects somatic growth and adiposity. 
Mice congenitally null for Fto exhibit a complex phenotype that includes postnatal 
lethality (Fischer, Koch et al. 2009, Gao, Shin et al. 2010, McMurray, Church et al. 2013). Those 
mice that survive have impaired linear growth and in adulthood (~20 weeks), these mice are 
protected from diet-induced obesity and develop lipoatrophy (Church, Lee et al. 2009, Fischer, 
Koch et al. 2009, Ronkainen, Huusko et al. 2015). Conversely, Fto-overexpressing mice display 
increased body weight and adiposity (Church, Moir et al. 2010). As indicated in Chapter 1, we 
(Stratigopoulos, Burnett et al. 2016) and others (Gao, Shin et al. 2010, McMurray, Church et al. 
2013) have found that at earlier timepoints (~15 weeks), adiposity is actually increased as a 
percentage of body weight in Fto-/- mice. And, consistent with reports by Fischer et al. and 
Ronkainen et al. (Fischer, Koch et al. 2009, Ronkainen, Huusko et al. 2015), we observed 
dramatic loss of adipose tissue as these mice aged (G. Stratigopoulos, personal communication). 
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We suggest that this early increase in adiposity is due to the primary role of Fto in regulating 
energy balance centrally, and that the loss in adiposity seen later in life is due to a defect in 
adipose tissue structure and function. Mice lacking Fto have smaller adipocytes (Fischer, Koch et 
al. 2009) and Fto-overexpressing mice have larger adipocytes than controls (Church, Moir et al. 
2010). These phenotypes suggest a role for Fto in enabling facultative adipose tissue expansion, 
possibly in the context of diet-induced obesity. Despite decreased body weight and adiposity, 24 
week old mice segregating for a dominant-negative Fto mutation exhibit increased circulating 
concentrations of fasting glucose, triglyceride, cholesterol and high-density lipoprotein (HDL) 
levels, consistent with a lipodystrophic metabolic profile (Church, Lee et al. 2009, Unger and 
Scherer 2010, Virtue and Vidal-Puig 2010).  
Humans homozygous for null mutations of FTO display characteristic brain 
(microcephaly, hydrocephalus and lissencephaly) and cardiac malformations (ventricular septal 
and atrial ventricular defects, patent ductus arteriosus) and hypertrophic cardiomyopathy that 
result in growth retardation and death within the first few years of life (Boissel, Reish et al. 2009, 
Daoud, Zhang et al. 2016, Rohena, Lawson et al. 2016). If the obesity-associated region on 
chromosome 16 is conveyed the FTO protein itself, partial function of this protein must be 
preserved, as these extreme malformations are not evident in individuals segregating for the risk 
alleles located in intron 1 of FTO. Additionally, FTO risk alleles are not associated with any 
change in height, compared to humans with FTO mutations and Fto loss-of-function mouse 
models that exhibit dramatic growth retardation (Frayling, Timpson et al. 2007).  
The effects on adiposity cannot be accurately studied in individuals with FTO loss-of-
function mutations, as the developmental defects and their medical consequences mask potential 
effects on adiposity. Heterozygotes for a variety of FTO mutations have no obvious phenotypic 
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characteristics (Meyre, Proulx et al. 2010, Deliard, Panossian et al. 2013, Zheng, Hong et al. 
2013). The number of these individuals with variants predicted or proven to have a deleterious 
effect on FTO function is extremely small, however, and studies attempting to associate these 
variants with adiposity are likely underpowered to make conclusions regarding metabolic 
homeostasis.  
Fto is a putative m6A RNA demethylase  
FTO is a member of the ALKB homolog family of non-heme dioxygenases (Fe(II)- and 
α-ketoglutarate dependent dioxygenases) (Gerken, Girard et al. 2007, Sanchez-Pulido and 
Andrade-Navarro 2007), and exhibits RNA N6-methyladenosine (m6A) and 3-methyluridine 
(m3U) demethylation activity in vivo (Jia, Fu et al. 2011). m6A is an abundant mRNA 
modification and is thought to play a role in the regulation of mRNA stability, splicing and 
translation. These modifications are increased around stop codons and 3’UTRs, as well as along 
long exons (Dominissini, Moshitch-Moshkovitz et al. 2012, Meyer, Saletore et al. 2012, Fu, 
Dominissini et al. 2014).  
 
FTO plays a role in maintaining adipocyte lipid handling and endocrine functions 
Although expressed most highly in the brain, Fto is also expressed in adipose tissue 
(Gerken, Girard et al. 2007, Gao, Shin et al. 2010) where its role remains unclear. While eQTL 
studies examining the expression of FTO in individuals segregating for risk or protective alleles 
have not shown different levels of expression, sample sizes were small and in some cases, whole 
adipose tissue was examined, potentially masking effects in single cell types such as adipocytes 
or preadipocytes (Kloting, Schleinitz et al. 2008, Grunnet, Nilsson et al. 2009, Zabena, 
Gonzalez-Sanchez et al. 2009, Claussnitzer, Dankel et al. 2015). In mice, Fto expression is 
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decreased in mesenteric adipose tissue upon fasting (Stratigopoulos, Padilla et al. 2008) and 
increased in subcutaneous and visceral adipose tissue upon acute exposure to high fat diets 
(Wang, Shie et al. 2015), indicating that nutritional status might confound efforts to attribute 
expression of FTO to risk genotype.  
Fto has recently been implicated in the differentiation of adipocytes (Zhao, Yang et al. 
2014, Merkestein, Laber et al. 2015, Zhang, Zhang et al. 2015). In particular, Fto’s demethylase 
function is required for adipogenesis, and may be involved in regulating mRNA splicing (Zhao, 
Yang et al. 2014, Zhang, Zhang et al. 2015). Whether this effect on adipogenesis contributes to 
the adiposity or metabolic phenotypes described in Fto-/- mice is unclear. The effects on m6A 
RNA methylation, purported to be regulated by Fto, are incompletely characterized with regard 
to adipogenesis. One possible mediator of Fto’s demethylase function in adipocytes is an 
alternatively spliced version of Runt related transcription factor 1 (Runx1t1) lacking exon 6. 
Inclusion of exon 6 may be due to enhanced binding of m6A-methylated RNA by serine/arginine 
rich splicing factor 2 (SRSF2) in 3T3-L1 cells lacking Fto (increased methylation) (Zhao, Yang 
et al. 2014, Merkestein, Laber et al. 2015). Exon 6 skipping, possibly due to the lack of SRSF2 
binding sites in cells with functional Fto demethylase activity, generates a short isoform that is 
pro-adipogenic in 3T3-L1 cells and mouse embryonic fibroblasts in vitro (Zhao, Yang et al. 
2014, Merkestein, Laber et al. 2015).  
We assessed the possibility that Fto may be involved in adipocyte differentiation by 
developmentally-timed manipulation of Fto gene expression in 3T3-L1 preadipocytes. We also 
analyzed the effect of FTO knockdown on adipogenesis in human adipose tissue-derived 
preadipocytes. We found that Fto expression was required for adipogenesis; and using RNAseq 
we identified molecular targets of Fto that might mediate this effect. While we identified C/ebpβ 
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and C/ebpδ expression and function as primary targets of Fto, we did not find evidence that these 
transcripts are differentially methylated or exhibit altered stability or translational efficiency 
following Fto knockdown. Surprisingly, Fto knockdown enhanced Akt signaling despite the net 
inhibition of adipogenesis.  
 
Methods 
Cell culture and transfection  
3T3-L1 preadipocytes were purchased from ATCC and maintained in non-confluent 
cultures. Growth medium consisted of DMEM (with 25mM glucose, GlutaMAX™, and sodium 
pyruvate) supplemented with 10% newborn calf serum (both Thermo Fisher). Differentiation 
was achieved by treating cells two days after they reached confluence with differentiation media 
containing DMEM plus insulin (from Bovine Pancreas 1 μg/ml), dexamethasone (0.25 μM) and 
isobutylmethylxanthine (IBMX; 0.5mM; all Sigma-Aldrich) supplemented with 10% fetal 
bovine serum (Thermo Fisher). Two days later, differentiation media was replaced with DMEM 
containing only 1 μg/ml insulin and 10% FBS. Insulin media was replaced every two to three 
days and cells were filled with lipid and considered mature adipocytes by days 8-12.  
Human ASCs were generously provided by the Boston NORC and were cultured and 
differentiated as previously described (Lee and Fried 2014). Briefly, cells were maintained in 
αMEM supplemented with 10% FBS (all Thermo Fisher) to avoid confluence. To differentiate, 
cells were allowed to reach confluence and 2 days later were treated with a chemically defined, 
serum free media (DMEM/F12 containing HEPES and Antibiotic-Antimycotic (Thermo Fisher), 
NaHCO3, d-Biotin, Pantothenate, Dexamethasone, human insulin, Rosiglitazone, IBMX, T3 and 
Transferrin (Sigma Aldrich)). Differentiation media was replaced regularly and switched to 
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maintenance media after 3-7 days (differentiation media without Rosiglitazone, IBMX, T3 and 
Transferrin). Cells were filled with lipid and assayed between 10-14 days after initial treatment 
with differentiation factors. 
Transfections were performed prior to differentiation using a mix of 3 Stealth siRNAs 
targeted against Fto or 3 nontargeted controls with Lipofectamine 2000 or 3000 (all Thermo 
Fisher). Fto/Ptprv and Fto/Spon2 double knockdowns were performed by adding a single Stealth 
siRNA against Ptprv or Spon2 to the mix of 3 anti-Fto siRNAs (all Thermo Fisher). Knockdown 
of Fto in mature adipocytes was achieved by electroporation (Jiang, Zhou et al. 2003, Okada, 
Mori et al. 2003, Kilpeläinen, Carli et al. 2016) using the same siRNAs after 3T3-L1 cells had 
been differentiated.  
RNA expression studies, RNAseq and m6A-RIP 
Total RNA was isolated using RNeasy Lipid Tissue Mini Kit and columns were treated 
with DNase (both Qiagen). cDNA was reverse transcribed with Transcriptor First Strand cDNA 
Synthesis Kit (Roche) using both OligoDT and random hexamer primers. Quantitative real time 
PCR (qPCR) was performed on a Lightcycler 480 using SYBR Green I Master (Roche). 
Analysis was performed by the LightCycler 480 software (Roche) using the 2nd derivative max 
calculation based on a standard curve. qPCR primers were designed using Primer 3: 
http://bioinfo.ut.ee/primer3/ to span exon-exon junctions and are provided in Supplementary 
Table 1. 
Sample integrity for RNA utilized for RNAseq was assessed with an Agilent 2100 
Bioanalyzer. All samples had RIN numbers greater than 8.0. mRNA was isolated using poly-A 
pulldown and reverse transcribed to generate cDNA (Wang, Gerstein et al. 2009). cDNA was 
sequenced using single-ended sequencing on a HiSeq2000 according to manufacturer’s 
89 
 
recommendations (Illumina). The pass filter reads were mapped to mouse reference genome 
mm9 using TopHat (version 2.0.4). TopHat infers novel exon-exon junctions and combines them 
with junctions from known mRNA sequences as the reference annotation (Trapnell, Pachter et al. 
2009). For each read, up to 3 mismatches and 10 multiple hits were allowed during mapping. 
RNA Immunoprecipitation was performed based on previously published protocols 
(Meyer, Saletore et al. 2012, Dominissini, Moshitch-Moshkovitz et al. 2013). Briefly, RNA was 
isolated (as described above, including DNase treatment) from 2-day post-confluent 3T3-L1 
preadipocytes following Fto knockdown and a 5µg aliquot was treated with RiboMinus (Thermo 
Fisher) to decrease rRNA content. 300ng of heat-denatured RNA was pulled down with rabbit 
anti-m6A antibody (Synaptic Systems) coupled to Protein A/G Dynabeads in the presence of an 
RNase inhibitor SUPERase•In (both Thermo Fisher). Eluted RNA was isolated by 
QIAzol:chloroform extraction and column purification (as described above, without DNase 
treatment). The resulting RNA and a reserved aliquot containing 10% of the input were reverse 
transcribed and analyzed by qPCR. mRNA expression was calculated using the Delta Delta C(T) 
method and normalized to 36B4 transcript levels (Livak and Schmittgen 2001).  
Transcript stability was measured following treatment with Actinomycin D (ActD). Cells 
were treated with 1 µg/ml (stock: 1 mg/ml in DMSO; Thermo Fisher) for the indicated time 
periods prior to isolation of RNA for analysis by qPCR. Transcript levels were normalized by the 
amount of 18S transcript present, which remained constant throughout all 8 hours of ActD 
treatment. 
Lipid Staining 
Mature adipocytes were stained with Oil Red O for lipid content by first fixing cells with 
4% paraformaldehyde for 10 minutes. A freshly mixed solution of 3:2 Oil Red O stock (25mg 
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Oil Red O in 50ml isopropanol; Sigma) was prepared and filtered prior to staining for 30 mins. 
Cells were then washed with PBS and imaged. For quantification, Oil Red O was extracted in 
300µl of isopropanol with 4% IGEPAL CA-630 for 5 mins and 100µl were used to measure 
absorbance at 490nm (Church, Berry et al. 2014). 
Nile Red staining was performed based on the protocol developed by Smyth et. al. 
(Smyth and Wharton 1992). Mature adipocytes were trypsinized and treated with 4% 
paraformaldehyde for 10 mins. Nile Red (stock: 1mg/ml in DMSO; Thermo Fisher) was then 
added for a final concentration of 500ng/µl and cells were acquired within 30 mins by flow 
cytometry using the PE-TR channel to measure Nile Red fluorescence. Prior to acquisition, equal 
volumes of 8.0-12.9 µm counting beads (Spherotech) were added to quantify cell numbers per 
condition. Live cells were gated to include all events except debris (very low FSC & SSC). The 
Nile Red gate was set on Nile Red-negative preadipocytes. 
Protein isolation and quantification  
Whole cell lysates were collected in RIPA buffer in the presence of Halt protease-
phosphatase inhibitor and quantified by BCA assay (all Thermo Fisher). Following denaturing 
gel electrophoresis, proteins were transferred to nitrocellulose membranes and probed with the 
following primary antibodies: βAct (Abcam), Fto (Santa Cruz), αTub, C/ebpβ, pAkt, Akt, pAkt1, 
Akt1, pAkt2, pFoxo1, Foxo1, and Adiponectin (Cell Signaling). Fluorescent secondary IRDye 
680LT and 800CW antibodies were from LI-COR. Blots were imaged using LI-COR’s Odyssey 
Classic and bands were quantified with Image Studio software (LI-COR). 
Leptin and Adiponectin ELISAs were performed using kits from R&D Systems. Cell 
culture supernatants from mature adipocytes were removed 3 days after media had been changed. 
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Samples (from 12 well plates) were diluted 1:20 for Leptin ELISA and 1:1,000 for Adiponectin 
ELISA.  
Glucose uptake was measured using the Glucose Uptake Colorimetric Assay Kit (Sigma) 
according to the manufacturer’s instructions. Briefly, following Fto knockdown, 2-day post-
confluent 3T3-L1 preadipocytes were serum starved overnight and then glucose starved for 40 
mins. Cells were treated with or without insulin (1µM) for 20 mins and then treated with or 
without 2-deoxyglucose (2-DG) for 20 mins. Lysed cells were assayed for 2-DG concentration 
using the colorimetric assay. 
Mice 
Mice were group housed by gender and maintained at an ambient temperature of 22 °C–
24 °C with a 12-h dark–light cycle (lights on at 0700, h) in a pathogen-free barrier facility. The 
protocol was approved by the Columbia University Institutional Animal Care and Use 
Committee. Fto expression was evaluated in isolated adipocytes and preadipocyte-containing 
stromal vascular cells from perigonadal and subcutaneous adipose tissue from 4-month-old 
C57BL/6 mice (derived from Jackson, Stock number 000664) fed chow (Purina PicoLab 5058). 
Adipose depots were excised and digested with collagenase (Roche) for 45min-1hr prior to 
separation by centrifugation. The SVC pellet was treated with erythrocyte lysis buffer (0.154 M 
NH4Cl, 10 mM KHCO3 and 0.1mM EDTA) for 3 minutes. RNA was isolated, cDNA was 
generated and qPCR was performed as described above. mRNA expression was normalized to 




Fto knockdown impairs adipogenesis in mouse and human cells 
To determine whether Fto participates in adipogenesis – and by that process in energy 
storage capacity – we treated 3T3-L1 preadipocytes with siRNA targeted to Fto prior to in vitro 
adipogenesis. mRNA transcript and protein levels of Fto were decreased during the entire 
differentiation timecourse in the Fto knockdown condition (Fig. 4.1A, Sup. Fig. 4.1A&B). 
Knockdown of Fto impaired the ability of 3T3-L1 cells to develop into mature adipocytes, as 
demonstrated by Oil Red O staining (Fig. 41B, Sup. Fig. 4.1D). Quantitative RT-PCR (qPCR) 
analysis of preadipocytes showed decreased expression of Cebpd, and a modest but statistically 
non-significant decrease in Cebpb (Fig. 4.1C). Expression of adipocyte developmental and 
functional genes, Pparg, Cebpa, Fabp4, Glut4, Plin1, Lpl, Adipoq and Lep was decreased in 
mature adipocytes (Fig. 4.1D, Sup. Fig. 4.1C). The total amount of leptin secreted into the 
culture media was decreased as well (Sup. Fig. 4.1E); however, when normalized to the number 
of adipocytes per well/condition (Sup. Fig. 4.1F), there was no difference in amount of leptin 
secreted per cell (Sup. Fig. 4.1G), suggesting that Fto does not directly regulate leptin synthesis 
or release on a per adipocyte basis (Kilpeläinen, Carli et al. 2016). The decrease in lipid content 
and adipocyte gene expression in bulk culture could have been caused by a decrease in the 
number of cells that could fully develop into adipocytes or by a limitation causing cells to arrest 
at a less mature stage. We analyzed Nile Red staining for neutral lipids by flow cytometry and 
found that both factors contributed to the decrease in lipid per well. There were both fewer Nile 
Red positive cells as a percentage of total cells analyzed (Fig. 4.1E), and of the cells that were 
Nile Red positive, there was less lipid in each cell, indicated by the median fluorescence 
intensity of the Nile Red+ adipocyte population (Sup. Fig. 4.1H). As previously reported 
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(Merkestein, Laber et al. 2015), we also saw a decrease in the total number of live cells (Sup. 
Fig. 4.1I).  
To confirm the observed effects of Fto on adipogenesis in 3T3-L1 we manipulated FTO 
expression in primary human adipose tissue-derived stromal cells (ASCs) (Lee and Fried 2014). 
Using the same experimental paradigm (FTO knockdown prior to differentiation) with cells from 
four different individuals (males and females), we found that knockdown of FTO expression 
(Fig. 4.1F, Sup. Fig. 4.1J&K) impaired adipogenesis. We observed the same decrease in Oil 
Red O (Fig. 4.1G, Sup. Fig. 4.1L) staining and percentage of Nile Red positive adipocytes (Fig. 
4.1J), although there was no difference in Nile Red fluorescence in mature cells (Sup. Fig. 
4.1M) in the FTO knockdown condition. In preadipocytes, expression of both CEBPB and 
CEBPD was decreased (Fig. 4.1H), and in mature adipocytes, expression of adipocyte 
developmental and functional genes PPARG, CEBPA, FABP4, GLUT4, PLIN1, LEP and 
ADIPOQ (Fig. 4.1I) was decreased in the FTO knockdown condition compared to non-targeted 
siRNA controls.  
Previous reports have suggested that Fto may affect splicing of exon 6 of Runx1t1 as a 
mechanism for alterations in adipogenesis (Zhao, Yang et al. 2014, Merkestein, Laber et al. 
2015). We measured long (containing exon 6) and short (missing exon 6) splice variants of 
Runx1t1 by qPCR and were unable to detect any significant difference in total amounts or the 
ratio of the isoforms between control and Fto knockdown conditions in either the preadipocyte or 
mature adipocyte stage in 3T3-L1 cells (Sup. Fig. 4.1N-P). It has also been suggested that Fto 
inhibits the “browning” or “beiging” of white adipose tissue, decreasing thermogenesis driven by 
the uncoupling of oxidative phosphorylation (Tews, Fischer-Posovszky et al. 2013, Ronkainen, 
Mondini et al. 2016). We did not detect an increase in brown adipocyte markers Ucp1, Cidea, 
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Pgc1a and Cox7a following Fto knockdown. We observed a decrease in expression of these 
genes, likely due to the blunting of adipogenesis (Sup. Fig. 4.1Q).  
Preliminary evidence suggests that C/ebpδ binds to rs8050136 in the first intron of FTO 
(data not shown). Because of the decrease in CEBPD expression following FTO knockdown in 
preadipocytes, we evaluated whether FTO knockdown affected the expression of genes near the 
FTO locus (CHD9, RBL2, AKTIP, RPGRIP1L, IRX3, IRX5, CRNDE; Fig. 4.2A&B), in 3T3-L1 
and human ASC preadipocytes. RBL2 expression was decreased modestly after FTO knockdown 
in both mouse and human cells. Rpgrip1l expression was decreased more dramatically, but only 
in murine 3T3-L1 preadipocytes (Fig. 4.2C&D).  
 
RNAseq analysis identifies Fto-targeted genes as candidates for regulation of adipogenesis 
To identify a mechanism for Fto’s adipogenic functions in 3T3-L1 cells, we analyzed the 
gene expression profile following Fto knockdown by RNAseq. We chose to examine 2-day post-
confluent preadipocytes prior to the induction of differentiation in order to focus on primary 
targets of Fto, minimizing secondary effects produced by an altered adipogenic program. There 
were 20 genes significantly (p<0.05) up- or downregulated following Bonferroni correction (See 
Fig. 4.3D). We identified four additional genes (Clca1, Rhob, Tusc5 and Klf2) with differential 
expression that was not as statistically significant (uncorrected p<1x10-5; Bonferroni corrected 
p<0.23) but with effect sizes of ≥2-fold or ≤0.5-fold (Fig. 4.3A). One other notable change was 
the decrease in Pten expression (p=0.1 following Bonferroni correction, 0.8-fold). We then 
confirmed the effect of Fto knockdown on these genes by measuring transcript levels in Fto-
knockdown preadipocytes from two independent experiments by qPCR. We verified the effect of 
Fto on 20 of 24 genes identified by RNAseq (Fig. 4.3D).  
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We also examined the effects of FTO knockdown on human homologs of the most highly 
regulated targets by RNAseq in 3T3-L1 preadipocytes (>3-fold increase or <0.3-fold decrease 
after Fto knockdown in 3T3-L1 cells by qPCR confirmation: PTPRVP, TMED5 and SPON2) as 
well as genes known to be associated with adipogenesis (GREM2, KLF2 and WNT4 (Banerjee, 
Feinberg et al. 2003, Wu, Srinivasan et al. 2005, Nishizuka, Koyanagi et al. 2008, Wu, Tang et 
al. 2015)) and PTEN, an inhibitor of insulin signaling (Sasaoka, Wada et al. 2006). These studies 
were conducted in human ASC-derived preadipocytes (Fig. 4.3E) and mature adipocytes (Fig. 
4.3F) to identify molecules that might enable FTO to regulate adipogenesis.  
Upregulation in adipocytes of SPON2 (spondin 2), a gene not previously associated with 
adipogenesis, and downregulation of PTEN (phosphatase and tensin homolog) in preadipocytes, 
were consistent with the results of the RNAseq and qPCR analyses in 3T3-L1 preadipocytes. We 
were unable to detect mRNA expression of PTPRVP (protein tyrosine phosphatase, receptor type 
V, pseudogene), consistent with a report indicating that it is a pseudogene in humans (Cousin, 
Courseaux et al. 2004). Ptprv in murine cells, however, is dramatically upregulated in conditions 
of p53-regulated G1 cell cycle arrest, and loss of this gene restores cell cycle progression in a 
manner similar to loss of p53 (Doumont, Martoriati et al. 2005, Doumont, Martoriati et al. 2005). 
Expression of other p53-induced cell cycle arrest effectors, GADD45A, MDM2 and CDKN1A, 
was upregulated in human ASC preadipocytes (Fig. 4.3G) and mature adipocytes (Fig. 4.3H).  
We analyzed our 3T3-L1 preadipocyte Fto knockdown RNAseq dataset using Enrichr 
(http://amp.pharm.mssm.edu/Enrichr/; (Chen, Tan et al. 2013, Kuleshov, Jones et al. 2016)), a 
publicly available tool for enrichment analysis. We analyzed genes that were up- or down-
regulated by more than 10% with p<0.05 (without correction; 2,455 genes). The most striking 
results came from the ChEA 2016 analysis, which queries a database of chromatin 
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immunoprecipitation (ChIP) datasets for transcription factor targets. The Fto-knockdown 
condition was highly enriched for C/ebpβ and C/ebpδ targets identified in ChIP studies 
performed in 3T3-L1 cells, with Enrichr’s calculated combined scores of 85.74 (adjusted 
p=1.12E-25; 410/2000 overlap (Fto-affected transcripts/all C/ebpβ-regulated transcripts) and 
80.53 (adjusted p=6.34E-23; 358/1735 overlap), respectively. This result is consistent with the 
decreased expression of Cebpd (57%) demonstrated in Fig. 4.1. We observed a non-statistically 
significant (14%) decrease in Cebpb expression in 3T3-L1 Fto-knockdowns, but consistent, 
significant downregulation of both CEBPB and CEBPD in FTO-knockdown human ASCs. Peak 
expression of Cebpb (after 2 hrs) and Cebpd (after 1 hr) immediately after the addition of 
differentiation media in 3T3-L1 preadipocytes displayed the same pattern (Fig. 4.3B&C). 
 
Differentially-expressed Fto targets identified by RNAseq are not likely to be direct targets 
of Fto’s demethylation function 
As noted, Fto acts as a demethylase of m6A (Gerken, Girard et al. 2007, Jia, Fu et al. 
2011). We looked for changes in RNA methylation of the abovementioned candidate genes 
(Cebpb, Cebpd, Ptprv, Tmed5, Spon2, Grem2, Klf2, Wnt4 and Pten). We immunoprecipitated 
RNA using an anti-m6A antibody and then quantified transcript levels by qPCR to assess 
whether any of these transcripts is a direct target of Fto’s demethylase function. When 
normalized to the amount of transcript found in input samples prior to m6A 
immunoprecipitation, there were no changes in m6A status in any of the transcripts evaluated 
(Fig. 4.4A&B). This finding suggests that these transcripts are secondary targets of an upstream 
target of Fto’s m6A demethylase function or are direct targets of Fto via a mechanism 
independent of m6A demethylation, such as transcriptional activation. A recent report indicates 
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that the preferred target of Fto’s demethylase function is actually N6,2′-O-dimethyladenosine 
(m6Am), a subset of m6A found only at the 5’ end of mRNA transcripts (Mauer, Luo et al. 
2016). Loss of m6Am demethylation may be masked by precipitating transcripts with an 
antibody specific for all m6A modifications, indicating that ours are not conclusive negative 
results regarding the possible direct demethylation action of Fto on these transcripts. 
Demethylation of m6A and, more specifically, m6Am, by Fto has been associated with 
altered transcript stability (Wang, Lu et al. 2014, Mauer, Luo et al. 2016). Thus, if Cebpb, 
Cebpd, Ptprv, Spon2 and/or Pten are direct targets of Fto despite their unchanged m6A pattern, 
the increased transcript levels observed may be the result of increased stability. To test this 
possibility, we inhibited nascent transcription with Actinomycin D (ActD) following knockdown 
of Fto in 3T3-L1 preadipocytes (Fig. 4.4B-F, H-L). We did not observe any change in transcript 
stability of Cebpb (Fig. 4.4B&H), Cebpd (Fig. 4.4C&I), Ptprv (Fig. 4.4D&J) Spon2 (Fig. 
4.4E&K) or Pten (Fig. 4.4F&L) that might account for the altered expression levels observed 
following Fto knockdown. Methylation of m6A residues may also contribute to changes in 
translation from the RNA transcript (Meyer, Patil et al. 2015). We anticipated that this reaction 
might contribute to the altered expression of C/ebpβ target genes observed by RNAseq despite 
the absence of a decrease in Cebpb transcript levels, as it is possible that Cebpb was not being 
properly translated or was being translated from alternative start sites. Western blotting for 
C/ebpβ protein in 3T3-L1 preadipocytes showed slightly (but not statistically significant) 
decreased levels of all isoforms in the Fto-knockdown condition compared to controls (Fig. 
4.4N&O), consistent with the mRNA expression data described. These data indicate that Cebpb, 
Cebpd, Ptprv, Spon2 and Pten may not be direct targets of Fto’s demethylase function, even 




Ptprv and Spon2 contribute to Fto’s role in adipogenesis in 3T3-L1 cells 
We evaluated the importance of candidate genes identified as Fto targets by RNAseq to 
the adipogenesis phenotypes we observed. Simultaneous knockdown of both Fto and Ptprv (Fig. 
4.5A&B) restored adipogenesis lost when Fto alone was knocked down. Pparg expression (Fig. 
4.5C) and Oil Red O staining (Fig. 4.5D; Sup. Fig. 4.2A) were increased in these cells. 
Fto/Ptprv double knockdown also increased the percentage of Nile Red staining (Fig. 4.5F) and 
fluorescence of Nile Red+ cells (Sup. Fig. 4.2B) compared to Fto knockdown alone. Elevated 
expression of Spon2 after Fto knockdown (Fig. 4.5E) is attributable to Ptprv, as Fto/Ptprv 
knockdown restored Spon2 expression to control levels. Fto/Ptprv knockdown did not increase 
Cebpb (Fig. 4.5H) or Cebpd (Fig. 4.5I) expression, however, indicating that Ptprv is either 
downstream of Cebpb and Cebpd, or functioning in a different pathway from these critical 
regulators of adipogenesis. Knockdown of Fto in addition to Spon2 also restored adipogenesis 
but to a lesser degree (Sup. Fig. 4.3A-G), and like Fto/Ptprv knockdown, did not increase Cebpb 
(Sup. Fig. 4.3H) or Cebpd (Sup. Fig. 4.3I) expression. As Spon2 and Pten (discussed below) 
were the only genes differentially regulated in both 3T3-L1 and human ASC preadipocytes 
following Fto/FTO knockdown, we propose that they are critical effectors of Fto’s function.  
 
Fto regulates Akt signaling in adipocytes  
The decrease in Pten expression associated with Fto knockdown – identified by RNAseq 
and illustrated in Fig. 4.3 – was unexpected, as Pten is a well characterized tumor suppressor 
(Song, Salmena et al. 2012), and its decreased expression after Fto knockdown would be 
predicted to increase cell proliferation, in contrast to the decreased cell proliferation that we 
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observed. Pten also inhibits insulin signaling, however, by dephosphorylating 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to PtdIns(4,5)P2 (PIP2), thereby inhibiting Akt 
phosphorylation (Nakashima, Sharma et al. 2000, Sasaoka, Wada et al. 2006). A previous report 
(Pitman, Fong et al. 2012) indicated that Fto knockdown increases Akt phosphorylation of 
Ser473 in 3T3-L1 cells. This finding is consistent with the decreased Pten expression we 
observed following Fto knockdown. We also observed increased phosphorylation of Akt at 
Ser473 in 3T3-L1 preadipocytes after 4hr serum starvation and after serum starvation plus 
exposure to 1µg/ml insulin for 15 mins (Fig. 4.6A). This effect was seen in both the Akt1 and 
Akt2 isoform (Fig. 4.6B&C, Sup. Fig. 4.4A&B), and elevated pAkt/Akt ratios were sustained 
until the cells became mature adipocytes (Fig. 4.6D, Sup. Fig. 4.4C). Foxo1 is also 
phosphorylated via the Akt signaling pathway (Guo, Rena et al. 1999, Jackson, Kreisberg et al. 
2000), and pFoxo1/Foxo1 ratios were elevated in 3T3-L1 adipocytes in response to insulin (Fig. 
4.6F, Sup. Fig. 4.4D).  
Insulin regulates adiponectin production via a PI3K-dependent mechanism (Blumer, van 
Roomen et al. 2008). The increased pAkt signaling we observed following Fto knockdown was 
associated with an increase in adiponectin protein levels (Fig. 4.6G, Sup. Fig. 4.4E). In Fto-
knockdown 3T3-L1 adipocytes, adiponectin was secreted into the media in almost the same 
quantity as in the non-targeted control knockdown condition (Fig. 4.6H), despite the knockdown 
cells exhibiting roughly half the adipogenesis as controls.  
Increased Akt signaling in the Fto knockdown condition was not associated with an 
increase in glucose uptake in either the serum/glucose-starved or insulin treated state. Uptake of 
2-deoxyglucose, a non-metabolizable glucose analog, into 3T3-L1 preadipocytes was decreased 
in the Fto knockdown condition (Fig. 4.6I). This result is consistent with the decrease in Glut4 
100 
 
expression described above (Fig. 4.1D). Additionally, expression of the non-insulin sensitive 
glucose transporter, Glut2 (Slc2a1), was decreased by Fto knockdown in both 3T3-L1 
preadipocytes and mature adipocytes (Fig. 4.6J). Fto/Ptprv knockdown did not restore Pten 
expression (Sup. Fig. 4.2C), suggesting that Pten is not regulated by Fto by the same mechanism 
as Ptprv and Spon2.  
 
Fto knockdown in mature adipocytes leads to impaired adipocyte lipid handling and 
endocrine function. 
We and others have demonstrated an impairment in the ability of cells to undergo 
adipogenesis when Fto expression is decreased prior to differentiation (Zhao, Yang et al. 2014, 
Merkestein, Laber et al. 2015). Fto expression increases as 3T3-L1 and human ASC 
preadipocytes differentiate into mature adipocytes (Fig. 4.1A&F). We collagenase digested 
perigonadal and subcutaneous adipose tissue of 4-month-old male C57BL/6 mice to isolate 
mature adipocytes and preadipocyte-containing stromal vascular cells (SVCs). Fto expression in 
mature adipocytes was approximately 3-fold higher than that in the SVCs (Fig. 4.7A) suggesting 
that Fto may play a more substantial role in mature, lipid filled cells. We assessed knockdown of 
Fto in mature (8-10 days post differentiation) 3T3-L1 adipocytes (Fig. 4.7B) to understand 
whether Fto affects adipocyte function after cells have undergone differentiation. Expression of 
developmental (Cebpd, Pparg2 and Cebpa) and functional (Fabp4, Glut4, Plin1, Lpl and 
Adipoq) adipocyte genes were decreased in the Fto knockdown condition, with no change in 
Cebpb expression (Fig. 4.7C); however, there was no detectable difference in lipid content by 
staining with Oil Red O (Fig. 4.7D&E). We did not observe any change in total cell number 
(Fig. 4.7F) or the percentage (Fig. 4.7G) or number (Fig. 4.7H) of Nile Red positive cells 
101 
 
reported by flow cytometry. There was a modest decrease, however, in the amount of Nile Red 
staining per cell (Fig. 4.7I) and a decrease in the amount of adiponectin (Fig. 4.7J&K) secreted 
into the cell culture media per adipocyte. There was no difference in the amount of leptin 
expressed (Fig. 4.7C) or secreted per cell (Fig. 4.7L&M). There was no difference in Akt 
phosphorylation in the Fto knockdown condition following insulin treatment (Data not shown). 
This finding is consistent with the lack of effect of Fto knockdown in mature adipocytes on Pten 





 The molecular bases for the strong association of sequence variants in intron one of FTO 
with human adiposity remain unclear. FTO itself, and nearby RPGRIP1L, IRX3, and IRX5, have 
all been implicated by mechanisms relating to food intake, adipocyte differentiation and energy 
expenditure. Here, we provide evidence that FTO plays a permissive role in in vitro adipogenesis 
in both murine 3T3-L1 cells and human adipose-derived stromal cells.  
In humans, the effects of intronic alleles of FTO are conveyed primarily by effects on 
food intake (Cecil, Tavendale et al. 2008, Speakman, Rance et al. 2008, Wardle, Carnell et al. 
2008, Tanofsky-Kraff, Han et al. 2009), though not necessarily by the FTO molecule itself 
(Smemo, Tena et al. 2014, Stratigopoulos, Martin Carli et al. 2014, Claussnitzer, Dankel et al. 
2015). Adipose tissue mass is determined by complex interactions of cell autonomous, metabolic 
and behavioral processes. Adipose tissue may affect metabolic and behavioral phenotypes by 
hormonal secretions (leptin, adiponectin, TNF-α), effects on circulating metabolites (free fatty 
acids), and possibly by direct neural interactions with the CNS (via sympathetic innervation of 
white adipose tissue (Bartness, Liu et al. 2014)). Thus, genetic effects on adipose tissue 
development and/or function can have consequences for adiposity by both simple anatomic and 
indirect systemic effects.  
Previous studies have not implicated FTO as a primary regulator of adipogenesis in 
human cells (Tews, Fischer-Posovszky et al. 2013). However, the cells used for these 
experiments, SGBS preadipocytes, were derived from a patient with X-linked Simpson-Golabi-
Behmel (SGBS) syndrome (Fischer-Posovszky, Newell et al. 2008). SGBS is characterized as an 
overgrowth syndrome caused by mutations in the gene encoding glypican-3, which regulates 
signaling in response to growth factors such as Wnts, Hedgehogs, FGFs and BMPs (Filmus, 
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Capurro et al. 2008, Tenorio, Arias et al. 2014). Our data, and those of others (Merkestein, Laber 
et al. 2015, Chen, Zhou et al. 2016, Jiao, Zhang et al. 2016), indicate that Fto positively regulates 
adipocyte proliferation. The proliferative decrease in the FTO knockdown condition might have 
been circumvented in SGBS cells which are hyper-responsive to growth signals.  
An in vivo adipose tissue-specific role for Fto remains unclear, although the effect of Fto 
knockdown in in vitro models is striking, and suggests an adipocyte-autonomous effect of Fto. 
Fto knockout mice exhibit decreased body weight and adiposity as well as protection from diet-
induced obesity late in life (Church, Lee et al. 2009, Fischer, Koch et al. 2009, Ronkainen, 
Huusko et al. 2015). However, there is no deficiency of fat tissue in young animals; there is, in 
fact, an increase in adiposity relative to body mass (G. Stratigopoulos, personal communication 
(Gao, Shin et al. 2010, McMurray, Church et al. 2013)). Conversely, overexpression of Fto 
increases adiposity which is accentuated by high fat diet feeding (Church, Moir et al. 2010). 
Growth retardation and postnatal lethality occurs with loss of Fto in mice (Fischer, Koch et al. 
2009, Gao, Shin et al. 2010, McMurray, Church et al. 2013), consistent with the human 
polymalformation syndrome seen in individuals homozygous for loss-of-function mutations in 
FTO (Boissel, Reish et al. 2009, Daoud, Zhang et al. 2016, Rohena, Lawson et al. 2016). We 
suggest that this early increase in adiposity is due to the hyperphagia resulting from a reduction 
of Fto expression centrally. The decrease in total body weight, due to decreased lean mass, of 
Fto knockout animals is recapitulated in a neuron-specific Fto knockout model (utilizing Nestin-
Cre), although these latter mice exhibit a secondary increase in percent body fat, indicative of 
positive energy balance (Gao, Shin et al. 2010). Additionally, the downregulation in Rpgrip1l 
expression in preadipocytes due to loss of Fto, which only occurs in murine (3T3-L1) cells and 
not in human ASCs, could – during embryonic development – create the cellular anlagen for 
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subsequent increased adiposity. While the effect of decreased Fto expression in vitro (inhibited 
adipogenesis) supercedes the effect of decreased Rpgrip1l expression (enhanced adipogenesis), 
there are likely to be many factors to which preadipocytes may be sensitive to in vivo that were 
not represented in cell culture that may alter this balance between the effects of these co-
regulated genes.  
We suggest that the late loss of fat mass in Fto-/- mice is a form of lipodystrophy, with 
impaired lipid handling and endocrine function in adipocytes. Fto expression is increased during 
adipogenesis, and this correlation could point to its primary function in mature adipocytes. We 
tested the role of Fto in mature adipocytes by knocking it down in mature 3T3-L1 cells after 
differentiation. We observed decreased expression of developmental genes (Cebpd, Pparg and 
Cebpa) glucose (Glut4) and fatty acid and lipid uptake (Fabp4 and Lpl) genes in addition to 
decreased lipid content. Adiponectin expression and secretion were also decreased. Although we 
did not observe a significant decrease in leptin produced per cell, 3T3-L1 adipocytes in culture 
express low levels of leptin (Slieker, Sloop et al. 1998), making them unreliable reporters of 
leptin production in vivo. Adiponectin itself may also impact food intake, although 
overexpression of adiponectin in mice has had divergent effects on body weight and food intake 
(Qi, Takahashi et al. 2004, Kim, van de Wall et al. 2007, Kubota, Yano et al. 2007). Mice 
segregating for a dominant negative mutation of Fto, while protected from diet-induced obesity, 
exhibit metabolic defects consistent with a lipodystrophic phenotype; namely increased 
circulating glucose, triglycerides and cholesterol (Church, Lee et al. 2009). Growing evidence, 
including a recent meta-analysis, has suggested that there may be some contribution of the FTO 
locus to diabetes beyond its effect on adiposity (Hertel, Johansson et al. 2011, Li, Kilpelainen et 
al. 2012, Fall, Hagg et al. 2013, Yang, Liu et al. 2017). With risk alleles of rs8050136 and 
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rs1421085 decreasing expression of FTO by limiting binding of the activator form of CUX1, 
p110, adipocytes might be limited in their ability to properly store lipid, leading to ectopic lipid 
accumulation and adverse metabolic consequences (Unger and Scherer 2010, Virtue and Vidal-
Puig 2010).  
Fto has been shown to be decreased upon fasting in mesenteric adipose tissue, likely due 
to the decreased enzymatic activity of Cathepsin L, the proteolytic enzyme responsible for 
processing full length Cux1 p200 into p110 (Stratigopoulos, LeDuc et al. 2011). We anticipate 
that adipocytes in mesenteric adipose tissue might be especially responsive to the presence of 
FTO risk alleles, thereby reducing FTO expression. This decreased expression of FTO might 
allow normal to increased lipid handling in subcutaneous adipose depots, while rendering 
adipocytes of the mesenteric depot incapable of performing their lipid handling duties, which are 
already functionally impaired, compared to other depots (Karastergiou, Smith et al. 2012). These 
effects could explain the association of the FTO obesity locus to type 2 diabetes, beyond that 
attributable to elevated body weight.  
We performed RNAseq in preadipocytes to identify primary regulators of Fto’s effect on 
adipogenesis and found that C/ebpβ and C/ebpδ-mediated transcription, required for 
adipogenesis, is dramatically altered. Fto has been identified as an RNA demethylase of m6A 
modifications (Gerken, Girard et al. 2007, Jia, Fu et al. 2011) and the locations and functions of 
m6A modifications have been increasingly well described (Dominissini, Moshitch-Moshkovitz 
et al. 2012, Meyer, Saletore et al. 2012, Dominissini, Moshitch-Moshkovitz et al. 2013, Meyer, 
Patil et al. 2015). Although the demethylase function of Fto is clearly required for its effects on 
adipogenesis (Zhao, Yang et al. 2014, Merkestein, Laber et al. 2015, Wang, Zhu et al. 2015, 
Zhang, Zhang et al. 2015), we did not identify any changes by m6A-RIP in the m6A methylation 
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status of candidates most highly regulated by Fto knockdown. It is possible we were unable to 
detect differences in m6Am, which Fto preferentially demethylates, among a large number of 
m6A moieties (Mauer, Luo et al. 2016). Additionally, we did not observe any effects on Fto-
regulated targets which would be predicted by the purported mechanisms of m6A demethylation, 
such as changes in transcript stability or translational differences. We did not test for variations 
in splicing, but the most promising candidates, Cebpb and Cebpd, are monoexonic genes that 
lack splice variants. Also, we were unable to recapitulate previous results indicating that Runx1t1 
is differentially spliced in the Fto knockdown condition (Zhao, Yang et al. 2014, Merkestein and 
Sellayah 2015). Our results are consistent with the report by Wu et. al. (Wu, Saunders et al. 
2010) identifying Fto as a transcriptional coactivator that facilitates C/ebpβ transactivation of the 
unmethylated C/ebp-response element (CEBPRE). Additionally, Fto activates C/ebpβ-driven 
transcription from methyl-inhibited CEBPREs. Whether Fto demethylates CpGs in CEBPREs 
directly or m6A modifications of transcripts which modify CEBPRE methylation remains 
unclear. 
We also identified Ptprv and Spon2 as effectors of Fto’s effect on proliferation. Although 
the human homolog of murine Ptprv, PTPRVP, is a pseudogene (Cousin, Courseaux et al. 2004), 
and undetectable by qPCR, other effectors of cell cycle arrest – GADD45A, MDM2 and 
CDKN1A – are upregulated in human ASCs following FTO knockdown. C/ebpβ has been 
demonstrated to inhibit expression of the tumor suppressor p53 (Ewing, Zhu et al. 2008), which 
drives expression of Ptprv (Doumont, Martoriati et al. 2005) suggesting that the upregulation of 
Ptprv after Fto knockdown is an effect of impaired C/ebpβ function. SPON2, a gene encoding an 
extracellular matrix protein (Feinstein, Borrell et al. 1999) is upregulated in human ASCs upon 
FTO knockdown. Spon2 upregulation is due to elevated Ptprv expression in 3T3-L1 cells 
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following Fto knockdown, suggesting that a similar pathway is being regulated by FTO in 
human cells. We suggest that this pathway may contribute to the severe malformations evident in 
humans with FTO loss-of-function mutations, and in the runting of Fto-/- mice. 
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Figure 4.1 Knockdown of Fto/FTO prior to differentiation impairs adipogenesis in 3T3-L1 




Results in upper panels (A-E) are from murine 3T3-L1 cells treated prior to confluence with 
siRNA targeted against Fto (siFto; dark gray bars) vs non-targeted controls (siCtr; black bars). 
Results in lower panels (F-J) are from human ASCs treated at confluence with siRNA targeted 
against FTO (siFTO; dark gray checkered bars) vs non-targeted controls (siCtr; black checkered 
bars). (A&F) qPCR analysis of Fto/FTO transcript levels in preadipocytes (2 days post-
confluence) and mature adipocytes (3T3-L1: 2-day post-confluent cells differentiated with 
insulin, dexamethasone and 3-Isobutyl-1-methylxanthine (IBMX) for 2 days, followed by 
maintenance for 5-9 days with insulin only; human ASCs: 2-day post-confluent cells incubated 
with differentiation cocktail for 7 days, followed by maintenance media for 3-7 days (Lee and 
Fried 2014)) after treatment with siRNA targeted against Fto/FTO. (B&G) Representative 
images of Oil Red O staining of adipocytes for neutral lipid. mRNA transcript levels of 
adipocyte developmental and functional genes (C&H) Cebpb/CEBPB and Cebpd/CEBPD in 
preadipocytes and (D&I) Pparg/PPARG, Cebpa/CEBPA, Fabp4/FABP4, Glut4/GLUT4, 
Plin1/PLIN1, Lep/LEP, and AdipoQ/ADIPOQ in mature adipocytes. (E&J) Percentage of live 
cells positive for Nile Red staining for intracellular lipid analyzed by flow cytometry. mRNA 
expression has been normalized to Rplp0 or RPLP0. For human ASCs, results are replicated in 
cells from 4 individuals total (2 females and 2 males, adults) and mRNA expression is 
represented as the mean (± SEM) of data points from all four individuals where each data point 
is the mean of 4-6 technical replicates; paired t-test. All other plots represent means (± SEM) for 




Figure 4.2 Fto knockdown decreases expression of proximate genes Rbl2 and Rpgrip1l in 3T3-
L1 cells but only affects RBL2 in human ASCs. 
 
Map of the murine (A) and human (B) Fto/FTO gene and vicinal genes created from the 
GRCm38/mm10 and GRCh38/hg38 assemblies using the UCSC Genome browser: 
http://genome.ucsc.edu (Kent, Sugnet et al. 2002). Region of linkage disequilibrium surrounding 
the most significant SNPs shaded gray (Loos and Yeo 2014). qPCR analysis of expression of 
genes vicinal to Fto/FTO in 3T3-L1 (C; n=6, unpaired t-test) and human ASC (D) preadipocytes 
following Fto/FTO knockdown. mRNA expression has been normalized to Rplp0 or RPLP0. For 
human ASCs, results have been replicated in cells from 4 individuals total (2 females and 2 
males) and mRNA expression is represented as the mean (± SEM) of datapoints from all four 








Volcano plot (A) of RNAseq analysis of 2-day post-confluent 3T3-L1 preadipocytes following 
Fto knockdown. Differentially expressed genes (p<0.05 following Bonferroni correction for 
multiple testing) are marked in red. Genes with ≥2-fold increase or ≤0.5-fold decrease and 
unadjusted p<10-5 indicated in green. Peak mRNA expression of Cebpb (2 hrs; B) and Cebpd (1 
hr; C) after adding differentiation media to 2-day post-confluent 3T3-L1 preadipocytes. qPCR 
confirmation (D) of the most significantly up- or downregulated candidate genes in post-
confluent 3T3-L1 preadipocytes, following knockdown of Fto vs non-targeted controls (n=6; 
unpaired t-test; representative of 2 independent experiments); listed in order of effect size 
observed by RNAseq (most downregulated to most upregulated). Expression of homologs of 
Fto-targeted genes in human ASC preadipocytes (E) and mature adipocytes (F) following FTO 
knockdown identified by RNAseq in murine 3T3-L1 preadipocytes. Expression of cell cycle 
arrest genes in human ASC (G) preadipocytes and (H) mature adipocytes. nd=none detected. 
Three different primer pairs were used to examine PTPRVP expression in human ASCs. mRNA 
expression has been normalized to RPLP0 and is represented as the mean (± SEM) of data points 
from four individuals (2 females and 2 males, adults) where each data point is the mean of 6 
technical replicates; paired t-test. Plots represent mean (± SEM); * p<0.05, ** p<0.01, 




Figure 4.4 Candidate genes regulated by Fto do not exhibit altered m6A patterns, transcript 
stability or translation in 3T3-L1 preadipocytes.  
 
qPCR of Fto-regulated genes in 2-day post-confluent 3T3-L1 preadipocytes after pulldown with 
anti-m6A antibody following Fto knockdown, normalized to transcript levels in input sample (A) 
and calculated as fold-change (B; n=3-4 per condition). mRNA expression of Cebpb (B&H), 
Cebpd (C&I), Ptprv (D&J), Spon2 (E&K) and Pten (F&L) after treatment with Actinomycin D 
(ActD) to inhibit transcription, reported as expression relative to 18s rRNA levels (B-F) and 
calculated as a percentage of initial expression (H-L). Protein levels of C/ebpβ isoforms, 
measured by western blot (M), quantified in (N). All plots represent means (± SEM) for n=4-6 




Figure 4.5 Knockdown of siFto-upregulated Ptprv restores adipogenesis. 
 
qPCR analysis of Fto (A), Ptprv (B), Spon2 (E), Cebpb (H) and Cebpd (I) expression in 3T3-L1 
preadipocytes and Pparg2 (C) expression in mature adipocytes following single Fto knockdown 
(solid gray bars) or double Fto/Ptprv expression (open gray bars) prior to confluence and 
differentiation. Mature adipocytes stained for Oil Red O (D) and % of live cells positive for Nile 
Red staining analyzed by flow cytometry (F). Total number of live cells collected by flow 
cytometry (G) after differentiation. All plots represent means (± SEM) for n=3-4 per condition; 











Western blot (A) and quantification (B) of phospho-Akt (Ser473) normalized to total Akt in 3T3-
L1 preadipocytes after 4hrs of serum starvation followed by treatment with or without 1µg/ml 
insulin for 15 minutes. Quantification of western blots for phospho-Akt1/total Akt1 (C) and 
phospho-Akt2/ total Akt2 (D) in serum-starved preadipocytes treated with insulin for 15 mins. 
Quantification of western blots for phospho-Akt/total Akt (E) and phospho-Foxo1 (Ser256)/total 
Foxo1 (F) in mature 3T3-L1 adipocytes treated with 1µg/ml insulin for 15 mins. Quantification 
of western blot for adiponectin (G) in mature 3T3-L1 adipocytes and ELISA of adiponectin (H) 
secreted into 1ml of culture media 3 days after the previous media change (cells were cultured in 
a 12 well plate). 3T3-L1 preadipocytes (2 days post-confluence) were serum starved overnight 
and then glucose starved for 40 mins prior to stimulation with or without insulin (1µM) for 20 
mins. This was followed by addition of 2-deoxyglucose (2-DG) for 20 mins (n=3 for 2-DG 
treated conditions, n=1 for 2-DG untreated negative controls). Cells were lysed and 2-DG 
concentrations were assayed (I). mRNA expression of Slc2a1 (J) in 3T3-L1 preadipocytes and 
mature adipocytes. mRNA expression was normalized to 36B4. pAkt (total, pAkt1 and pAkt2), 
Akt (total, Akt1 and Akt2), pFoxo1 and Foxo1 protein bands were first normalized to αTub 
before determining the ratios of phospho/total protein levels. Adiponectin bands were normalized 










Fto expression (A) in the isolated preadipocyte-containing stromal vascular fraction (SVCs; dark 
blue) and mature adipocytes (light blue) of perigonadal (PGAT) and subcutaneous (SCAT) 
adipose tissue of 4-month-old male C57BL/6 mice. mRNA expression of Fto (B) three days after 
electroporation of mature 3T3-L1 adipocytes with siRNA targeted against Fto. mRNA 
expression of Pparg2, Cebpa, Fabp4, Glut4, Plin2, Lpl, Lep and Adipoq (C). Representative 
image (D) and quantification (E) of Oil Red O lipid staining. Total number of live cells (F), 
percentage of cells stained positive for Nile Red (G), number of Nile Red positive cells (H) and 
amount of lipid per Nile Red positive cell (I) acquired by flow cytometry. Adiponectin (J) and 
leptin (K) secretion into cell culture media, and amount of adiponectin (L) and leptin (M) 
secreted, normalized to total number of adipocytes (N). mRNA expression of Pten after Fto 
knockdown. mRNA expression was normalized to 36B4 in in vitro experiments and to the 
arithmetic mean of 36B4, bAct, Gapdh and Ppia in adipose tissue expression analyses. n=4-5 per 





Supplementary Figure 4.1 Knockdown of Fto/FTO prior to differentiation impairs adipogenesis 
in 3T3-L1 adipocytes and human adipose stromal cells (ASCs) but does not affect Runx1t1 






Representative images (A) and quantification (B) of western blots for Fto and bAct protein in 
3T3-L1 preadipocytes and mature adipocytes following Fto knockdown prior to confluence. 
mRNA expression of Lpl in mature 3T3-L1 adipocytes (C). Quantification (D) by absorbance at 
490 nm of extracted Oil Red O stain of mature adipocytes. ELISA analysis of total leptin 
secretion into media (E) by mature adipocytes and leptin secretion (G) normalized by number of 
adipocytes (determined by flow cytometry; F). Median Nile Red fluorescence intensity (H) of 
Nile Red positive cells and number of live cells (I) normalized to counting beads measured by 
flow cytometry in adipocytes. Representative images (J) and quantification (K; n=3/condition) 
of western blot for FTO and βACT protein in human ASCs differentiated into mature adipocytes 
following FTO knockdown. Quantification (L) by absorbance at 490 nm of extracted Oil Red O 
stain and median Nile Red fluorescence intensity (M) of Nile Red positive human ASCs. 
Transcript levels of short (N) and long (O) Runx1t1 splice variants as well as the ratio of 
short/long Runx1t1 (P) in 3T3-L1 preadipocytes and mature adipocytes. mRNA levels of brown 
adipocyte markers Ucp1, Cidea, Pgc1a and Cox7a in 3T3-L1 adipocytes (Q). RNA expression is 
normalized to Rplp0. Plots represent means (± SEM) for n=4-6 per condition except where 




Supplementary Figure 4.2 Knockdown of Ptprv in siFto-treated 3T3-L1 adipocytes restores 
adipogenesis.  
 
Quantification by absorbance at 490 nm of extracted Oil Red O stain (A) in mature 3T3-L1 
adipocytes following single Fto knockdown (solid gray bars) or double Fto/Ptprv expression 
(open gray bars) prior to differentiation. Total number of live cells (B) normalized to counting 
beads measured by flow cytometry after differentiation. Pten (C) expression in 3T3-L1 
preadipocytes. All plots represent means (± SEM) for n=3-4 per condition; unpaired t-test. * 





Supplementary Figure 4.3 Knockdown of Spon2 in siFto-treated 3T3-L1 adipocytes restores 
adipogenesis. 
qPCR analysis of Fto (A), Spon2 (B), Cebpb (H) and Cebpd (I) expression in 3T3-L1 
preadipocytes following single Fto knockdown (solid gray bars) or double Fto/Spon2 expression 
(hatched gray bars) prior to confluence and differentiation. Percentage of mature adipocytes 
stained for Nile Red (C) and median Nile Red fluorescence in the adipocyte population (D) 
analyzed by flow cytometry. Total number of live cells collected by flow cytometry (E) after 
differentiation. Representative image (F) and quantification (G) of Oil Red O staining of mature 
adipocytes. All plots represent means (± SEM) for n=3-4 per condition; unpaired t-test. * p<0.05, 




Supplementary Figure 4.4 Fto knockdown increases Akt signaling in 3T3-L1 cells. 
 
Western blots of phospho-Akt1, total Akt1 and αTub (A) as well as phospho-Akt2, total 
Akt2 and αTub (B) in 3T3-L1 preadipocytes after 4hrs of serum starvation followed by treatment 
with or without 1µg/ml insulin for 15 minutes. Western blots for phospho-Akt (Ser473), total 
Akt and αTub (C) and phospho-Foxo1 (Ser256), total Foxo1 and αTub (D) in mature 3T3-L1 
adipocytes treated with 1µg/ml insulin for 15 mins. Western blot for adiponectin and βAct (E) in 





Supplementary Table 4.1 qPCR primers Mm 
Mm: Forward Reverse 
36B4 (Rplp0) ACCTCCTTCTTCCAGGCTTTGG CGAAGGAGAAGGGGGAGATGTT 
ActB   CGGGCTGTATTCCCCTCCAT GGGCCTCGTCACCCACATAG 
Gapdh CTGGAGAAACCTGCCAAGTATGATG GAGACAACCTGGTCCTCAGTGTAGC 
Ppia CTTCGAGCTGTTTGCAGACAAAGTT GGAGGAACCCTTATAGCCAAATCCT 
Fto GGCGGCTTTAGTAGCAGCAT CCAAGTGTCTTCAAGCTCCTC 
Cebpb CAAGCTGAGCGACGAGTACA  AGCTGCTCCACCTTCTTCTG 
Cebpd GACGAGAGCGCCATCGACTT CCGCTTTGTGGTTGCTGTTG 
Pparg2 TTTGAAAGAAGCGGTGAACCA CGAAGTTGGTGGGCCAGAAT 
Cebpa GCCATGCCGGGAGAACTCTA GGGCTCTGGAGGTGACTGCT 
Fabp4 TTGGTCACCATCCGGTCAGA TCCACCACCAGCTTGTCACC 
Glut4 AGCTGTGCTTGGCTCCCTTC CCCAGCCACGTTGCATTGTA 
Plin1 GTGTACAGGGTGCCAGCAA CTCTGCAGGCCAACTCATTG 
Lep CGAGGAATCGTTCTGCAAATCC GCCAGGTTAAGTGCAGCTATCACA 
Adipoq CAGGCCGTGATGGCAGAGAT GTGGCCCTTCAGCTCCTGTC 
Lpl CCACAGCAGCAAGACCTTCG TACAGGGCGGCCACAAGTTT 
Chd9 CCCCACTGTCTACCAACCAT  TGTCCCAGAACCATCACTCT 
Rbl2 TACCGCAGCATGAGCGAGAG GCGGTCCCTTTGCTCACAGT 
Aktip GAACCCTTTGTGGAGCATGT  TTCGTGGAGGACTGGTTTTC 
Rpgrip1l ATTGCAGCGTGTCAGTTGAG  TGCTGACTCGACAATTGCAT 
Irx3 AGCTGCCCATCTTCCCACAG  CGGGTCCCCGAACTGGTACT 
Irx5 CCGGCTACAACTCGCACCTC  CCAAGGAACCTGCCATACCG 
Crnde GTCCAGGACGAAGACTTCTGA  CCTCCAAACATGACACCAGC 
Adi1 CTATCACCGCTTCACACTGGA  GGCCGGTTGTATGGTGTCC 
Lpcat2 GTCCAGCAGACTACGATCAGT  GCAGCAAAATTATTCCAACCAGT 
Clca1 GAAGCAACAAGGTGTTCCACCA  GCACGCCCTTGTGACACAGT 
Mlec1 AGCCTCGGACTATGGCATGA  TGTACCGCTCTGTCTGATATAGG 
Akr1c14 GTGTGGTACTAAACGATGGTCAC CAAATAAGCGGAGTCAAAATGGC 
Abhd13 TTCCCGCCTTTATGTTCCCAT TGTCTCCAGTGTATCTCACCAA 
Pofut1 CGGCCCTATGTGGGCATTC  AAGCCATGAAGTGTGACCCTG 
B4galt1 CTGGCTGTATTATTTGCATCCCA  AGCTCGATTGAACATGGTGTC 
Tmed5 CAAGGCCAAGAAGACTGGAA  TTGTATGTGGCCACTTTTGC 
Rmnd5a TGCGAAAAATTTCCAGCCATT  CCCTTGTCGCAGGTACACGA 
Zfp617 AGGACAGAAATTGGGAGAACAGA  TACACATGGCTTTCACAGGGC 
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Cd2ap CTCTCCACAAAATGAGGACGAA  CTTATTGTTCAGGGTTCCACTCC 
Cops4 TCTGGCGGGCAAATATCGTC  GATCACGAGGCTGACATTCTC 
Txndc16 AGAAGCGTCAAGGTACTGTGG  GAAGGTCTTCCAGGGTGGTAA 
Pten ACACCGCCAAATTTAACTGC  CGTCCCTTTCCAGCTTTACA 
Yap1 TGAGATCCCTGATGATGTACCAC TGTTGTTGTCTGATCGTTGTGAT 
Rell1 GGTCGGCCAGATTGTCCAG TGACAGGGCTTTCAATATCGC 
Grem2 GGTAGCTGAAACACGGAAGAA TCTTGCACCAGTCACTCTTGA 
Spon2 ACCGGGCAGACTTCCACAGA  AGTCAGGGCTGGGGACAATG 
Ptprv AGGTAGTCAGTATGTCTTGGAGG  GGCACGCAGTGTTAGGTGA 
Grpr155 CTTGTGGGCGTGCTTCTGATA  TGACACCCCAGCTATGAGAATG 
Tusc5 CCTTGCCATTGCCTCTTGCT  GGTCCCCCTGCTGCACACTA 
Rhob GTGCCTGCTGATCGTGTTCA  CCGAGAAGCACATAAGGATGAC 
Wnt4 GCCGGGCACTCATGAATCTT  CACCCCGTGACACTTGCACT 
Klf2 CTCGCACCTAAAGGCGCATC  GTGGCGGGTAAGCTCGTCAG 
Slc2a1 TTCTCTGTCGGCCTCTTTGT  GAGAAGCCCATAAGCACAGC 
Runx1t1 S GCGAACTCCAGACAGGGTTACATGG CCACCATGTCCATGATGCAG 
Runx1t1 L GAACTCCAGACAGAACCAAAGAAAAT  CAGGCCATTTGGCTGGTAGG 
Ucp1 CGGGCATTCAGAGGCAAATC  ATGGCTCTGGGCTTGCATTC 
Cidea AGTAGCCGGCGTGGGGTGAT  CCTCCAGCACCAGCGTAACC 
Pgc1a ACCAGCCTCTTTGCCCAGAT CCGCTAGCAAGTTTGCCTCA 
Cox7a CAGGCTCTGGTCCGGTCTTTT  TCCCCCGCCTTTCAAGTGTA 





Supplementary Table 4.2 qPCR primers Hs 
Hs: Forward Reverse 
36B4 (RPLP0) GAAGACAGGGCGACCTGGAA TCTGCTTGGAGCCCACATTG 
FTO GACTGCCGAGGAACGAGAGC GGGGTCAGATAAGGGAGCCAAG 
CEBPB CAAGAAGACCGTGGACAAGC  AGCTGCTCCACCTTCTTCTG 
CEBPD ATCGACTTCAGCGCCTACAT  CGCCTTGTGATTGCTGTTGA 
PPARG TCATGCTTGTGAAGGATGCAA TGTGGATCCGACAGTTAAGATCACAT 
CEBPA GCCATGCCGGGAGAACTCTA TCTGCAGGTGGCTGCTCATC 
FABL4 CACAAAATGTGTGATGCTTTTGTAGG GCCACTTTCCTGGTGGCAAA 
GLUT4 GTGCTTGGCTCCCTGCAGTT CTCCCCAGCCACGTCTCATT 
PLIN1 TGCAGAGCGCCAGTAGCTTG  GCGGGGATCTTTTCCTCCAG 
LEP TGACACCAAAACCCTCATCAAGA  GGTGGAGCCCAGGAATGAAG 
ADIPOQ CGGGATTTCACCATGTTGTCC TCATGACCGGGCAGAGCTAA 
CHD9 CAAAGTCAGGCTCGGAGTTG  CCCAGAACCATCGCTCTTCT 
RBL2 ACGCTGGAGGGAAATGATCT  TGCCATGTCTTCCCACTTCT 
AKTIP AGGCTGGTGGGTAAAGTGAA  TTCTTTGGTGCAGTTCGTGG 
RPGRIP1L ACTGCAGGAGACTTGCCTGT  CCAGTTCCTCACGACTGACA 
IRX3 GGAGCTGCCCATCTTCCC  CATACGGGTAGAAGGCGGG 
IRX5 ACCTGGAGAAGAACGACGAG  GCGGCTCCTTAAAATCCGAG 
CRNDE TTTCCGGAGTAGAGCCCTTG  TTTCCAGTGGCATCCTCCTT 
PTPRVP 
(Cousin, Courseaux 
et al. 2004) CCTAGAATCCCAGACATTGGCA GCTGGTTGTTGCTTGGAGGTT 
PTPRVP 
(Doumont, 
Martoriati et al. 
2005) GTTGATGCCTTACAACCTGTGGCG  AGCTGCTTCACGCGCCTCTGTT 
PTPRVP ACACCTGGATGCAACCTCTC  GGTGTAGCCTGGGATGAAGT 
TMED5 GGGAGAACAGGCACAAGAAC TGATGGATTCCAGGATGTCT 
SPON2 CGCTGATGAAGGAGATCGAG  ATGCGCACCACAAACGAG 
GREM2 CAGAGAAGGCAGAGGGAGAG CCAGGAACAAGGACAGGGAA 
KLF2 TGCGGCAAGACCTACACCAA GTCTGAGCGCGCAAACTTCC 
WNT4 CCTTCGTGTACGCCATCTCT  TCAGAGCATCCTGACCACTG 
PTEN ACACCGCCAAATTTAATTGC  TAGGGCCTCTTGTGCCTTTA 
GADD45A ACGAGGACGACGACAGAGAT  GCAGGATCCTTCCATTGAGA 
MDM2 ATGAAAGCCTGGCTCTGTGT  CCTGATCCAACCAATCACCT 




Chapter 5 Genome-wide meta-analysis uncovers novel loci influencing circulating leptin 
levels  
 
Tuomas O. Kilpeläinen, Jayne F. Martin Carli*, Alicja A. Skowronski*, et al. (…) Rudolph L. 
Leibel, and Ruth J. F. Loos  
Author contributions:  
* These authors contributed equally to this work. 
For a full list of authors please refer to:  
https://www.nature.com/articles/ncomms10494#author-information 
T.O.K. and R.J.F.L. conceived and designed the study. T.O.K. and Q.S. performed the meta-
analyses. J.F.M.C., A.A.S., C.A.L., Y.Z. and R.L.L. carried out the knockdown studies in mouse 
adipose tissue explants. T.O.K., J.F.M.C., A.A.S., Q.S., J.K., M.F.F., P.W.F., C.M.L., R.L.L. and 
R.J.F.L. wrote the manuscript. 





Leptin is an adipocyte-secreted hormone, the circulating levels of which correlate closely 
with overall adiposity. Although rare mutations in the leptin (LEP) gene are well known to cause 
leptin deficiency and severe obesity, no common loci regulating circulating leptin levels have 
been uncovered. Therefore, we performed a genome-wide association study (GWAS) of 
circulating leptin levels from 32,161 individuals and followed up loci reaching P<10−6 in 19,979 
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additional individuals. We identify five loci robustly associated (P<5 × 10−8) with leptin levels 
in/near LEP, SLC32A1, GCKR, CCNL1 and FTO. Although the association of the FTO obesity 
locus with leptin levels is abolished by adjustment for BMI, associations of the four other loci 
are independent of adiposity. The GCKR locus was found associated with multiple metabolic 
traits in previous GWAS and the CCNL1 locus with birth weight. Knockdown experiments in 
mouse adipose tissue explants show convincing evidence for adipogenin, a regulator of 
adipocyte differentiation, as the novel causal gene in the SLC32A1 locus influencing leptin 
levels. Our findings provide novel insights into the regulation of leptin production by adipose 
tissue and open new avenues for examining the influence of variation in leptin levels on 






Leptin is an adipocyte-secreted hormone that influences long-term regulation of energy 
homeostasis by informing the brain about the amount of stored body fat (Ahima, Prabakaran et 
al. 1996, Montague, Farooqi et al. 1997). Circulating leptin levels correlate closely with 
measures of adiposity, such as body fat mass and body mass index (BMI) (Shah and Braverman 
2012). Yet, at any given level of adiposity, there is substantial variation in circulating leptin 
levels (Considine, Sinha et al. 1996), of which estimated 30–50% is explained by genetic factors 
(Narkiewicz, Szczech et al. 1999, Rice, Chagnon et al. 2002, Liu, Butler et al. 2010). 
Rare homozygous loss-of-function mutations in the leptin-encoding gene (LEP) cause 
leptin deficiency that leads to hyperphagia and severe obesity, which can be corrected by 
exogenous leptin administration (Farooqi, Jebb et al. 1999). Leptin-deficient children are born 
with a normal birth weight but exhibit rapid weight gain in the first few months of life. They 
show marked abnormalities of T-cell number and function, and have high rates of childhood 
infection (Farooqi, Matarese et al. 2002). Hypothalamic hypothyroidism is present, characterized 
by a low free thyroxine and high serum thyroid-stimulating hormone levels (Strobel, Issad et al. 
1998). Pubertal development generally does not occur due to hypogonadotropic hypogonadism 
(Strobel, Issad et al. 1998). Individuals heterozygous for leptin mutations exhibit a partial leptin 
deficiency with higher body fat than control individuals (Farooqi, Keogh et al. 2001). 
Candidate gene studies, typically small in size, have reported associations of two 
common variants (A19G (rs2167270, minor allele frequency (MAF) 35%) and G2548A 
(rs7799039, MAF 49%)) in the promoter or 5′-untranslated region of LEP with circulating leptin 
levels in the general population, but these results are inconclusive (Hager, Clement et al. 1998, 
Le Stunff, Le Bihan et al. 2000, Mammes, Betoulle et al. 2000, Ben Ali, Kallel et al. 2009, 
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Fourati, Mnif et al. 2013). The same LEP variants have been studied for association with obesity, 
but a meta-analysis of the published results (nA19G=918 and nG2548A=2,174) found no evidence of 
such association17. Candidate gene studies of LEP were published before the human genome 
sequence was extensively characterized and are therefore restricted to the variants known at that 
time. Furthermore, although LEP is an obvious candidate, variants in other genes may also 
influence circulating leptin levels by regulating leptin production, secretion, clearance or 
response. Identification of such leptin-regulating genes could provide novel insights into 
mechanisms that regulate energy homeostasis and neuro-endocrine function (Ahima, Prabakaran 
et al. 1996, Montague, Farooqi et al. 1997). 
In this study, we sought to identify genetic loci associated with circulating leptin levels 
by a genome-wide meta-analysis. Given the strong correlation between leptin and adiposity, we 
also examined genome-wide associations with circulating leptin levels adjusted for BMI, to 







Study design. We conducted a two-stage meta-analysis to identify leptin-associated loci 
in adults of European ancestry. In stage 1, we performed a meta-analysis of 23 GWAS 
(n=32,161) (Supplementary Table 5.1) for BMI-unadjusted and BMI-adjusted circulating levels 
of leptin. Stage 2 included 13 additional studies (n=19,979), which provided either de novo or in 
silico data for the lead SNPs of the independent loci reaching P<1 × 10−6 in Stage 1 
(Supplementary Table 5.5). Secondary meta-analyses were conducted in men (n=13,363) and 
women (n=18,698) separately, and with adjustment for body fat percentage (assessed by dual-
energy X-ray absorptiometry or bioimpedance analysis) instead of BMI (n=18,980). The study-
specific descriptive statistics are presented in Supplementary Table 5.23. 
Stage 1 genome-wide association analyses. Following study-specific quality control 
measures, the genotype data were imputed using the HapMap Phase II CEU reference panel 
(Supplementary Table 5.24). Directly genotyped and imputed variants were then tested for 
association with logarithmically transformed leptin (ng ml−1), adjusting for age, age (Montague, 
Farooqi et al. 1997) and any necessary study-specific covariates (for example, genotype-derived 
principal components) in a linear regression model. The analyses were performed with and 
without additional adjustment for BMI. In studies that had assessed body fat percentage with 
bioimpedance analysis or dual-energy X-ray absorptiometry, additional analyses were performed 
with adjustment for body fat percentage. The analyses were performed in men and women 
separately. In studies that included closely related individuals, regression coefficients were also 
estimated in the context of a variance component model that modeled relatedness in men and 
women combined, with sex as a covariate. 
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Before performing meta-analyses on the data from individual studies, SNPs with poor 
imputation quality scores (r2-hat <0.3 in MACH, proper-info <0.4 in IMPUTE, INFO <0.8 in 
PLINK) or with a minor allele count <6 were excluded for each study (Supplementary Table 
5.24). The genotype data for the leptin-associated lead SNPs was of high quality with a median 
imputation score of ≥0.94 (Supplementary Table 5.26). The fifth percentile for all SNPs was 
≥0.80, except for the previously established rs900400 SNP near CCNL1. 
All individual GWAS were genomic control corrected before meta-analyses. Individual 
study-specific genomic control values ranged from 0.977 to 1.051. Fixed effects meta-analyses 
were then conducted using the inverse variance-weighted method implemented in METAL. The 
genomic control values for the meta-analysed results were 1.050, 1.026 and 1.022 in the BMI-
unadjusted meta-analyses of all individuals, men and women, and 1.046, 1.022 and 1.015 in the 
BMI-adjusted meta-analyses, respectively. Using the LD score regression method (Farooqi, 
Wangensteen et al. 2007) in the Stage 1 meta-analyses suggests that the observed inflation is not 
due to population substructure. The regression intercept, which estimates inflation after 
removing polygenic signals, was 0.994 for BMI-unadjusted and 1.004 for BMI-adjusted meta-
analyses of men and women combined. 
Selection of SNPs for follow-up. We used a pairwise distance criterion of ±500 kb and 
r2<0.1 between SNPs that reached P<10−6in the meta-analysis of BMI-adjusted or -unadjusted 
meta-analysis of leptin levels in Stage 1 in men and women combined or separately, to select loci 
forward for follow-up in Stage 2. We tested the association of the lead SNPs in up to 19,929 
adults of white European ancestry in Stage 2. 
Stage 2 follow-up of the loci reaching P<10−6 in Stage 1. Association results were 
obtained from 13 studies that had not been included in the Stage 1 meta-analyses 
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(Supplementary Table 5.5). Samples and SNPs that did not meet the quality control criteria 
defined by each individual study were excluded. Minimum genotyping quality control criteria 
were defined as Hardy–Weinberg equilibrium P>10−7, call rate >90% and concordance >99% in 
duplicate samples in each of the follow-up studies. 
We tested the association between the SNPs and leptin in each Stage 2 study using 
approaches similar to those described for the Stage 1 studies. We subsequently performed a 
meta-analysis of β-coefficients and s.e. from Stage 2 using the inverse variance fixed effects 
method. The final meta-analysis combined GWAS results from Stage 1 with the Stage 2 results. 
The conventional P-value threshold of <5 × 10−8 in the combined Stage 1 and Stage 2 meta-
analysis was used to determine genome-wide significance. 
Identifying genes and biological pathways at associated loci 
Cross-trait look-ups. To further examine the relationship between the leptin-associated 
loci and anthropometric and metabolic parameters, we acquired association results for the loci in 
or near LEP, SLC32A1, GCKR, CCNL1 and COBLL1 from nine GWAS meta-analysis consortia: 
ADIPOGen (BMI-adjusted adiponectin), BCGC (body fat percentage), DIAGRAM (T2D), Early 
growth genetics (birth weight, early-onset obesity), ICBP (systolic and diastolic blood pressure), 
GIANT (height, BMI, waist–hip ratio adjusted for BMI), GLGC (circulating levels of high-
density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides and total 
cholesterol), MAGIC (fasting glucose, fasting insulin) and ReproGen (age at menarche) 
(Supplementary Table 5.7). 
National Human Genome Research Institute GWAS Catalog look-ups. To identify the 
associations of the leptin-associated loci in published GWAS, we extracted previously reported 
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GWAS associations within 500 kb and r2>0.7 with any of the lead leptin-associated SNPs, from 
the GWAS Catalog of the National Human Genome Research Institute 
(www.genome.gov/gwastudies) (Supplementary Table 5.11). 
Overlap with functional regulatory elements. We used the Uncovering Enrichment 
Through Simulation method to combine the leptin association data with the Roadmap 
Epigenomics Project segmentation data (Hayes, Trynka et al. 2015). The pipeline chose 10,000 
sets of random SNPs among HapMap2 SNPs with a MAF>0.05 and that matched the original 
input SNPs based on proximity to a transcription start site and the number of LD partners (r2>0.8 
in individuals of European ancestry in the 1000 Genomes Project). The LD partners were 
combined with their original lead SNP to create 10,000 sets of matched random SNPs and their 
respective LD partners. These sets were intersected with the 15-state ChromHMM data from the 
Roadmap Epigenomics Project and resultant co-localizations were collapsed from total SNPs 
down to loci, which were then used to calculate an empirical P-value when comparing the 
original SNPs with the random sets. In addition to examining overall enrichment for all leptin-
associated loci combined, we examined the variant-specific overlap with regulatory elements for 
each of the leptin-associated index SNPs and variants in strong LD (r2>0.8). 
Expression quantitative trait loci. We examined the cis-associations of the leptin-
associated loci with the expression of nearby genes in the lymphocytes, skin, liver, omental fat, 
subcutaneous fat and brain tissue (Supplementary Table 5.8). Conditional analyses were 
performed by including both the leptin-associated SNP and the most significant cis-associated 
SNP in the association model for a given transcript. To minimize the potential for false positives, 
we only considered associations that reached study-specific Bonferroni-corrected significance 





GRAIL analyses: We used GRAIL to identify genes near the leptin-associated loci having 
similarities in the published scientific text using PubMed abstracts as of December 2006 
(Raychaudhuri, Plenge et al. 2009). The leptin loci were queried against HapMap release 22 for 
the European panel and we controlled for gene size. 
DEPICT analyses: We used DEPICT to identify the most probable causal gene at a given 
associated locus, reconstituted gene sets enriched for BMI associations, and tissues and cell types 
in which genes from associated loci are highly expressed (Pers, Karjalainen et al. 2015). We 
clumped GWAS-based meta-analysis summary statistics using 500 kb flanking regions, LD 
r2>0.1 and excluded SNPs with P≥1 × 10−5. HapMap Project Phase II CEU genotype data were 
used to compute LD and genomic coordinates were defined by genome build GRCh37. 
 
Knockdown of genes in mouse adipose tissue explants 
Materials. Expression analyses were performed on PGAT and SCAT from 4-month-old 
male C57BL/6J mice (derived from Jackson, Stock number 000664) fed chow (Purina PicoLab 
5058) or high-fat diet (Research Diets, Inc., D12492i, 60% kcal from fat), to increase adiposity 
and circulating leptin levels. We measured expression of genes located ±100 kb of each lead 
variant or genes including SNPs with r2>0.4 with the lead variant. Tiparp was included after its 
identification by eQTL analysis, and Ucn and Mpv17 were included based on their proximity to 
variants with r2>0.4 with the lead variant. 
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For knockdown experiments, 15-week-old male C57BL/6J mice fed high-fat diet ad 
libitum starting at 6 weeks of age were purchased from Jackson Laboratory (Stock Number 
380050, Bar Harbor, ME). Animals were maintained at Columbia University animal facility for 
up to an additional 5 weeks until they reached ∼30% fat mass as determined by time-domain 
NMR (Minispec Analyst AD; Bruker Optics, Silberstreifen, Germany). 
Mice were maintained at an ambient temperature of 22 °C–24 °C with a 12-h dark–light 
cycle (lights on at 0700, h) in a pathogen-free barrier facility. The protocol was approved by the 
Columbia University Institutional Animal Care and Use Committee. 
Electroporation and culture of adipose tissue explants. Non-fasted mice were killed at 
around 20 weeks of age at ∼1000, h. PGAT was dissected and minced into 1- to 2-mm 
fragments. These fragments were evenly distributed into three replicates per control or 
knockdown condition. Approximately 7–11 fragments were added per well (for a total amount of 
∼80 mg tissue) in 12-well culture dishes containing 1 ml M199 with Antibiotic-Antimycotic 
(Anti-Anti, 5 ×; Invitrogen). Following a 20-min incubation in 5 × Anti-Anti media, tissue 
fragments were washed twice with 1 ml PBS and then transferred to 4 mm Gene Pulser cuvettes 
(Bio-Rad) and electroporated in 400 μl PBS with 1 nmol siRNA against Lep, Adig, Ift172, 
Mpv17, Tiparp or Cobll1 (Stealth siRNA, Invitrogen). Non-targeting sequences were used as 
negative controls (Invitrogen). Electroporation was performed with a Gene Pulser XceII (Bio-
Rad) using 50 V, 102 wave pulses, with a pulse length of 30 ms and 0.1 ms between pulses (Puri, 
Chakladar et al. 2007). The tissue fragments were subsequently cultured at 37 °C in 5% CO2 in 
12-well plates for 20 h in basal media consisting of M199 media with 10% fetal bovine serum 
(Invitrogen) plus 1 × Anti-Anti before stimulation for 12 h with basal media plus 7 nM insulin 
and 25 nM dexamethasone (both from Sigma), to maintain leptin expression in the explants at 
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levels comparable to those of in vivo tissues (Lee, Wang et al. 2007). Knockdown was 
considered successful if candidate expression was decreased by ≥30%. The effect of insulin and 
dexamethasone on expression of candidate genes was determined using the same mincing and 
culturing strategy without electroporation. 
Measuring mRNA levels and leptin and adiponectin secretion. Total RNA was isolated 
using TRIzol reagent (Invitrogen) and reverse transcribed using Transcriptor First Strand cDNA 
Synthesis Kit (Roche) using both OligoDT and random hexamer primers. Lightcycler 480 SYBR 
Green I Master was used for quantitative PCR assays (Roche). Expression of murine homologues 
of candidate genes in PGAT and SCAT was determined using the 2(−ΔΔC(T)) method (Livak 
and Schmittgen 2001). Gene expression in the knockdown experiments was calculated by 
Lightcycler 480 software (Roche) based on a standard curve. Primers used are listed in 
Supplementary Table 5.25. Culture media was collected from the same samples used for RNA 
analyses. Following the 12 h insulin/dexamethasone stimulation, secreted leptin and adiponectin 
were measured using the Perkin-Elmer AlphaLISA kits for mouse leptin and adiponectin 
(according to the manufacturer's protocol). Not all samples were included for adiponectin 
measurement due to the discontinuation of the AlphaLISA kit by Perkin-Elmer. 
Statistics. Each gene knockdown was tested on tissue from 5 to 13 different mice, as 
indicated. Control and knockdown samples from each mouse were treated as matched pairs. 
Each data point represents the mean of three replicates from a single mouse. Differences between 
control and knockdown conditions were calculated by two-way repeated measures analysis of 





Stage 1 genome-wide meta-analysis in 32,161 individuals 
We first performed a meta-analysis of the results from genome-wide associations 
between ∼2.5 million genotyped and HapMap-imputed single-nucleotide polymorphisms (SNPs) 
and circulating leptin levels, including up to 32,161 individuals of European descent from 23 
studies (Supplementary Table 5.1). After logarithmic transformation that normalized the 
distribution of leptin levels and adjusting for age and sex, we carried out association analyses 
within each study and subsequently meta-analysed the study-specific results. To identify loci 
associated with circulating leptin levels independently of adiposity, we performed a meta-
analysis of genome-wide associations in which we additionally adjusted for BMI. We also 
performed secondary genome-wide meta-analyses in men (n=13,363) and women (n=18,698) 
separately, as women generally have higher leptin levels than men, primarily due to larger 
percentage of body fat and greater subcutaneous fat storage (Hellstrom, Wahrenberg et al. 2000). 
Two loci, near the LEP and SLC32A1 genes, reached genome-wide significance (P<5 × 
10−8) in the BMI-adjusted meta-analysis of men and women combined (Table 5.1). To confirm 
these associations and to identify additional leptin-associated loci, we took forward all 
independent (pairwise distance >500 kb and r2<0.1) SNPs reachingP<10−6 with leptin levels with 
or without adjustment for BMI in meta-analyses of all individuals combined, men only or 




Stage 2 follow-up in 19,979 individuals identifies five loci 
We examined the associations of the loci taken forward from stage 1 in up to 19,979 
additional individuals of European descent from 13 studies (Supplementary Table 5.5). All 
studies performed the same association analyses as described in Stage 1; that is, with and without 
adjustment for BMI and in men and women combined, as well as separately. Finally, after 
performing a joint meta-analysis of the stage 1 and stage 2 results, five independent SNPs 
reached genome-wide significance (P<5 × 10−8) in the combined meta-analyses of men and 
women (Table 5.1). In the BMI-adjusted meta-analysis, we confirmed genome-wide significant 
associations for the loci near LEP and SLC32A1, and identified an additional locus in GCKR. In 
the BMI-unadjusted meta-analysis, we identified two additional loci near CCNL1 and in FTO. A 
locus in COBLL1, previously identified for association with BMI-adjusted waist–hip ratio 
(WHRadjBMI) (Shungin, Winkler et al. 2015), blood triglycerides (Global Lipids Genetics, Willer 
et al. 2013) and risk of T2D (Morris, Voight et al. 2012), reached P=1 × 10−6 with BMI-
unadjusted leptin and P=2 × 10−6 with BMI-adjusted leptin levels, with the leptin-increasing 
allele being associated with lower WHRadjBMI, triglycerides and risk of T2D. 
The estimated effects of five of the six loci (in/near LEP, SLC32A1, GCKR, CCNL1 or 
COBLL1) on leptin levels did not markedly differ in magnitude between the BMI-unadjusted and 
BMI-adjusted models, suggesting that these associations are not mediated by adiposity per se 
(Figure 5.1). In contrast, the association between the FTO locus and leptin levels was 
completely abolished after adjusting for BMI, indicating that the association with leptin is 
entirely mediated by the well-established association between FTO and BMI (Locke, Kahali et 
al. 2015) (Figure 5.1). 
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BMI is the most commonly used index of adiposity, but it is not a direct measure of 
adiposity and it does not distinguish between lean and fat body mass. To assess whether 
adjustment for a more direct measure of adiposity could enhance our ability to identify adiposity-
independent loci, we performed secondary analyses in 13 studies that had data on both BMI and 
body fat percentage assessed by dual-energy X-ray absorptiometry or bioimpedance analysis 
(n=18,980 or 59% of stage 1 sample). The analysis showed no marked differences in the effect 
sizes between the BMI and body fat percentage-adjusted results for the leptin-associated LEP, 
SLC32A1, CCNL1, GCKR, COBLL1 and FTO loci (Supplementary Table 5.6), suggesting that 
adjustment for BMI as compared with a more direct measure of adiposity did not compromise 
our ability to identify adiposity-independent leptin-associated loci. 
Effects on other traits and potential functional roles 
We took forward the genome-wide significant leptin loci near LEP, near SLC32A1, in 
GCKR and near CCNL1, to examine their associations with obesity-related and metabolic traits 
and to more directly assess their putative roles in the control of circulating leptin. We also took 
forward the locus near COBLL1, given its robust association with WHRadjBMI (Shungin, Winkler 
et al. 2015), even though it just missed the genome-wide significance threshold for association 
with BMI-adjusted and BMI-unadjusted leptin levels (Table 5.1). As the FTO-leptin association 
was completely accounted for by FTO's association with BMI (Figure 5.1), extensively 
described in the literature (Loos and Yeo 2014), we did not include this locus in our follow-up 
analyses. 
To examine the associations of the identified loci with obesity-related and metabolic 
traits, we performed look-ups in the data from relevant genetic consortia (Supplementary Table 
5.7). To study the associations of the leptin-associated loci with the expression of nearby genes, 
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we performed cis-expression quantitative trait locus (eQTL) analyses in several human tissues, 
including the subcutaneous (n=776) and omental fat (n=742), liver (n=567), lymphocytes 
(n=778), brain (n=193) and skin (n=667) (Supplementary Table 5.8). We also examined the 
regulatory functions of these loci by studying their enrichment with functional genomic elements 
in data from the Roadmap Epigenomics Project (Roadmap Epigenomics, Kundaje et al. 2015). 
Finally, to identify the causal genes in the leptin-associated loci, we performed ex vivo 
knockdown studies of adipocyte-expressed genes using small interfering RNA (siRNA) in 
explanted mouse adipose tissue. 
Common variation near LEP regulates leptin levels 
The rs10487505 variant (MAF 49%) is located 21 kb from LEP (Figure 5.2A) and is in 
modest linkage disequilibrium (LD) (r2=0.4,D′=0.8) with the A19G (rs2167270, MAF 35%) 
variant that has been extensively studied in candidate gene studies but whose associations with 
increased levels of leptin and obesity have been inconclusive (Hager, Clement et al. 1998, 
Fourati, Mnif et al. 2013). The leptin-increasing allele of the rs10487505 variant has been 
nominally associated with weight regain after bariatric surgery in a candidate gene-based 
analysis of 1,443 patients (Sarzynski, Jacobson et al. 2011). Look-ups in consortium data showed 
a nominally significant association for the leptin-decreasing allele of rs10487505 with higher 
BMI in the GIANT Consortium (P=0.03, N=221,677), as well as with increased risk of early-
onset obesity (P=0.04, N=13,848) and higher birth weight (P=0.02, N=26,836) in the EGG 
Consortium (Supplementary Table 5.7). Although LEP is an obvious candidate gene to account 
for the association with circulating leptin levels, the rs10487505 variant was not associated with 
LEP messenger RNA expression in the omental or subcutaneous adipose tissue (SCAT), liver, 
lymphocytes, brain or skin (Supplementary Tables 5.8&5.9). 
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A variant in strong LD with rs10487505 (rs6979832, r2=0.98) overlapped with predicted 
enhancer elements in all three adipose cell lines of the Roadmap Epigenomics Project (Roadmap 
Epigenomics, Kundaje et al. 2015). Further, a previous study identified a 465-bp adipocyte-
specific enhancer region 4.5 kb upstream from the LEP transcription start site by using luciferase 
assays and chromatin state mapping (Wrann, Eguchi et al. 2012). This region harbours 
rs10249476 that is in modest LD with rs10487505 (r2=0.4,D′=0.8) and reached the second most 
significant association with BMI-adjusted leptin levels in stage 1 meta-analysis (P=3 × 
10−10;n=30,810) (Figure 5.2A). 
Collectively, although the locus near LEP overlaps with predicted enhancer elements, the 
lack of association with LEP transcript expression in the fasting state suggests that other 
mechanisms may be involved in mediating the association of this locus with leptin levels, such as 
an effect on LEP expression in the fed state (Zhang, Matheny et al. 2002) or an effect on leptin 
protein secretion. 
To validate our knockdown strategy for subsequent analyses of candidate genes in loci 
other than the locus near LEP, we used siRNA against Lep in mouse adipose tissue explants. 
Electroporation of the perigonadal adipose tissue (PGAT) explants with siRNA against Lep 
resulted in a 92% decrease in Lep mRNA (P<1 × 10−4) and a 92% decrease in secreted leptin 
(P=4 × 10−4) (Figure 5.4A&B, Supplementary Figure 5.1C&D and Supplementary Table 
5.10). In addition, to determine whether electroporation with siRNA altered other secretory 
function(s) of the perigonadal explants, we measured secretion of adiponectin and found no 
changes associated with Lep knockdown (Figure 5.4D and Supplementary Figure 5.1E). 
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ADIG may regulate leptin expression 
The intergenic rs6071166 variant, ∼20 kb from the SLC32A1 gene (Figure 5.2C), 
reached genome-wide significance for association with BMI-adjusted leptin levels and has not 
been previously identified for association with any other traits. In look-ups of genome-wide 
association study (GWAS) consortium data, we did not find significant association with other 
obesity-related or metabolic traits (Supplementary Table 5.7). The rs6071166 variant was not 
associated with the mRNA expression of nearby genes in the adipose tissue, liver, lymphocytes, 
brain or skin (Supplementary Tables 5.8 and 5.9). 
To identify the potential causal gene in this locus using the mouse PGAT explant model 
described above, we first measured the expression levels of murine homologues of genes 
surrounding the lead variant associated with circulating leptin levels. We tested PGAT and 
SCAT of 4-month-old C57BL/6J mice fed chow or high-fat diet (Figure 5.3C&D). In addition, 
we analyzed candidate gene expression in other tissues (liver and hypothalamus) that we 
predicted could play a role in circulating leptin levels via effects on leptin clearance or response 
(Supplementary Figure 5.7). Genes were considered strong candidates if they were highly 
expressed in adipose tissue and/or if they were regulated by high-fat diet feeding in a manner 
similar to Lep. This analysis identified adipogenin (Adig) as a candidate gene in the SLC32A1 
locus; Adig is highly expressed in the adipose tissue, in contrast to other nearby genes. To test 
whether Adig affected Lep expression, we performed ex vivo knockdown studies using siRNA 
against Adig in mouse PGAT explants. We found that knockdown of Adig decreased Lep 
expression by 26% (P=4 × 10−4) and leptin secretion by 23% (P=0.003), consistent with a causal 




ADIG is located ∼116 kb from the rs6071166 variant and encodes a cytoplasmic 
adipocyte protein adipogenin, that is, similar to leptin, highly and specifically expressed in the 
adipose tissue (Hong, Hishikawa et al. 2005, Kim, Tillison et al. 2005, Ren, Eskandari et al. 
2016) and upregulated by treatment with insulin and glucose (Ren, Eskandari et al. 2016). Adig 
expression is also strongly upregulated in murine 3T3-L1 preadipocytes during in vitro 
differentiation into adipocytes (Hong, Hishikawa et al. 2005, Kim, Tillison et al. 2005). Two 
studies have investigated the effect of Adig knockdown on the differentiation of 3T3-L1 cells and 
expression of Pparγ2, a master regulator of adipocyte differentiation, but with conflicting results; 
whereas the first study found Adig knockdown to block adipocyte differentiation and decrease 
Pparγ2 expression (Hong, Hishikawa et al. 2005), a later study found no similar changes (Ren, 
Eskandari et al. 2016). When we measured Pparγ2 expression following Adig knockdown in 
PGAT explants containing mature adipocytes, we did not see a change as compared with 
controls (Supplementary Figure 5.2F). 
Common variation in GCKR regulates leptin levels 
Variants (r2≥0.9 with our lead SNP rs780093) of the leptin-associated locus in GCKR 
have previously shown genome-wide significant associations with more than 25 metabolic traits; 
the leptin-increasing allele has been associated with increased fasting glucose and fasting insulin 
but decreased 2-h glucose and higher high-density lipoprotein cholesterol, and lower total 
cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein and circulating 
uric acid levels, among others (Supplementary Table 5.11). The GCKR gene encodes a 
regulatory protein in the liver that inhibits the activity of glucokinase, the enzyme responsible for 
regulating the uptake, metabolism and storage of circulating glucose (de la Iglesia, Mukhtar et al. 
2000). A putative causal variant in this gene is the common nonsynonymous Pro446Leu variant 
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(rs1260326), for which rs780093 acts as a good proxy (r2=0.9). Carriers of the glucose-lowering 
Leu allele have a reduced ability to sequester and inhibit glucokinase and a blunted response to 
fructose 6-phosphate, both of which favour the generation of free and active cytoplasmic 
glucokinase (Rees, Wincovitch et al. 2012). 
The mechanisms that might link changes in GCKR function to leptin levels are not 
known. As insulin increases leptin secretion from adipocytes (Kolaczynski, Nyce et al. 1996) and 
the GCKR locus is strongly associated with circulating levels of insulin, the association of the 
GCKR locus with leptin levels could be the consequence of the GCKR locus' effect on insulin 
levels. The leptin-increasing allele of the rs780093 variant was significantly associated with 
higher levels of fasting insulin in studies included in our stage 2 meta-analyses (P=2 × 10−5, 
N=8,953). To test whether insulin mediated the association of rs780093 with circulating leptin 
levels, we analysed the association of rs780093 with leptin, while adjusting for fasting insulin 
levels. Although the effect size was somewhat attenuated, the association of rs780093 with BMI-
adjusted leptin levels remained significant after adjustment for fasting insulin (β=0.047, P=2 × 
10−4 versusβ=0.034, P=0.004 before and after the adjustment, respectively), suggesting that the 
association of the GCKR locus with leptin is at least in part independent of effects on insulin 
levels. 
Although GCKR's function renders it a potential candidate among the genes in this 
region, cis-eQTL analyses showed association of the leptin-increasing allele of rs780093 with 
increased expression of the nearby IFT172 in the liver (P=7 × 10−30), omental fat (P=6 × 10−64) 
and subcutaneous fat (P=3 × 10−52) (Supplementary Table 5.9). The rs780093 variant is, 
however, only in moderate LD (r2=0.4) with the peak SNP influencing IFT172 expression in the 
region and the peak SNP remained significantly associated with IFT172expression after 
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adjustment for rs780093, whereas the association of rs780093 was abolished after adjustment for 
the peak SNP (Supplementary Table 5.9). 
Because of the observations in human tissues, we examined Ift172 in the mouse explant 
model. Ift172 was not highly expressed in mouse PGAT or SCAT and levels were not 
upregulated by high-fat diet (Figure 5.3E&F). Ift172 was, however, upregulated in the liver 
under high-fat diet feeding (Supplementary Figure 5.7E). Knockdown of Ift172 in PGAT 
explants decreased Lep mRNA expression by 22% (P=0.02), but did not decrease leptin protein 
secretion (P=0.6) (Figure 5.4A&B and Supplementary Figure 5.3C&D). IFT172 is known to 
play a major role in assembly and maintenance of primary cilia that act as critical signaling hubs 
for cellular pathways during development (Halbritter, Bizet et al. 2013). Knockout of Ift genes in 
central neurons causes obesity in mice (Davenport, Watts et al. 2007) and obesity is a clinical 
feature in two human ciliopathic syndromes, the Alström and Bardet–Biedl syndromes (Zaghloul 
and Katsanis 2009, Girard and Petrovsky 2011). In the hypothalamus, alterations in the function 
of the primary cilium lead to impaired leptin signaling (Stratigopoulos, LeDuc et al. 2011). 
Therefore, we cannot exclude a role for IFT172 in the regulation of circulating leptin levels. 
Another nearby gene, MpV17 mitochondrial inner membrane protein, is a potential 
candidate in the region based on its expression in mice fed chow or high-fat diet; Mpv17 
expression was increased by high-fat diet, in a manner similar to Lep (Figure 5.3C&D). 
However, knockdown of Mpv17 did not change Lep mRNA expression (P=0.2) or leptin 
secretion (P=0.2) by PGAT explants (Figure 5.4A&B and Supplementary Figure 5.4C&D), 
suggesting that the involvement of MPV17 in leptin regulation is unlikely. 
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Locus near CCNL1 regulates leptin levels and birth weight 
The leptin-decreasing allele of rs900400, located 67 kb upstream from CCNL1 (Figure 
5.2D), was previously reported for its association with lower birth weight (Horikoshi, 
Yaghootkar et al. 2013). This cross-phenotype association could indicate a mechanism that is 
shared between birth weight and leptin levels in adulthood. Fetal adipose tissue is capable of 
producing leptin (Atanassova and Popova 2000) and fetal leptin levels are correlated with fetal 
fat mass (Clapp and Kiess 1998, Jaquet, Leger et al. 1998). Placenta provides an additional 
source of leptin for the fetus, however, and it has been suggested that leptin could mediate fetal 
growth (Hassink, de Lancey et al. 1997, Tamura, Goldenberg et al. 1998). Assuming that leptin 
levels track from birth through adulthood, increased leptin levels could drive the association of 
the CCNL1 locus with birth weight. Other studies suggest that leptin production is decreased in 
cultured adipocytes from men born with a low birth weight (Schultz, Broholm et al. 2014). 
Therefore, the association of the CCNL1 locus with leptin levels in adulthood could be mediated 
by its association with birth weight. 
Although CCNL1 is the nearest gene to rs900400, our cis-eQTL analyses identified 
rs900400 as the variant most significantly associated with the expression of another nearby gene, 
TIPARP (Supplementary Table 5.9). The TIPARP gene encodes a poly (ADP-ribose) 
polymerase involved in DNA repair. The leptin-increasing allele of rs900400 was associated 
with lower TIPARP expression in omental fat (3 × 10−30) and subcutaneous fat (P=7 × 10−58) 
(Supplementary Table 5.9). Tiparp was also implicated as a causal gene by our expression 
analysis of mouse adipose tissue and its expression was increased in SCAT and liver in mice fed 
with high-fat diet (Figure 5.3H and Supplementary Figure 5.7G). Knockdown of Tiparpin 
mouse PGAT explants did not, however, significantly alter the expression of Lep mRNA (P=0.7) 
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or leptin secretion (P=0.8) (Figure 5.4A&B and Supplementary Figure 5.5D&E). Although we 
attempted to use SCAT for explant knockdown studies, high intra-depot variability compromised 
this approach. Interestingly, stimulation of the explants with insulin and dexamethasone 
increased explant expression of Tiparp by 50% (P=0.003) over incubation in basal media alone, 
in a manner similar to Lep expression (Figure 5.4C and Supplementary Figure 5.5A). 
Collectively, although TIPARP remains a putative causal gene within the locus near CCNL1, 
further evidence is required to confirm its role in the regulation of circulating leptin levels. 
COBLL1 or GRB14 may regulate leptin levels 
The intronic rs6738627 variant in COBLL1 (Figure 5.2E) did not reach genome-wide 
significance for the association with leptin levels (Figure 5.1 and Table 5.1). However, as 
previous GWAS have shown robust associations of the leptin-increasing allele with a lower 
WHRadjBMI
19, we chose to take it forward for follow-up analyses, to examine the role of leptin 
levels in the previous associations. 
Look-ups in data from genetic consortia showed a strong association of the leptin-
increasing allele of rs6738627 with higher body fat percentage (P=2 × 10−8, n=76,338; 
Supplementary Table 5.7). As reported previously, the rs6738627 variant was also strongly 
associated with decreased WHRadjBMI (P=2 × 10
−8, n=174,672; Supplementary Table 5.7), 
suggestive of a preferential gluteal rather than abdominal fat storage, which may contribute to 
the association of rs6738627 with increased leptin levels (Van Harmelen, Reynisdottir et al. 
1998). 
In PGAT and SCAT expression analyses in mice, we found an upregulation of Cobll1 in 
high-fat diet-fed mice in both depots (Figure 5.3I&J). Although knockdown of Cobll1 in the 
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perigonadal explants did not influence Lep mRNA expression (P=0.2), it did decrease leptin 
protein secretion by 16% (P=3 × 10−4, Figure 5.4A&B), suggesting a potential causal role for 
Cobll1. In addition, stimulation of explants with insulin and dexamethasone increased explant 
expression of Cobll1 by 78% (P=0.004) over incubation in basal media alone (Figure 5.4C and 
Supplementary Figure 5.6A). COBLL1 is known to be involved in neural tube formation 
(Carroll, Gerrelli et al. 2003), but its possible functions in adipose tissue are unknown. 
In human eQTL analyses, the leptin-increasing allele of the COBLL1 locus showed an 
association with lower expression of GRB14 in omental fat (P=5 × 10−12) and subcutaneous fat 
(P=3 × 10−5) (Supplementary Table 5.9). We did not, however, find high expression of Grb14 
in PGAT or SCAT explants from mice and the levels were not regulated by high-fat diet feeding 
(Figure 5.3I&J). The protein product of GRB14 is the growth factor receptor-bound protein 14 
that binds directly to the insulin receptor and inhibits insulin signaling (Depetris, Hu et al. 2005). 
The adipose tissue expression of GRB14 may play a role in regulating insulin sensitivity (Cariou, 
Capitaine et al. 2004). Grb14-deficient mice exhibit improved glucose tolerance, lower 
circulating insulin levels and increased incorporation of glucose into glycogen in the liver and 
skeletal muscle (Cooney, Lyons et al. 2004). Both COBLL1 and GRB14 are thus possible 
candidates to account for the association of the COBLL1 locus with leptin levels. 
Enrichment with pathways and regulatory elements 
We used the Data-driven Expression Prioritized Integration for Complex Traits 
(DEPICT) software (Pers, Karjalainen et al. 2015) to identify enrichment of gene sets and 
pathways across loci reaching P<1 × 10−5 for association with leptin levels. However, none of 
our findings reached the false discovery rate threshold of 5% (Supplementary Tables 5.12–
5.17). Next, we used the Gene Relationships Across Implicated traits (GRAIL) tool 
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(Raychaudhuri, Plenge et al. 2009) to identify genes near the leptin-associated loci having 
similarities in the text describing them within published article abstracts. However, no 
statistically significant results were found in these analyses either (Supplementary Tables 5.18 
and 5.19). Finally, we used the Uncovering Enrichment Through Simulation method (Hayes, 
Trynka et al. 2015) to test for the overall enrichment of leptin-associated loci reaching P<10−5 
with ChromHMM annotations for adipose and brain tissues available from the Roadmap 
Epigenomics Project (Roadmap Epigenomics, Kundaje et al. 2015). However, we did not find 
significant enrichment of our leptin-associated loci in any chromatin states once corrected for 
multiple testing (Supplementary Table 5.20). The lack of significant findings may be due to the 
small number of loci identified and the limited knowledge available on leptin-regulating 
pathways in adipose tissue. 
Established adiposity loci and leptin 
Circulating leptin levels correlate closely with BMI and other measures of adiposity3. The 
most recent GWAS meta-analysis for BMI, including nearly 340,000 individuals, identified 97 
loci that reached genome-wide significance (Locke, Kahali et al. 2015). Of the 97 BMI-
increasing loci, 89 showed a directionally concordant association with increased BMI-unadjusted 
leptin levels (Pbinomal=2 × 10
−18), of which 25 reached nominal significance (Supplementary 
Table 5.21). Previous GWAS of extreme and early-onset obesity have identified 12 genome-
wide significant loci (Meyre, Delplanque et al. 2009, Scherag, Dina et al. 2010, Berndt, 
Gustafsson et al. 2013, Wheeler, Huang et al. 2013). Of these, ten showed a directionally 
consistent association with increased BMI-unadjusted leptin levels (Pbinomal=0.04), of which five 
reached nominal significance (Supplementary Table 5.21). 
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We also examined leptin associations for 49 loci identified in GWAS for WHRadjBMI, a 
measure of body fat distribution independent of overall adiposity (Shungin, Winkler et al. 2015). 
Of the 49 WHRadjBMI-increasing loci, only 24 showed a directionally concordant association with 
increased BMI-adjusted leptin levels (Supplementary Table 5.22). As the distribution of body 
fat differs between men and women, we also examined the leptin associations for the 49 
WHRadjBMI loci in men and women separately. There was no enrichment of leptin associations in 
either of the sexes, with 27 loci showing a directionally concordant association with increased 
leptin levels in men and 20 loci in women (Supplementary Table 5.22). 
 
Discussion 
In a meta-analysis of genetic association data in up to 52,126 individuals, we identified 5 
common loci associated with circulating leptin levels. In addition, a locus near COBLL1, 
previously identified for association with a lower WHRadjBMI (Shungin, Winkler et al. 2015), 
reached P=1 × 10−6 for association with increased leptin levels. Even though leptin correlates 
strongly with adiposity, we did not identify loci previously associated with BMI, other than FTO, 
despite having a sample size similar to early GWAS meta-analyses of BMI that identified 
multiple loci (Willer, Speliotes et al. 2009). On the contrary, five of the six loci we identified 
were associated with leptin independently of BMI or body fat percentage. Our findings indicate 
that genetic mechanisms not influencing adiposity may have an important role in the regulation 
of circulating leptin levels. 
Our strongest adiposity-independent leptin signal was near LEP, but we also identified 
leptin-associated variants in four other genomic loci, providing evidence that mechanisms other 
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than those that involve LEP per se may regulate leptin production and release from adipose 
tissue. In one of these loci, near SLC32A1, our knockdown studies indicated a role for 
adipogenin, a gene involved in the regulation of adipocyte differentiation (Hong, Hishikawa et 
al. 2005, Kim, Tillison et al. 2005). Although adipogenin was identified as a potent regulator of 
adipogenesis a decade ago (Hong, Hishikawa et al. 2005, Kim, Tillison et al. 2005), our results 
provide the first evidence linking this function to leptin regulation. We anticipate that our 
findings will motivate and inform eventual testing of Adig by transgenic manipulation in mice. 
No clear effect on leptin production was seen following knockdown of candidate genes in 
the GCKR and CCNL1 loci, which may indicate that the gene implicated by position plays no 
role in the phenotype, or that the effect was undetectable in our experimental conditions. 
Alternatively, the association with leptin levels may be explained by effects of non-coding 
elements on other genes outside the implicated genetic interval, or by inter-species differences. 
Furthermore, although adipose tissue is the most direct contributor to circulating leptin levels, 
the effect of the causal gene may be conveyed by another tissue; leptin production and secretion 
are influenced by insulin, catecholamines and other hormones, as well as paracrine effects of 
local inflammatory cells on adipocytes (Fried, Ricci et al. 2000). 
Although the locus near SLC32A1 had not been identified previously for association with 
other traits, the leptin-associated loci in/near GCKR, CCNL1 and COBLL1 have been associated 
with multiple obesity-related and metabolic traits (Willer, Speliotes et al. 2009, Saxena, Hivert et 
al. 2010, Manning, Hivert et al. 2012, Horikoshi, Yaghootkar et al. 2013, Shungin, Winkler et al. 
2015). These cross-phenotype associations may either reflect pleiotropy, where a gene product 
influences multiple traits, and/or mediation effects, where one phenotype is causally related to a 
second phenotype. For example, the association of the pleiotropic GCKR locus with leptin levels 
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may be partly mediated through GCKR's role in the regulation of glucose homeostasis and 
insulin levels (Saxena, Hivert et al. 2010, Manning, Hivert et al. 2012), which may influence 
leptin production and secretion in adipose tissue (Kolaczynski, Nyce et al. 1996). The COBLL1 
locus is strongly associated with decreased WHRadjBMI, indicative of a preferential accumulation 
of gluteal subcutaneous fat, which may contribute to the observed association with circulating 
leptin levels (Van Harmelen, Reynisdottir et al. 1998). The identification of the birth weight 
locus, CCNL1, as a leptin-regulating locus may provide an intriguing link between leptin 
regulation and fetal growth, albeit such a link remains to be more firmly established (Tamura, 
Goldenberg et al. 1998). 
Unraveling the polygenic basis of leptin production could provide opportunities for 
targeted leptin supplementation in obese individuals. Although leptin therapy is an efficient 
weight-loss treatment for obese individuals with congenital leptin deficiency, the beneficial 
effects of leptin supplementation do not translate to all obese patients (Heymsfield, Greenberg et 
al. 1999). Sensitivity to changes in circulating concentration of leptin may be enhanced at very 
low values (Farooqi, Keogh et al. 2001) where a relatively small increase in leptin production 
may be sensed by the homeostatic feedback system that controls energy balance. As a substantial 
minority of individuals with common forms of obesity, not associated with leptin mutations, 
have relatively low levels of circulating leptin (Ravussin, Pratley et al. 1997), augmenting leptin 
levels in this subgroup could be therapeutically worthwhile. Identification of leptin-regulating 
loci may provide new tools for identifying obese individuals with susceptibility to low leptin 
levels and who may benefit of leptin treatment. 
In 2010, Sun et al. (Sun, Cornelis et al. 2010) identified two common non-synonymous 
SNPs in the leptin receptor (LEPR) gene associated with leptin receptor levels. Leptin receptor 
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plays an essential role in mediating the physiological effects of leptin. Although some studies 
have described abnormally high circulating leptin levels in carriers of rare LEPR mutations 
(Clement, Vaisse et al. 1998), others have not (Farooqi, Wangensteen et al. 2007). We did not 
find association between LEPR variants and circulating leptin levels, suggesting that common 
variants in LEPR are not important regulators of circulating leptin levels. 
Our meta-analyses were limited by the number of available studies with leptin data, 
imputation by HapMap reference panel for autosomal chromosomes and the fact that we 
examined additive effects only. In addition, we corrected for adiposity by adjusting for BMI, 
which is a heterogeneous measure of adiposity as it does not account for individual differences in 
body fat and lean mass. Future discovery efforts in extended sample sizes based on genome-wide 
imputation of 1000 Genomes reference panels, which include X and Y chromosomes and which 
also test for recessive and dominant inheritance, will allow for the discovery of more and lower-
frequency variants, and for refining association signatures of already established leptin-
associated loci. 
In summary, we identified six genetic loci associated with circulating leptin levels, of 
which five showed associations independently of adiposity. Our findings represent a step 
forward in the understanding of biological mechanisms regulating leptin production in adipose 
tissue and open new avenues for examining the influence of variation in leptin levels on 












P N P N Beta SE P N P N P N Beta SE P N
rs10487505 LEP 7:127647399 G/C 0.50 4.0E-06 29470 2.0E-01 17110 0.023 0.005 9.0E-06 46580 2.7E-11 29255 5.2E-03 16781 0.029 0.004 2.0E-12 46036
rs780093 GCKR 2:27596107 C/T 0.61 1.8E-07 32147 3.6E-04 19979 0.032 0.005 2.3E-10 52126 6.3E-07 31802 1.4E-04 19648 0.024 0.004 3.8E-10 51450
rs900400 CCNL1 3:158281469 T/C 0.60 7.3E-07 32128 1.7E-03 19685 0.030 0.005 5.6E-09 51813 9.8E-07 31785 1.7E-02 19354 0.021 0.004 1.2E-07 51139
rs6071166 SLC32A1 20:36766426 C/A 0.37 2.0E-07 29471 1.6E-01 17007 0.027 0.006 6.6E-07 46478 2.9E-08 29256 3.9E-02 16678 0.024 0.004 1.8E-08 45934
rs6738627 COBLL1 2:165252696 A/G 0.37 8.3E-07 25573 8.6E-02 19573 0.027 0.006 1.4E-06 45146 4.6E-06 25229 4.5E-02 19242 0.020 0.004 1.9E-06 44471
rs8043757 FTO 16:52370951 T/A 0.40 8.8E-08 32120 2.7E-03 19919 0.030 0.005 1.1E-09 52039 6.1E-01 31776 7.5E-01 19588 0.001 0.004 8.4E-01 51364
Leptin unadjusted for BMI Leptin adjusted for BMI








Leptin (µg/ml) was logarithmically transformed. The study-specific analyses were performed with linear regression models while accounting for sex, age and age 2. Meta-analyses of the study-specific results were performed 
using fixed effects meta-analysis. Beta refers to the change in logarithmically transformed leptin per each copy of the effect allele. EAF, effect allele frequency




Figure 5.1 Meta-analysis results for the leptin-associated loci. 
 
The bars show the additive effect of the loci in or near LEP, GCKR, CCNL1, SLC32A1, 
COBLL1 and FTO on BMI-unadjusted and BMI-adjusted leptin levels in the meta-analysis of 
Stage 1 and Stage 2 combined. The error bars indicate s.e.  
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Figure 5.2 Regional plots for the loci associated with circulating leptin concentrations. 
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Regional plots for the loci in or near LEP (A), GCKR (B), SLC32A1 (C) and CCNL1 (D), 
which reached genome-wide significance in the combined meta-analysis of Stage 1 and Stage 2 
for BMI-unadjusted or BMI-adjusted leptin levels. The COBLL1 locus (E) that reached P=1 × 
10−6 with BMI-unadjusted and P=2 × 10−6 with BMI-adjusted leptin levels is also shown. For the 
locus near LEP (A), the rs10249476 SNP, located in a previously identified adipocyte-specific 





















Expression of murine homologues of genes located within Lep (A&B), Slc32a1 (C&D), Gckr 
(E&F), Ccnl1 (G&H) and Cobll1 loci (I&J) in PGAT and SCAT from 4-month-old mice fed 
chow (black bars) or high-fat diet (HFD; grey bars). Quantitative PCR (qPCR) transcripts were 
normalized using ActB, Rplp0, Gapdh and Ppia as housekeeping genes. N=5 mice per group. T-









Changes in Lep mRNA expression (A) and secretion into media (B) following candidate gene 
knockdown in PGAT explants following stimulation with insulin and dexamethasone for 12 h. 
Gene expression induced by stimulation with insulin and dexamethasone (C) N=5–13 mice per 
group (3 replicates/condition/mouse). Secreted adiponectin was measured as a control for non-
leptin secretory function (D) N=5 mice per group. Two-way repeated measures analysis of 





Supplementary Figure 5.1 Effects of Lep knockdown on leptin transcription and secretion in 
perigonadal adipose tissue explants from mice fed with high fat diet. 
 
Lep transcription (A) and secretion (B) by explants in the basal or Ins/Dex stimulated state. N=5 
mice per group. Lep knockdown (C) decreased LEP secretion (D) following stimulation with 
insulin and dexamethasone for 12 hours. Adiponectin secretion (E) remained unchanged. N=5 
mice per group. Each point represents the average of 3 samples. 2 way repeated measures 
ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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Supplementary Figure 5.2 Effects of Adig knockdown on leptin transcription and secretion in 
perigonadal adipose tissue explants from mice fed with high fat diet. 
 
Adig expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Adig knockdown (B) decreased both Lep expression (C) and leptin secretion (D) following 
stimulation with insulin and dexamethasone for 12 hours. N=12 mice per group. Adiponectin 
secretion (E) remained unchanged. N=7 mice per group. Pparg2 expression (F) was unchanged 
as well. N=6 mice per group. Each point represents the average of 3 samples. 2 way repeated 
measures ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Supplementary Figure 5.3 Effects of Ift172 knockdown on leptin transcription and secretion in 
perigonadal adipose tissue explants from mice fed with high fat diet. 
 
Ift172 expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Ift172 knockdown (B) decreased Lep expression (C) but did not change leptin secretion (D) 
following stimulation with insulin and dexamethasone for 12 hours. N=9 mice per group. 
Adiponectin secretion (E) remained unchanged. N=6 mice per group. Each point represents the 




Supplementary Figure 5.4 Effects of Mpv17 knockdown on leptin transcription and secretion in 
perigonadal adipose tissue explants from mice fed with high fat diet. 
 
Mpv17 expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Mpv17 knockdown (B) did not change Lep expression (C) or secretion (D) following stimulation 
with insulin and dexamethasone for 12 hours. Adiponectin secretion (E) remained unchanged. 
N=12 mice per group. Each point represents the average of 3 samples. 2 way repeated measures 




Supplementary Figure 5.5 Effects of Tiparp knockdown on leptin transcription and secretion in 
perigonadal adipose tissue explants from mice fed with high fat diet. 
 
Tiparp expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Tiparp knockdown (B) did not change Lep expression (C) or secretion (D) following stimulation 
with insulin and dexamethasone for 12 hours. Adiponectin secretion (E) remained unchanged. 
N=9 mice per group. Each point represents the average of 3 samples. 2 way repeated measures 
ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Supplementary Figure 5.6 Effects of Cobll1 knockdown on leptin transcription and secretion in 
perigonadal adipose tissue explants from mice fed with high fat diet. 
 
Cobll1 expression (A) by explants in the basal or Ins/Dex stimulated state. N=5 mice per group. 
Cobll1 knockdown (B) did not change Lep expression (C) but decreased Lep secretion (D) 
following stimulation with insulin and dexamethasone for 12 hours. N=13 mice per group. 
Adiponectin secretion (E) remained unchanged. N=8 mice per group. Each point represents the 














Expression of murine homologs of genes located within LEP (A&B), SLC32A1 (C&D), GCKR (E&F), CCNL1 (G&H), and COBLL1 
loci (I&J) in liver and hypothalamus from 4-month-old mice fed chow (black bars) or high fat diet (HFD; gray bars). qPCR transcripts 
were normalized using ActB, 36B4, Gapdh and Ppia as housekeeping genes. N=5 mice per group. T-test. *p<0.05, **p<0.01. 
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Chapter 6 Concluding Remarks  
 
While the association between intron 1 alleles of the FTO locus and adiposity is 
statistically extremely strong, ten years of research into the molecular genetics of this locus have 
not revealed a clear explanation for this association. A number of genes in the vicinity of the 
intronic alleles have been implicated in a variety of mechanisms that may – possibly 
concordantly – contribute to the adiposity/obesity associations (Fig. 4.1.1). 
 
Genes distant from the FTO obesity-associated locus may convey effects on adiposity 
RBL2, a gene 270 kb from the FTO intronic adiposity signals has been implicated on the 
basis of eQTL studies showing increased RBL2 expression in lymphocytes of individuals 
segregating for the obesity-risk allele of rs8050136 in the first intron of FTO (Jowett, Curran et 
al. 2010). We observed a decrease in RBL2 expression in both murine 3T3-L1 and human 
preadipocyte-containing adipose tissue-derived stromal cells following FTO knockdown 
(Chapter 4, Fig. 4.4.2). RBL2 might play a role in the cardiac and craniofacial malformation 
syndrome seen in humans with FTO mutations, and in the runting and postnatal lethality in Fto-/- 
mice.  
Other genes located further from the FTO intronic adiposity signals have also been 
implicated by eQTL studies. Expression of IRX3 (approximately 500 kb away) is elevated in 
cerebellum of individuals segregating for the FTO risk allele at rs9930506. Expression of IRX3 
and IRX5 (approximately 1.2 Mb away) were also elevated in cultured preadipocytes from 
individuals with this same risk allele (Smemo, Tena et al. 2014, Claussnitzer, Dankel et al. 
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2015). This regulation has been attributed to long-range genetic interactions between the FTO 
locus and the IRX3 promoter identified using circular chromosome conformation capture 
followed by high throughput sequencing (4C-seq) (Smemo, Tena et al. 2014). Additionally, the 
risk allele of rs1421085 in the first intron of FTO disrupts binding of a transcriptional repressor, 
ARID5B. Knockdown of ARID5B in preadipocytes isolated from humans segregating for the 
protective rs1421085 allele increases IRX3 and IRX5 expression, further supporting the assertion 
that the FTO locus participates in long-range interactions with its neighboring genes 
(Claussnitzer, Dankel et al. 2015). Irx3-/- mice exhibit reduced lean and fat mass, due to elevated 
energy expenditure. This increase in energy expenditure is attributed to “browning” of the 
adipose tissue which promotes thermogenesis by the uncoupling of oxidative phosphorylation 
(Smemo, Tena et al. 2014, Claussnitzer, Dankel et al. 2015). However, the increased adiposity of 
individuals segregating for the susceptibility allele of rs9939609 in the FTO locus is due 
primarily to increased food intake (Cecil, Tavendale et al. 2008, Speakman, Rance et al. 2008, 
Wardle, Carnell et al. 2008, Tanofsky-Kraff, Han et al. 2009, Herman and Rosen 2015). Irx3 is 
reportedly regulated by both Rpgrip1l (Vierkotten, Dildrop et al. 2007) and Fto (Ronkainen, 
Huusko et al. 2015), further complicating the molecular physiology of transcriptional control 
attributed to the FTO locus. 
 
FTO and RPGRIP1L may convey effects of the FTO obesity-associated locus 
The location of the obesity-associated SNPs in FTO suggests that they might regulate 
FTO itself, a purported RNA m6A demethylase and/or RPGRIP1L, a gene vicinal to FTO that 
encodes a critical component of the primary cilium. eQTL studies have not demonstrated an 
association between FTO or RPGRIP1L expression and FTO risk allele genotypes in any human 
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tissues (Kloting, Schleinitz et al. 2008, Wahlen, Sjolin et al. 2008, Grunnet, Nilsson et al. 2009, 
Zabena, Gonzalez-Sanchez et al. 2009, Jowett, Curran et al. 2010, Lappalainen, Kolehmainen et 
al. 2010, Smemo, Tena et al. 2014, Claussnitzer, Dankel et al. 2015). However, human eQTL 
studies are limited by the developmental stage and cellular heterogeneity of tissues being studied 
(Pastinen and Hudson 2004), a caveat highlighted by our data regarding the developmental 
timing of FTO and RPGRIP1l in adipose tissue development and function. Variants rs8050136 
and rs1421085 in the first intron of FTO have been identified by our laboratory to regulate 
expression of FTO and RPGRIP1L by differential binding of the transcriptional regulator, CUX1 
(Stratigopoulos, Padilla et al. 2008, Stratigopoulos, LeDuc et al. 2011, Stratigopoulos, Burnett et 
al. 2016). CUX1 p200 repressor binding results in reduced expression of RPGRIP1L and FTO in 
fibroblasts and induced pluripotent stem cells of individuals segregating for FTO risk alleles 
(Stratigopoulos, LeDuc et al. 2011, Stratigopoulos, Burnett et al. 2016).  
Work from our laboratory has demonstrated that a primary site of Fto and Rpgrip1l 
function is in the hypothalamus, where these genes are metabolically regulated: decreased upon 
fasting and restored by leptin administration due to regulation of the proteolytic activity of 
Cathepsin L which performs Cux1 p200 processing (Stratigopoulos, LeDuc et al. 2011). These 
data confirm a role for these molecules in the regulation of food intake and energy expenditure 
governed by hypothalamic circuitry. Studies in rats support these inferences: in adult male 
Wistar rats, overexpression of Fto by injection of an AAV-vector into the ARC and PVH 
decreased food intake whereas Fto knockdown in the ARC increased food intake (Tung, Ayuso 




FTO and RPGRIP1L exhibit opposing effects in adipose tissue 
We propose that the FTO locus also contributes to adipose tissue development and 
function. And that these actions – mediated by RPGRIP1L and FTO – influence the cellular 
anlagen of developing adipose tissue (RPGRIP1L) and the expansiveness of the adipose tissue 
depot under circumstances of positive energy balance (FTO).  
 We show that both RPGRIP1L (Chapters 2&3) and FTO (Chapter 4) have cell-
autonomous effects on adipogenesis and adipocyte physiology. Knockdown of these genes 
induces reciprocal effects on adipogenesis. Rpgrip1l knockdown increases adipogenesis 
(Chapter 3), whereas Fto knockdown inhibits adipogenesis (Chapter 4). When Fto is knocked 
down in murine 3T3-L1 cells, Rpgrip1l expression is decreased. When expression of both genes 
is downregulated in this case, the effect of Fto knockdown predominates and these cells exhibit 
decreased lipid filling and adipocyte effector gene expression, such as Pparg2, Cebpa, Glut4, 
Fabp4, Lpl and Atgl. 
 
RPGRIP1L may act to limit adipose tissue expansion 
Rpgrip1l is located in the transition zone of the cilium, where it directs traffic to and from 
the ciliary compartment. Primary cilia, while present in preadipocytes, are lost during 
differentiation. Hence, we propose that Rpgrip1l functions primarily in early stages of 
adipogenesis. This inference is consistent with our knockdown studies, in which Rpgrip1l 
knockdown prior to differentiation enhanced adipogenesis, whereas knockdown in mature cells 
had no obvious effect (Chapter 3).  
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In Chapter 2 we describe elevated adiposity in a mouse congenitally systemically 
hypomorphic for Rpgrip1l due to hyperphagia (Stratigopoulos, Martin Carli et al. 2014). The loss 
of hypothalamic activity of Rpgrip1l, which normally inhibits hyperphagia by facilitating leptin 
signaling, is the likely mechanism for this hyperphagia. However, we propose that the permissive 
effects of hypomorphism for Rpgrip1l on expansion of adipocyte precursors during development, 
facilitates the adipose tissue depot accommodation to storage of excess ingested calories 
(Chapter 3). We knocked out Rpgrip1l in mature adipocytes of mice using the Adiponectin-Cre 
driver to excise a loxP-flanked exon 5 of Rpgrip1l and did not observe any difference in body 
weight between Adipoq-Cre;Rpgrip1lfl/fl mice and their Rpgrip1l+/+ littermates, when fed either 
chow or high fat diet. We interpret this result as further evidence that in adipose tissue Rpgrip1l 
may function primarily during developmental initiation of adipogenesis, at which point primary 
cilia are sensing environmental signals which determine cellular developmental fates. Critical to 
further testing of this hypothesis is the development of sufficiently specific preadipocyte Cre.  
 
FTO may convey effects of the FTO obesity-associated locus on type 2 diabetes 
In 3T3-L1 cells and human ASCs, we detected upregulation of Fto expression throughout 
adipogenesis (Chapter 4). Additionally, Fto expression was elevated in isolated mature 
adipocytes compared to the preadipocyte-containing SVC fractions of perigonadal and 
subcutaneous depots of C57BL/6 mice.  
We propose that Fto functions mainly in mature adipocytes to maintain their critical lipid 
handling and possibly endocrine functions. We observed anti-adipogenic effects when Fto was 
knocked down before adipogenesis in 3T3-L1 cells and human ASCs. We also observed 
decreased lipid content in 3T3-L1 cells when Fto was knocked down after adipogenesis. Fto-/- 
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mice are not lipodystrophic early in life, indicating that the molecule is not critical for 
early/embryonic development of adipose tissue. Embryonic development of adipose tissue is 
regulated by mechanisms distinct from those which govern adipogenesis in adult mice (Jeffery, 
Church et al. 2015, Wang, Tao et al. 2015). The late lipodystrophy seen in Fto-/- mice (loss of 
adiposity, accompanied by elevated blood concentrations of glucose, triglycerides and 
cholesterol) is indicative of a cell autonomous derangement of adipocyte function (Church, Lee 
et al. 2009, Fischer, Koch et al. 2009, Ronkainen, Huusko et al. 2015). Similar metabolic defects 
are seen in Pparg knockout mice, which exhibit impaired adipocyte lipid storage and utilization 
(Wang, Mullican et al. 2013). The decrease in Pparg2 expression following Fto knockdown is 
consistent with this hypothesis, as Pparg2 expression is critically required for adipocytes to 
maintain their lipid handling and endocrine functions. Our results, demonstrating altered 
regulation of C/ebpβ- and C/ebpδ-targets following Fto knockdown, are consistent with a report 
implicating Fto as a transcriptional coactivator of C/ebp response elements acting via 
reactivation of methyl-inhibited transcription in conjunction with C/ebpβ (Wu, Saunders et al. 
2010). Contrary to reports indicating that the main function of Fto is m6A RNA demethylation 
(Zhao, Yang et al. 2014), we did not find evidence of altered RNA m6A patterns or changes in 
the stability or translation of Fto-regulated targets Cebpb, Cebpd, Ptprv, Spon2 or Pten  
These distinctive and discrete effects of RPGRIP1L and FTO on adipocyte development 
and function are illustrated in Fig. 4.6.1. In individuals segregating for the rs8050136 and 
rs1421085 FTO obesity risk alleles, binding of the CUX1 p200 isoform decreases RPGRIP1L 
and FTO expression. In the hypothalamus, one consequence of this transcriptional regulation is 
increased food intake. We propose that RPGRIP1L and FTO play complementary roles in 
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adipose tissue, contributing, respectively, to developmental adipogenesis, and adipose tissue 
expansion in response to positive energy balance.  
 
Figure 6.1 RPGRIP1L and FTO modify the adiposity and metabolic effects conveyed by FTO 
risk alleles. 
 
A primary effect of FTO obesity risk alleles at rs8050136 and rs1421085 is to decrease 
FTO and RPGRIP1L expression in response to CUX1 p200 binding. Decreased expression of 
FTO and RPGRIP1L increases food intake and adiposity (A). Peripherally mediating/modifying 
this central effect on energy balance are decreases of RPGRIP1L and FTO expression in 
preadipocytes and mature adipocytes, respectively. During development of adipose tissue depots, 
decreased RPGRIP1L expression in preadipocytes of individuals segregating for FTO risk alleles 
(lower section) causes adipose depots to expand preadipocyte pools that are accommodative of 
increased fat storage (B). As adipocytes mature they express increased levels of FTO. However, 
in older individuals segregating for the rs8050136 and rs1421085 FTO obesity risk alleles that 
also suppress FTO expression, this lack of FTO upregulation, which may be further exacerbated 
in individuals maintaining positive energy balance (C), impairs the lipid handling and endocrine 
functions of adipocytes which can lead to the eventual loss of adipose tissue, ectopic lipid 
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storage and the ensuing metabolic sequelae. This formulation is consistent with the association of 
the FTO locus with T2D beyond the risk attributable to increased adiposity. There may also be 
anatomic regional differences in the FTO-mediated effects on adipocyte replacement/expansion, 
further contributing to the effects of FTO genotypes on insulin sensitivity and diabetes risk. 
 
The FTO obesity-associated locus does not mediate food intake by altering leptin 
production by adipocytes 
Adipose tissue development and function are critical determinants of metabolic health. In 
addition to the developmental effects on adiposity mediated by RPGRIP1L, and the effects 
conveyed on adipocyte function and survival related to FTO, the FTO locus could impact 
systemic energy homeostasis by modifying production of humoral signals which are integrated 
centrally to regulate energy balance. In Chapter 5, we explored molecular modifiers of 
adipocyte production of leptin identified by GWAS (Kilpeläinen, Carli et al. 2016) as reductions 
in leptin production by adipocytes could increase obesity risk (Zhang, Proenca et al. 1994). 
Knockdown of Adig and Cobll1, homologs of genes near the SLC32A1 and COBLL1 leptin-
associated loci, respectively, both decreased the amount of leptin produced by mouse adipose 
tissue explants cultured in vivo. The FTO locus was associated with elevated circulating leptin 
concentrations but this association was abrogated when corrected for BMI, indicating that this 
locus does not contribute to adiposity by dysregulating leptin production. Our in vitro findings 
are consistent in this regard, as knockdown of Rpgrip1l and Fto in 3T3-L1 cells did not affect 
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